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Abstract
There is a pressing need for new anti-parasitic drugs. Parasitic infection is an
enormous, and growing, worldwide problem. Current treatments are generally
ineffective and cause side-effects. Organisms resistant to some of the more effective
drugs are appearing.
A good target for drug intervention is glycolysis on which many parasites rely for
their energy supply. Phosphofructokinase (PFK) is a good choice of glycolytic enzyme
for targeting since it is believed to catalyse the major regulatory step of glycolysis.
However, inhibition of parasite PFK must take place with as little inhibition of the host
PFK as possible.
The aim of this work was to tackle this problem of species selectivity. In the absence of
much information about parasite PFKs, a model system was used which comprised
two of the best-studied PFKs. The goal was inhibition of Escherichia coli PFK by
compounds little affecting rabbit muscle PFK.
Models of the structure for rabbit muscle PFK were built based on the justified
assumption of a shared protein fold with Escherichia coli PFK. Several ligand design
approaches were used. Some used protein structure information like the program
LUDI. Database searches used information from the structures of known ligands. The
question of species selectivity was addressed during the design process. Several
classes of putative ligands were produced. These ranged from disparate organic
compounds suggested by LUDI to substrate analogs modelled using molecular
mechanics procedures. Testing of putative ligands was by a variety of techniques such
as enzyme assay, fluorescence and protection against protein denaturation. Finally, the
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Parasitic infection is an enormous worldwide problem. The figures are shocking. For
example, nearly half the world's population, some 2100 million people, are at risk from malaria
(Fullick and Fullick, 1993). The situation is worsening due to social factors. One of these is
migration of the population from the country into the cities. Frequently these people are too
poor to take account of the potential health advantages; better drinking water and sewerage
facilities, for example. The obvious health disadvantages of city dwelling like overcrowding,
however, remain. Ironically, potentially favourable developments such as reservoirs and
irrigation ditches can provide new environments in which parasites and their vectors may breed.
Parasitic infections are hugely more prevalent in tropical, generally poorer, nations than they
are in the developed world. The most common intestinal parasite in the U.S. causes around
4000 hospital admissions per year. Cryptosporidiosis infects 250-500 million people in Asia,
Africa and Latin America annually (Warhust and Smith, 1992). The great weighting of parasitic
diseases on poorer nations is the main reason why efforts towards pharmaceutical intervention
trail so far behind those directed at cancer, heart disease etc. Drug companies find the potential
profits in anti-parasitic compounds to be too small to justify research and development costs.
The onus has therefore fallen much more on public bodies like the World Health Organisation
(Patel, 1993).
There are two main ways to attack parasitic diseases; vaccines and drugs. Vaccines have been
effective against diseases such as smallpox (now virtually eradicated), measles and polio.
However there are intrinsic limits on their usefulness in preventing parasitic diseases. Those
parasites that live inside their host have generally evolved ways of evading the host's immune
system. For example, the parasite may live inside host cells or may change its external coat so
that host antibodies no longer recognise it. Drugs are not subject to these limitations but the
relative lack of research in this field means that those currently available are generally of limited
effectiveness and cause significant side-effects. Some of the better drugs, such as chloroquine
for malaria treatment, are now suffering from the evolution of resistant target organisms.
In this chapter I shall first discuss what makes glycolytic enzymes, and phosphofructokinase
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(PFK) in particular, such good targets for anti-parasitic drug design. I will then explain the
choice of E.coli and rabbit muscle PFKs as a model system for species-selective drug design.
1.1 Why target parasite PFKs ?
Various considerations influence the choice of pathway for drug targeting. Of course blockage
of the pathway should have as severe as possible consequences for the parasite. Less
obviously, the pathway chosen should be one about which basic biochemical knowledge is
available or easily obtained. Ideally, the enzymes of the pathway should be readily purified.
This is significant since one of the lessons of drug design is that the number of available
methods and the chance of success increase with increasing knowledge of the system. In
practise this often leads to avoidance of metabolic pathways unique to the parasite and
concentration instead on pathways that have been well studied in other organisms.
It is generally thought that most parasites use glycolysis exclusively for their energy
production. This is certainly the case in the helminths Ascaris suum and Fasciola
hepatica.(Kohler, 1985). Glycolysis is therefore a good target for anti-parasitic drug design.
The glycolytic pathway and its enzymes are shown in Fig 1.1.
The best choice of enzyme for targeting is that which has the greatest influence on the flux
through the pathway - the most Tate-controlling' enzyme or that with the highest flux control
coefficient. This arises from the recognition that complete inhibition of an enzyme is unlikely to
be achieved. Incomplete inhibition will have more effect on pathway flux if the enzyme is of the
above type rather than one with a lower flux control coefficient.
The activity of PFK has long been assumed to have an important effect on the rate of
glycolysis as a whole. This belief originated in the discovery that most PFKs are highly
regulated enzymes: why would they be so if glycolysis as a whole was not dependent, to some
extent, on PFK rate? Various modelling studies of erythrocytes (Rapoport et al., 1974), E.coli
(Torres and Babul, 1991), muscle tissue (Brooks and Storey, 1991) and ascites tumour cells


































































Figure 1.1 Glycolysis. The abbreviations for the enzymes are as follows:
HK, hexokinase; PGI, glucosephosphate isomerase; PFK, phosphofmctokinase;
ALD, aldolase; TIM, triosephosphate isomerase; GAPDH, glyceraldehyde-
phosphate dehydrogenase; PGK, phosphoglycerate kinase; PGAM,
phosphoglycerate mutase; ENO, enolase; PYK, pyruvate kinase. The letter 'P'
in the chemical structures represents a phospho group. Taken from Fothergill-






rate. In addition, the drastically increased rate of glycolysis seen in erythrocytes infected with
the malarial parasite Plasmodium berghei can be explained using a kinetic model of the parasite-
specific PFK (Buckwitz etal., 1990). Also suggestive of an important regulatory role for PFK
is the finding, in another parasite - Ascaris suum, that PFK is operating under physiological
conditions at only 2% of its maximal activity (Hofer et al., 1982).
The regulatory importance of an enzyme to a pathway can be determined experimentally by
modulating its activity, for example using inhibitors or over-expression. PFK has been over-
expressed five-fold in Saccharomyces cerevisiae and the consequences monitored using n.m.r.
spectroscopy and assays for enzymes and metabolites (Davies and Brindle, 1992). Glycolytic
flux measurements showed only small increases in the over-expressing cells suggesting a low
PFK flux control coefficient for glycolysis. However, these results could be explained by an
observed, compensatory decrease in 6-phosphofructo-2-kinase activity and hence fructose-2,6-
bisphosphate (F26BP) concentration. F26BP is a potent activator of yeast PFK so that the
decline in its concentration could explain the absence of a large increase in glycolytic flux.
Thus, frustratingly, no conclusion could be drawn about the importance of PFK in regulating
glycolytic flux.
It can be seen that there is little evidence to contradict the intuitive notion that PFK is an
important control enzyme of glycolysis. Amongst the glycolytic enzymes it is therefore a good
target for drug intervention. Indeed, some of the earliest anti-parasitic drugs, antimonial
compounds, acted on PFK (Bueding and Mansour, 1957).
There are a variety of 'phosphofructokinases' - enzymes capable of phosphorylating
phosphofructose. They may be categorised according to their substrates.
The first division that can be made is between those PFKs whose substrate is fructose-1-
phosphate and those acting on fructose-6-phosphate. The former class catalyses the reaction :-
Variety of PFKs
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F-l-P F-1.6-BP + ADP
This reaction is part of the fructose uptake pathway in bacteria such as E.coli (Buschmeier et
ai, 1985).
The enzymes whose substrate is fructose-6-phosphate can be further divided according to the
position at which they attach the new phospho group. Some phosphorylate the 2 position of
F6P
F6P + ATP F-2,6-BP + ADP.
These 'PFK-2' enzymes are located at the N-terminal portion of a bifunctional polypeptide chain
which has at its C-terminal portion a domain with F-2,6-BPase activity. F26BP is a quite recent
discovery (Furuya and Uyeda, 1980; Furuya and Uyeda, 1981). It is an important regulatory
molecule in liver, for example, since it both activates glycolytic PFK and inhibits F-l,6-BPase
(for a review see Pilkis et al., 1988). It therefore has a large effect on the balance between
glycolysis and gluconeogenesis.
The remaining PFKs form part of the glycolytic pathway. They can again be divided into two
groups - those using ATP as phospho donor
F6P + ATP F-1,6-BP + ADP
and those using inorganic pyrophosphate (PPj)
F6P + PPi F-1.6-BP +
The ATP-dependent PFK is much more commonly found. The PPpdependent PFK is present
in some prokaryotes and eukaryotes but not in archaebacteria. Two different situations have
been noted (Mertens, 1991). In higher plants and Euglena gracilis (a photosynthetic protist)
PPj-dependent PFK is allosterically regulated and coexists with ATP-dependent PFK. In all
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other organisms the PPj-dependent PFK appears not to be allosterically regulated, and ATP-
dependent PFK levels are very low.
1.2.1 Relationships between PFKs
With enzymes catalysing the same reaction or similar reactions it is interesting to speculate
about their possible evolutionary relationships; do they arise from a common ancestor? The
most fundamental tool here is sequence comparison. If two enzymes share a sufficiently high
degree of sequence identity then it is reasonable to assume that they have diverged from a
common ancestor, the probability of independent convergent evolution to similar sequences
becomes small. What then constitutes a 'sufficiently high degree of sequence identity'?
Gapped alignments of random sequences produce 10-20% sequence identity (Fothergill-
Gilmore and Michels, 1992) so observed values in this range must be considered doubtful.
Above these values the percentage identity required to be confident of common ancestry
decreases with the length of alignment. This has been studied by Sander and Schneider (1991).
Figure 2.2 illustrates their findings. For alignments of greater than 80 residues they suggest
common ancestry may be inferred from observed sequence identity of greater than 25-30%.
By these criteria, all the ATP-dependent glycolytic pathway PFKs share a common ancestor.
Interestingly, in the case of yeast PFK (both a and p subunits) and mammalian PFKs, separate
homology can be seen between the N- and C-terminal halves and the bacterial enzymes. From
this it has been inferred that they arose through duplication of a precursor PFK gene with
subsequent gene fusion. Sequence comparisons show that the C-terminal repeats of both yeast
and mammalian PFKs can no longer be catalytically active. In both cases the essential catalytic
aspartate residue has been replaced by a serine. Instead, it seems that the C-terminal repeats are
responsible for binding the much broader range of effector molecules active on eukaryotic
PFKs.
The situation is more complicated when considering the possible relatedness of ATP- and PPj-
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dependent glycolytic pathway PFKs. Unfortunately, there are still only three PPj-dependent
PFK sequences - the a and p subunits of the potato tuber enzyme (Carlisle et al., 1990) and the
enzyme from Propionibacteriiimfreudenreichii (Ladror et al., 1991). The potato tuber a and p
subunits are clearly related to each other since they have about 40% identical sequences.
However, comparison with the E.coli ATP-dependent PFK produced only 16 and 22% identity
with the a and p subunits respectively. This alone is insufficient to infer common ancestry, but
there is suggestive circumstantial evidence. For example, the predicted secondary structure of
the PPj-dependent enzyme closely matches that of the E.coli enzyme. In addition, the
alignments with the E.coli enzyme can explain the observation that the p, but not the a, subunit
is catalytically active. A 'low but significant' level of sequence identity between the
Propionibacterium enzyme and E.coli PFK has been asserted (Green etal., 1993). This value
is 23%, not in the region in which common ancestry may be confidently deduced. The effects
of mutations in two catalytic aspartates separated by one residue (Green etal., 1993) are
certainly consistent with homology. However, a D-X-D sequence is readily explained by
convergent evolution and the possible relationship of the Propionibacterium enzyme and E.coli
PFK must remain doubtful. Results obtained here using the PROFILESEARCH program (see
Section 2.3.1) strongly support the idea that the potato enzymes, but not the Propionibacterium
PFK, are evolutionarily divergently related to the ATP-dependent PFKs. These results are
consistent with the highly dispersed distribution of PPj-dependent PFKs among the prokaryotes
and eukaryotes (Mertens, 1991) that suggested that PPj-dependent PFK has evolved
independently, from ATP-dependent PFK or not, several times. Fig 1.2 illustrates the
distribution of PPj-dependent PFKs among prokaryotes and eukaryotes on a multi-kingdom tree
derived from rRNA sequences (taken from Mertens, 1991).
The ATP-dependent PFKs may share structural similarity and common ancestry with the PFK-
2s althought the evidence is not unequivocal (Bazan et al., 1989). A likely nucleotide-binding
fold can be identified from characteristic sequence motifs in the PFK-2 sequence. The match
between known secondary structure patterns of various ATP-binding proteins and the predicted
secondary structure of the PFK-2 sequence was best for bacterial PFK. Using this information


























Fig 1.2 Distribution of PPpdependent phosphofructokinases among
prokaryotes and eukaryotes. Taken from Mertens, 1991.
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site and subunit interface regions. The latter was important since dimerisation of PFK-2
domains is known to be required for activity. Nevertheless, proof of structural similarity must
await X-ray crystallographic studies.
Fructose-1-phosphate kinases from E.coli (Orchard and Kornberg, 1990) and Rhodobacter
capsulatus (Wu et al., 1991) show clear homology to other sugar kinases like
phosphotagatokinase and ribokinase and to Rubisco large subunits. A superfamily including all
these enzymes plus the ATP-dependent PFKs has been suggested (Wu et al., 1991). However,
the evidence for this is very weak: subunit size, similarity of function, ambiguous levels of
sequence identity, etc.
1.2.2 Parasite PFKs
Both ATP- and PPpdependent PFKs have been found individually, but not together, in
parasites. There seems to be a relationship between the environment of the parasite and the
presence of either ATP- or PPj-dependent PFK (Mertens, 1993). The obvious advantage of a
PPj-dependent PFK is greater efficiency; PPj, a by-product of other reactions that would
otherwise go to waste, is usefully harnessed instead of ATP. Consistent with this is the high
biomass yield of propionic bacteria which use this mechanism. This energy advantage would
be of greater importance to some parasites than others. Blood-dwelling parasites like
trypanosomes will always have a plentiful supply of glucose, and indeed PPj-linked glycolysis
is not found in these organisms. On the other hand, many parasites with less plentiful food
supplies depend on fermentation for energy since they lack mitochondria. More efficient
glycolysis is clearly highly desirable in these organisms.
There are as yet no extensive sequences of parasite ATP-dependent PFKs. The only
sequences available are those surrounding the phosphorylation sites of PFK from Ascaris
suum (Kulkarni et al., 1987) and Fasciola hepatica (Mahrenholz et al., 1991). These sequences
are only 11 and 12 residues long respectively, and neither shows any similarity to known PFK
sequences. Indirect evidence from the effect of proteolysis on Ascaris suum PFK has been
interpreted as indicating similarity between this parasite PFK and mammalian PFKs (Ahanotu
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etal., 1991). There are some sequences of peptide fragments from Trichomonas vaginalis PPj-
dependent PFK (Mertens, personal communication). These indicate 40-60% identity with ATP-
dependent PFKs; enough to suggest common ancestry.
Phosphorylation of parasite PFKs causes stimulation of their activity. This has been shown
for Dirofilaria immitis (Srinivasan etal., 1988), Ascaris suum (Kulkarni etal., 1987) and
Fasciola hepatica (Mahrenholz et al., 1991). Stimulation on phosphorylation has also been seen
for mollusc muscle PFK (Biethinger et al., 1991), but not for yeast PFK (Huse et al., 1988) or
mammalian enzymes such as rabbit muscle (Kemp and Foe, 1983). A possible alternative,
indirect, way to inhibit parasite PFK would therefore be to effect dephosphorylation of the
enzyme. In Ascaris suum at least, knowledge is accumulating about the kinases (Thalhofer et
al., 1988) and phosphatases (Daum etal., 1992) that act on PFK. However, since fully
dephosphorylated enzyme is still active to some extent it remains unclear whether this would be
very detrimental to the organism.
1.3 A model system for species selective drug
design
From the above discussion it will be apparent that rational drug design may not yet be
attempted for parasite PFKs. Rational drug design ideally uses 3D structural information on the
target enzyme (see Section 3.1.1.1). This is not available and neither is the sequence
information that could allow model building by homology with other PFKs. Also there is no
large body of information on parasite PFK ligands that could allow ligand-based drug design
efforts (see Section 3.1.1.2).
One particular problem that arises from targeting parasite glycolysis is species-selectivity. It
would clearly be undesirable to inhibit host glycolysis if, for example, drugs were being
administered to infected humans. Rational species-specific drug design has been the focus of
little attention although a recent attempt has been made to selectively target trypanosomal triose
.phosphate isomerase (Verlinde etal., 1993). It was therefore decided to use a model PFK
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system to study methods of species-specific drug design. Any effective compounds discovered
could well be useful against other PFK species or act as lead compounds.
It was eventually decided to search for compounds that might inhibit E.coli PFK but affect
rabbit muscle PFK to a lesser degree. The choice of E.coli PFK as target was made for two
important reasons. First, the only 3D PFK structures available are those for E.coli PFK and the
homologous enzyme from B.stearothermophilus. A 3D structure is required for many of the
currently available rational drug design methods. Secondly a system enabling the great
overexpression of E.coli PFK has been established (Lau et al., 1987) and was kindly made
available by Dr. P.R. Evans (University of Cambridge). The ready availability of target enzyme
enables the testing of putative ligands by even methods requiring relatively large amounts of
protein such as C.D. Rabbit muscle enzyme was chosen also for two reasons. First, the degree
of sequence identity to E.coli PFK (39%) is sufficiently high for protein modelling by
homology to be attempted while being low enough for there to exist significant exploitable
differences in structure. Secondly, after the bacterial enzymes, RMPFK is probably the best
studied PFK. Knowledge of the properties of an enzyme is crucial if testing of putative
inhibitors is to be carried out.
A stepwise design process was envisaged. First the E.coli PFK structure would be used to
rationally design inhibitors and these would then tested on both the E.coli and the rabbit muscle
enzymes. Any differential inhibition would be explained using the E.coli PFK structure and a
model of RMPFK built by homology. The two structures would then be used to suggest
modifications that might lead to enhanced selective inhibition of the E.coli enzyme.
I shall now introduce the two chosen enzymes, concentrating more on the E.coli PFK about
which more is known and on which most of the drug design and testing efforts focussed.
1.3.1 E.coli PFK
1.3.1.1 Structure
The determined X-ray crystal structures of bacterial PFKs reveal a tetramer of identical
subunits each 319-320 amino acids in length. Each subunit consists of two domains, both of
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which contain central (1-sheet surrounded by a-helices. The tetramer is a dimer-of-dimers with
222 symmetry. Each subunit has three binding sites. The allosteric site which binds inhibitor
PEP and activator ADP is situated at the interface between subunits in each dimer. The ATP
substrate site is composed solely of residues from the large domain whereas the F6P substrate
site consists of small domain residues and two arginines from the other dimer. Fig 1.3 shows a
ribbon diagram of the E.coli PFK dimer with effector ADP molecules bound between the
subunits. Figure 1.4 shows the E.coli PFK active site with products bound (Shirakihara and
Evans, 1988). Inferences drawn from the crystal structures about possible roles of residues at
binding sites have been confirmed by site-directed mutagenesis experiments (Evans, 1992 and
references therein).
Crystal structures determined for unligated PFK (Rypniewski and Evans, 1989) or PFK in the
presence of subtrates (Evans and Hudson, 1979; Evans et al., 1981) or products (Shirakihara
and Evans, 1988) can be identified with the R-state of the Monod-Wyman-Changeux allostery
model (see below). These and a T-state structure, determined in the presence of allosteric
inhibitor (Schirmer and Evans, 1990), have enabled a molecular description of the allosteric
transition of bacterial PFK (Schirmer and Evans, 1990).
1.3.1.2 Kinetics and Regulation
The Monod-Wyman-Changeux (MWC) Model
This allostery model (Monod et al., 1965), also known as the 'concerted' or 'two-state'
model, postulates two forms of an oligomeric protein. The T (tense) state and the R (relaxed)
state are in equilibrium with the T state having lower affinity for substrates. Each type of site
has binding constants for the T and R states - K-p and K^. Allosteric activators operate by
binding to, and stabilisation of, the active R state. Conversely, allosteric inhibitors bind to and
stabilise the inactive T state. The third constant defined is L, the allosteric constant, which is the
ratio [T]/[R] for the unligated states.
E.coli PFK shows hyperbolic kinetics with respect to ATP but strongly sigmoidal kinetics for
F6P. The kinetic behaviour of E.coli PFK has been studied in detail and found to be consistent
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Fig 1.3 Ribbon diagram of the E.coli PFK dimer. The ADP molecules bound
to the allosteric sites between subunits are shown in ball-and-stick representation.
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Fig 1.4 The active site of E.coli PFK with bound products. Taken from
Shirakihara and Evans, 1988.
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with the MWC model (Blangy et al., 1968) shown in Fig 1.5a. That model was further
supported by the observation of two states by X-ray crystallography (see above). However,
recent work, mostly using fluorimetry, has demonstrated features of the behaviour of E.coli
PFK that are inconsistent with the MWC model. These data are now briefly discussed.
Complications
The fluorescence behaviour of E.coli PFK has been studied in some detail (Berger and Evans,
1991; Deville-Bonne and Garel, 1992). The later results provide a consistent framework for
understanding ligand binding, although they differ in some details from the earlier data, and are
now summarised.
Deville-Bonne and Garel studied the individual effects of substrates, F6P and ATP (and its
analog AMPPCP), and effectors, ADP and PEP. They were able to divide these into two
classes. F6P and ADP produced a similar, around 20% fluorescence decrease relative to
unligated PFK. ATP (or AMPPCP) and PEP gave an 8-10% fluorescence increase. From this
they postulate the existence of two states, high-fluorescence and low-fluorescence with the
intermediate overall fluorescence of the unligated enzyme arising from a mixture of the two.
They assign the high-fluorescence form to the T-state of the concerted model (Blangy etal.,
1968) and the low-fluorescence form to the R-state. From this an allosteric constant, L, of
around two is inferred, in good agreement with equilibrium dialysis measurements of GDP
binding (Blangy, 1971) but very different from the 4x10^ calculated from steady state
measurements of activity (Blangy et al., 1968). An L value near unity provides the explanation
for the near hyperbolicity of binding of all ligands to the unligated state. However, when the
enzyme is put predominantly in one state by the presence of a ligand from one class, binding of
-ligands from the other class becomes sigmoidal. For example, in the presence of AMPPCP or
■PEP, F6P shows npj values of around two. This is in agreement with the equilibrium dialysis
-results (Deville-Bonne and Garel, 1992) that show two F6P binding sites per PFK tetramer.
5More surprisingly, AMPPCP and PEP binding in the presence of F6P also produces npj value
-around 2 despite the demonstration by equilibrium dialysis of four binding sites for ATP per
4etramer.
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1.5 Models of E.coli PFK allostery. Lower case ligand indicates
low affinity binding. Upper case indicates high affinity.
a) the two-state, Monod-Wyman-Changeux model.








b) the four-state model of Johnson and Reinhart, 1992.
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Many of the fluorescence data are in agreement with the concerted allosteric model of Monod
etal. (1965), particularly the identification of two states and the effects on affinities of
interacting ligands. However, other data are not. In particular, njj values of only 2 are
observed for F6P binding whereas steady-state activity measurements give npj=3.8-4.0. This
suggests a kinetic, as well as a binding, aspect to F6P cooperativity. The lack of a simple
relationship between npj and number of binding sites had already been suggested by npj values
as large as 5.5-6.0 seen under some conditions (Deville-Bonne etal., 1991a).
Another recent unexpected finding is the substrate antagonism of ATP and F6P; the apparent
Km for one is decreased about 20-fold on binding of the other (Deville-Bonne et al., 1991b).
In parallel, a regulatory role was suggested for ATP after the finding, by fluorimetry, that F6P
binds with much greater affinity in the absence of ATP than in the presence of saturating ATP
(Berger and Evans, 1991). A detailed fluorescence study of ATP and F6P interaction has been
carried out (Johnson and Reinhart, 1992). The authors explained their results using a four state
model (free enzyme, enzyme saturated with F6P, enzyme saturated with ATP and the
catalytically competent ternary complex) rather than the two state MWC model. The four states
have different affinities for the two substrates and probably for effectors too. Their four-state
model is shown in Fig 1.5b. The PFK.ATP state tetramer binds its first F6P molecule weakly
but later ones increasingly tightly.
In conclusion, the MWC model provides a good approximation to many basic characteristics
of E.coli PFK but there is much evidence that it is incapable of encompassing a detailed
description of the enzyme.
1.3.2 Rabbit Muscle PFK
RMPFK has been the best studied of eukaryotic PFKs but the attention focussed on this
enzyme, and consequently our level of understanding, lag well behind E.coli PFK. One reason
for this is the paucity of available biochemical methods for its study (see Section 4.1.3). The
enzyme is also less stable than E.coli PFK and has proved impossible, so far, to crystallise.
The regulatory properties of RMPFK have been reviewed (Kemp and Foe, 1983). RMPFK
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has six binding sites. Two of these are the catalytic ATP and F6P binding sites. There are
activating allosteric sites for adenine nucleotides and sugar bisphosphates and inhibitory
allosteric sites for citrate and ATP. A three state model for allosteric transitions in RMPFK has
been proposed (Kemp and Foe, 1983). This includes two tetrameric states, one active and the
other inhibited, and an inactive dimeric state. The tertiary and quaternary structures of RMPFK
and potential locations of binding sites have been a matter for speculation (Poorman et al.,






Recent advances in DNA technology have made possible the facile determination of
nucleotide sequences. Consequently the number of protein sequences known has risen
rapidly. There are over 40,000 sequences deposited in the GenBank sequence
database. Detailed understanding of the action of proteins requires the determination of
their three-dimensional atomic structure. There are presently two ways to determine
this de novo. The n.m.r. method is still confined to relatively small proteins of fewer
than 150 residues. X-ray crystallography can be used for larger proteins but, despite
recent advances, remains a slow and laborious process. Thus despite an exponential
rise in the number of 3D protein structures deposited (Protein Databank Quarterly
Newsletter, April 1992), the number of known structures lags an increasing distance
behind the number of known sequences. This has focussed attention on prediction of
3D structure from protein sequence. Discussion of these efforts requires a brief
introduction to protein structure.
The database of known protein 3D structures has revealed the hierarchical nature of
protein structure. At the simplest level, the primary structure defines the sequence of
amino acids. The secondary structure is then defined by backbone conformation. The
three backbone torsion angles <>, y and co define rotation about the N-Ca, Ca-C and C-
N bonds respectively (see Fig 2.1a). The co angle is fixed at approximately 180° by the
planarity of the peptide bond. Some of the combinations are disallowed by steric
hindrance for non-glycine residues (Ramachandran, 1963). Of the remainder, some are
compatible with repeating structures such as helices (a, 3 ] q and polyproline-type) or p-
sheet. Such features are called secondary structure elements. When the amino acid
does not belong to one of these structures, it is said to have a random coil
conformation. The tertiary structure is defined by the packing of the secondary
structure elements. For soluble proteins, this usually produces a compact, globular
shape. The tertiary structure of a protein is sometimes called its fold. Finally,
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-iaure 2.1 : Definition of torsion angles
a) main chain angles
)) side chain angles
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quaternary structure refers to the arrangement of polypeptide protomers in an
oligomeric structure. Side chains are defined by a series of torsion angles x\-- -Xn
referring to rotation about bonds Ca-Cp, Cp-Cy etc. respectively. Figure 2.1b shows
the definition of these angles for glutamate. The 'virtual' torsion angle £ (Ca-N-C-Cp)
is sometimes used to measure Ca chirality.
For most proteins the three dimensional structure is thought to depend only on the
amino acid sequence. This assumption arises from the observation of unfolding and
refolding of isolated proteins on exposure to, and removal of, denaturants such as
GdnHCl (Kim and Baldwin, 1990). This is thought to hold true despite the discovery
of chaperonin proteins (Gething and Sambrook, 1992) which are required for folding
or assembly of some, generally large and oligomeric, proteins. Theoretically,
therefore, protein dynamics simulation should be able to determine protein structures.
However, the huge computational demands render this still impossible for proteins of
even moderate size (Abagyan, 1993).
Attempts can be made to use empirical guidelines to predict protein structure, generally
with decreasing success as the level of complexity increases. Secondary structure can
be predicted to some extent from primary structure. However, despite recent advances
such as the use of neural networks, the accuracy of assignment of alpha helix, beta
sheet or random coil remains stuck at just under 70%. The prediction of tertiary
structure is even more problematic. Recent work has demonstrated the feasibility of
determining overall protein folds if sufficient distance constraints between secondary
structure elements are known (Smith-Brown et al., 1993). Such constraints, for
example from n.m.r. or fluorescence experiments were incorporated into the energy
function used. Also included were torsion constraints from known or predicted
secondary structure, a Lennard-Jones contribution and a dihedral angle term. Monte
Carlo calculations on a polyglycine chain were used to sequentially satisfy the distance
constraints. The best final structures showed r.m.s. Ca differences of 3-5A to crystal
structures; of the order of difference between, for example, globins sharing the same
fold. However, modelling side chains, an obvious necessity for understanding of
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protein function, increases the computational demands enormously.
Hence, it is clear that at the present time all methods of prediction of protein 3D
structure de novo , even with low-resolution structural information from, for example,
CD and fluorescence, remain unsatisfactory.
2.1.1 The basis of modelling by homology
As the number of protein 3D structures determined has increased it has become clear
that rather than each protein having its own fold, there is a finite number of folds which
proteins can adopt. This has opened the way to modelling unknown protein sequences
into known folds. Where possible, this approach can be rapid and quite accurate, but
care must be taken in attributing to a new sequence a particular fold. The most obvious
indicator of a particular fold is sequence similarity with a protein adopting that fold.
The reliability of inferring shared fold from sequence similarity has been investigated
by Sander and Schneider (1991). They produced standard sequence alignments for all
proteins in a large structural database. Putting each alignment on a plot of length of
alignment against % identical residues enabled the authors to identify two zones (see
Fig 2.2). The region of safe structural homology contains essentially only sequence
alignments corresponding to good structural similarity. Short alignment lengths require
very high sequence identity whereas only >25% identity is required for alignments of
longer than 80 residues to be identified as structurally similar.
It has become clear that sequence alone is not an ideal guide to structural relatedness.
For example, distantly related globins, sharing the same fold, can show only 15%
identity, well into the 'grey zone' of 10-20% identity seen for gapped alignments of
random sequences. Function in this case would provide further evidence for structural
similarity although this is not always the case. Different classes of serine proteases
provide an example of similar function without structural similarity. Conversely, actin
and a bovine heat shock protein show very good structural agreement at low sequence
similarity (Kabsch etal., 1990). Efforts have therefore been made to provide more
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reliable indicators of structural relatedness. Three approaches have been able to predict
structural similarity in the absence of significant sequence similarity for various test
cases. Bowie etal. (1991) first calculate environments (including consideration of
secondary structure, buried side chain area, % polar buried area) for residues in all
known protein structures. A table is also compiled indicating the relative probabilities
of finding each residue in each environment. Alignment of the unknown with all
known 3D protein structures is then carried out to maximise a score relating to the
favourability of finding the unknown's residues in the environments of the database
protein. High scores indicate structural similarity. Jones etal. (1992) calculate
energies for various 'threadings' of the unknown sequence onto known structures in
three dimensions. This energy has two components, interaction potentials for each
residue pair and a solvation potential. Expressions for these potentials are derived from
database analysis. In most cases, threadings of sequences onto structures known to be
related gave energy scores at the extreme lower end of the range observed for the whole
database. Godzik et al. (1992) generate a 'structural fingerprint' for each protein in a
structural library. This contains information on solvent exposure, pairwise interactions
and triplet interactions. Again the energy parameters derive from database analysis.
Low energy threadings from an initial approximate assessment are subject to a more
detailed modelling. A protein lattice model is generated and a Monte Carlo
rearrangement regime applied. The two important consequences of this procedure are a
more accurate energy measurement and an indication of the stability of the model.
If structural relatedness is convincingly suggested by the above analysis then
modelling by homology can be confidently attempted. The methods available for this
are discussed in the following section.
2.1.2 Approaches to modelling by homology
A consensus approach has emerged from the work of a many groups. Here modelling
by homology is a sequential process as shown in Fig 2.3. Most of the process can be
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automated, the best known of these programs being COMPOSER (Blundell et al.,
1988). A different approach has been taken by Havel and Snow (1991) which will be
discussed later.
I shall now consider the various steps of the consensus method in turn.
2.1.2.1 Alignment
The method of alignment to use depends on whether or not multiple homologous
structures are available.
When only a single structure is available then it is used to modify a standard (multiple)
alignment produced by a program such as CLUSTAL (Higgins and Sharp, 1988).
Alterations are made to place insertions and deletions preferentially at the surface
between secondary structure elements (Barton and Sternberg, 1987) and in order to
avoid disturbance of the hydrophobic core (Kanaoka et al., 1989). This has been
shown to improve the quality of alignments.
When multiple structures are available then the first step is a structural alignment
carried out to minimise inter-Ca distances between residues that correspond in the
different structures. From this alignment Structurally Conserved Regions (SCRs),
defined as stretches of topologically equivalent residues having inter-Ca distance of
less than 3A, can be identified. A sequence alignment with the unknown protein is then
carried out incorporating this information to avoid placing insertions and deletions in
SCRs.
2.1.2.2 Framework
A framework can only be determined when multiple homologous structures are
available. Where only one structure has been determined then the main chain of this is
used as the basis of the model.
A framework derives from the multiple structural alignment determined above
(Sutcliffe et al., 1987a). SCRs for the unknown are constructed using SCRs of
homologous proteins. Previously this has been by either choosing the SCR with most
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sequence identity to the unknown or by using a mean Ca position at each topologically
equivalent position. Recently, superior results have been obtained using a weighted
average Ca position (Srinivasan and Blundell, 1993). The contribution of Ca atoms in
different SCRs is weighted either by sequence similarity to the unknown or the square
of the sequence similarity. Particularly large improvements in results are seen where
several distinct homologous structures are known that are equally related to the
unknown.
2.1.2.3 Structurally Variable Regions (SVRs), Insertions and Deletions
SVRs are the regions between the SCRs in the structural alignment described above.
They are the sites of any insertions and deletions but do not necessarily contain either.
Where no insertion or deletion is present then the SVR used in the model of the
unknown is chosen from the homologous set on the basis of best fit to the end of the
SCRs and steric interactions (Topham etal., 1990).
Various approaches have been developed for modelling insertions and deletions.
The most popular method for shorter loops is the database search. Polypeptide
segments from the database of known protein structures, both homologous and non¬
homologous, are scanned to find those that can closely match 'anchor' atoms on either
side of the insertion or deletion. This approach was first suggested by Jones and
Thirup (1986). The most significant advance since then has been the development of a
protocol to include energy assessment of the loop candidates (Summers and Karplus,
1990). Sequence similarity between the database loop and the unknown region of the
model has sometimes been used in loop selection although the work of Sternberg and
Islam (1990) shows that similar sequences can adopt very different conformations.
More valid is the use of environmental amino acid substitution tables to rank loop
candidates (Topham etal., 1993). An analysis of 33 homologous protein families was
used to assess the probability of substitution of one residue type with another in various
environments. The environment definition included main chain conformation, side
chain accessibility and side chain involvement in H-bonds. This analysis takes
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account of the special conformational characteristics of glycines and prolines. When
such analysis is unavailable these residues require special treatment. Glycines in
candidate loops should be examined carefully since they can adopt backbone
conformations not accessible to other amino acids. Prolines in the sequence to be
modelled require special consideration since they can only adopt certain backbone
conformations and influence the conformation of preceding residues (MacArthur and
Thornton, 1991).
Database searches can fail to produce good loop candidates, particularly if the region
to be modelled is large or contains residues that adopt unusual conformations. A more
successful approach in these cases can be generation of loops with random backbone
torsion angles which may then be assessed sterically and energetically. This approach
was first used for the prediction of antibody hypervariable loop conformations (Fine et
al., 1986). Care must be taken with such results since commonly available
implementations (such as present in SYBYL and INSIGHT) choose <J) and y angles
completely at random. In contrast, non-glycine amino acids are known to show strong
preferences due to steric clashes between side chains and main chain in some
conformations.
A third early approach to loop modelling has failed to gain favour. Moult and James
(1986) used a systematic search procedure, intended to sample all possible main chain
and side chain loop conformations, to model five-residue segments of a protease.
Filters, such as avoidance of clashes, low electrostatic energy and low exposed
hydrophobic surface area, were used to eliminate as many as possible of the huge
number of candidate loops. Reasonable results were obtained but this approach is very
demanding of computer time. Equally good results can be obtained with the quicker
database loop search method for loops of this size.
2.1.2.4 Side Chains
There are two situations that may apply to a residue of the model whose side chain is
to be constructed. In the first, side chains at equivalent positions in homologous
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structures are of similar or greater size to the side chain to be modelled. In this case
rules determined for substitution of homologous side chains (see below) can be
applied. In the other case, less information is available. For example, the residue may
be part of a non-homologous loop or may be the result of a mutation from Gly in
homologous structures. In such instances, typical side chain conformations are
modelled.
Analyses of amino acid substitutions in homologous proteins (Sutcliffe etal., 1987b;
Summers et al., 1987) have discovered the general rule that the replacement side chain
adopts a conformation such that it occupies as much of the space occupied by the
original side chain as possible. Chemical nature is also considered so that a Thr would
be modelled onto a Ser by overlay of the hydroxyls. In most cases this is implemented
by transfer of corresponding side chain torsion angles. Several special cases have been
discovered (Summers et al., 1987). An example is the case of aromatic angles
which are most commonly ±90°. These are not equivalent for Trp so that both possible
conformations should be considered.
The most commonly observed side chain conformations can be used when no
information is available from homologous structures. These have been analysed by
Sutcliffe etal. (1987b) and in more detail by Dunbrack and Karplus (1993).
Methods have been developed for the completely automatic addition of side chains to a
given main chain without reference to homologous proteins. A simulated annealing
method to optimise packing has been produced (Lee and Subbiah, 1991). Two groups
have used rotamer libraries for initial placement followed by iterative energy-
minimising refinement to model side chains (Wilson et al., 1993; Dunbrack and
Karplus, 1993). These methods are much more computer-intensive than rule-based
modelling and it remains to be seen whether they can produce superior results.
2.1.2.5 The distance geometry approach
A very different approach to modelling by homology to that described above has been
described (Havel and Snow, 1991). Their first step is the multiple alignment of
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homologous sequences. A subset of atoms is then defined consisting of Ca and Cy
atoms of residues that are identical in all sequences. Distance constraints applying to
the unknown structure are deduced from interatomic distances within this subset.
Additional distance constraints are deduced from conserved H-bonds and disulphide
bridges. Volume constraints from consecutive Ca positions are also determined in
order to ensure the appearance of conserved secondary structure elements in the models
of the unknown protein. Chirality constraints are also applicable from the knowledge
that all amino acids are of the L chirality. All of these constraints are used as input to
the DISGEO program (Havel and Wiithrich, 1984). This produces sets of structures
that satisfy the constraints in a way directly analogous to structure determination by
n.m.r. Advantages of this method are first its efficiency in terms of requirement for
human input and computer time. Secondly, multiple structures are usually produced
with the differences between them providing some indication of the reliability and
precision of the predictions. Failure of the method is informative too since it indicates
contradictions in the assumptions made in generating the constraints.
Performance seems to be worse than that of COMPOSER. In a test COMPOSER was
used to build a phospholipase structure from three homologous structures of 40-50%
identity (Srinivasan and Blundell, 1993). A comparable task was set for the DISGEO
method - build a trypsin inhibitor from two homologous structures, again of 40-50%
identity (Havel and Snow, 1991). Comparison of model with known structure gives an
r.m.s. deviation between Ca atoms of 1.56A for the COMPOSER model and 3.88A for
the DISGEO model. While remembering that these are distinct tasks, such a large
difference in overall result suggests that the DISGEO method performs significantly
worse.
There are many obvious improvements that could be made to the distance geometry
method such as incorporation of side chain rotamer preferences, but it remains to be
seen whether the method can perform as well as the established COMPOSER approach.
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2.1.3. Testing of modelling results
Many methods have been devised for testing the validity of protein models built by
homology and other methods. They can be divided into two classes. The first
compares stereochemical parameters such as bond lengths and angles with typical
values obtained from structures determined by crystallography or nuclear magnetic
resonance spectroscopy. The second class looks at the environments of amino acids,
particularly in relation to solvent or the hydrophobic protein core. Again expected
distributions are determined from the database of known structures. Where available,
biochemical information such as susceptibilty to proteolysis or chemical modification
can also be checked against the model.
2.1.3.1 Stereochemical checks
A detailed study of the stereochemistry of main and side chains of proteins from the
Brookhaven Protein Structure Databank (Bernstein etal., 1977) has recently been
published (Morris et al., 1992). The most important indicators of good structure were
found to be the main chain torsion angles <(> and y, the main chain hydrogen bond
energies and the first side chain torsion angle x\- A clear correlation was seen between
these properties and the resolution of the X-ray structures. Other properties such as
peptide bond planarity and disulphide bond angles were also studied.
The restrictions placed on the main chain dihedral angles of a protein, <|> and y, by the
presence of side chains, were first recognised by Ramachandran et al. (1963). Plots of
<)> against y for the whole protein database show pronounced clustering around values
for regular secondary structures - alpha helix, beta sheet and to a lesser extent left-
handed alpha helix. These plots can be digitised into zones by the degree to which they
are populated. Good protein structures may then be expected to densely populate the
most favoured regions of <f>,y space with few non-glycine residues in the sparsely-
populated 'disallowed' regions.
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Values for the side chain dihedral angle % i were found to cluster around three preferred
conformers g" (+60°), t (+180°) and g+ (-60°). The extent of clustering provides an
indication of the quality of the structure and outlying points should be treated as
suspicious.
The distribution of hydrogen bond energies calculated for backbone atoms was also
studied. It was found that the better, higher-resolution structures showed a tighter
distribution of energies around the mean so that this distribution too can be used as a
protein quality indicator.
A suite of programs (PROCHECK) has been written to check protein stereochemical
quality using such indicators (Laskowski etal., 1993).
2.1.3.2 PROFILE
The PROFILE program tests protein structures by assessing how well each amino
acid is suited to the environment in which it is placed.
Eighteen environment classes were defined on the basis of side chain polarity and area
buried (six classes) and secondary structure - alpha helix, beta sheet or other. (Bowie
et al., 1991). A database of sixteen protein structures and sets of homologous
sequences were used to determine the probabilities of finding each amino acid type in a
particular environment. A table was then produced containing entries for each residue
in each environment. Each entry was a score calculated from the probability of finding
a residue in a particular environment and the probability of finding that residue in any
environment. Charged residues in exposed environments, for example, consequently
score highly.
Used as a way of testing protein models (Liithy et al., 1992) PROFILE produces two
results. An overall score for a model can be calculated by adding the residue scores.
Typical values for proteins of different sizes have been determined with which the
model value can be compared. Mean scores can also be calculated over a running
window of a given length. Profile window plots can be used to localise probable
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defects in the protein model.
The program was tested on proteins from the Brookhaven Protein Data Bank
(Bernstein et al., 1977) and also on a series of deliberately misfolded structures and
early models later shown to be incorrect. Most incorrect models were identified by low
overall score. An incorrect ras p21 structure was subjected to profile window analysis
and the program shown to be capable of localising the known errors in the structure.
2.1.3.3 Other methods
Solvent Free Energy (S.F.E.) of folding was one of the earliest discriminators of
correct and incorrect protein models. Atomic solvation parameters for atom types
found in side chains were calculated by least squares fit to observed distribution data
relating to transfer of residues from octanol to water (Eisenberg and McLachlan, 1986).
These can be used, along with solvent accessible atom areas, to calculate S.F.E.s for
folded, misfolded and hypothetical unfolded states of a protein. The S.F.E.s of folding
of correct and incorrect protein structures enabled their easy discrimination. Later work
with a large database demonstrated a strong linear relationship between S.F.E. of
folding and protein length (Chiche et al., 1990).
Potentials of mean force (P.M.F.s) have been widely used to assess protein model
validity. P.M.F.s are calculated from the relative probabilities of finding atoms (C(5
atoms are commonly used) at a certain separation, by the inverse Boltzmann law. A
large dataset is used to derive the P.M.F.s which may then be used to calculate energies
for protein models. One such study (Hendlich etal., 1990) calculated potentials able to
discriminate consistently between correct and incorrect models, excepting only proteins
with prosthetic groups and non-globular proteins. Another study concentrating solely
on hydrophobic interactions was also capable of good discrimination (Casari and Sippl,
1992).
Better results have been produced by an approach in which contact potentials are
derived to discriminate best between a correct structure and a set of incorrect ones
(Maiorov and Crippen, 1992). Here three types of contacts were considered - side-
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chain-side chain, side chain-main chain and main chain-main chain, in contrast with
previous emphasis only on side chains (Hendlich etal., 1990). A linear relationship
was seen between contact energies of native structures and their length.
Holm and Sander (1992) use an approach similar to that used in PROFILE, focussing
on the favourability of the potential protein-solvent interactions present in a protein
structure. The differences are the consideration of different atom types within side
chains and the ignoring of secondary structure. Like PROFILE, their approach was
able to discriminate between correct and incorrect models by overall score and to give
an indication of the positions of poor regions of the model.
2.1.4 The structure of Rabbit Muscle PFK
The only 3D structural information available on RMPFK has come from sedimentation
studies and electron microscopy (Hesterberg etal., 1981). This established that the
active form of RMPFK was a tetramer with the individual subunits of 4 x 6 x 6 nm in
size arranged with D<? symmetry. With this knowledge and the recognition of internal
duplication in the RMPFK sequence Poorman et al. (1984) were able to speculate first
on the spatial arrangement of RMPFK protomers in the tetramer and then about
possible effector sites.
The N- and C-termini of adjacent subunits in the bacterial PFK structure are close
enough to be joined by the connecting peptide of about 30 residues that joins the N- and
C-terminal halves of the rabbit muscle enzyme. Given the dimer-of-dimers structure of
the bacterial enzyme there are two ways in which this could happen. The arrangement
preferred on packing grounds puts the larger interface containing the C sites between
N- and C-terminal RMPFK halves. This arrangement also puts the sites for the
cooperative substrate F6P between subunits. Two of these rabbit muscle protomers are
then equivalent to the bacterial tetramer. The quaternary structures of bacterial tetramer
and proposed rabbit muscle dimer are shown in Fig 2.4. In the rabbit enzyme one
protomer is shaded and one unshaded with the thick lines representing the connecting
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cterial PFK tetramer Rabbit Muscle PFK dimer
-re 2.4 : Quaternary structure of bacterial PFK tetramer and
predicted quaternary structure of rabbit muscle PFK dimer
See text for details.
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peptides. Beneath are two views of the rabbit muscle dimer showing A and A' sites
between protomers and C and C' sites within protomers. Generating a RMPFK
tetramer with D-? symmetry from two such dimers could be done in two ways, placing
all or none of the connecting peptides at the inter-dimer interface (see Fig 2.5).
Poorman et al. favoured an interface position for the connecting peptides since they are
susceptible to few proteases where as limit digestion with subtilisin degrades the N-
termini which are exposed in this arrangement.
From sequence comparisons Poorman et al. propose ligands for the mutated binding
sites of RMPFK. These they label A, B, C (in the N-terminal half) and A', B', C' (C-
terminal half) by analogy with the A, B, C sites defined for the bacterial enzyme.
Based on the conservation of the catalytic Serl27 in site A and its replacement by Ser in
site A' they suggest A is the F6P substrate binding site. They propose A' as the sugar
bisphosphate activating site since the Asp to Ser change would cause less repulsion of
the second phosphate group. They suggest C is the ADP activation site and C' the ATP
inhibitory site, rather than the reverse. This is because limit subtilisin digestion, which
removes some N-terminal residues abolishes inhibitory ATP binding but not activating
ADP binding. In the hypothetical RMPFK tetramer arrangement N-terminal residues
contribute to the C' site whereas the C site is composed of residues central in the
sequence. The assumption is made that site B remains the substrate ATP site but no
speculation is made about the role of site B'.
2.2 Methods
2.2.1 Modelling
Two models of rabbit muscle phosphofructokinase were produced. In each case the
N-terminal and C-terminal halves (which both show homology to bacterial PFKs - see
introduction) were modelled separately. They were then combined to produce RMPFK
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giaure 2.5 : The two possible RMPFK tetramers
with D2 symmetry
a) all connecting peptides together
b) connecting peptides apart
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dimers of the kind postulated by Poorman etal. (1984).
The earlier model was produced largely by manual modelling. Later the program
INSIGHT (INSIGHT II User Guide, 1992) became available including facilities for
more automatic modelling. The second model was produced with as little intervention
as possible so that a comparison of the two approaches could be made. The two
models will be referred to as the manual model and the INSIGHT model.
The X-ray crystallographic structures of B.stearothermophilus PFK (Evans etal.,
1981) and E.coli PFK (Shirakihara and Evans, 1988) were used as the basis for the
modelling. Both of these structures show PFK in the R-state, the former bound to
phosphate, the latter bound to allosteric activator ADP and reaction products ADP and
F16BP. These structures are very similar (Shirakihara and Evans, 1988) and show
equal sequence similarities with rabbit muscle and other mammalian PFKs.
A model of the C' site was built from T-state coordinates of B.stearothermophilus PFK
bound to inhibitor phosphoglycollate (Schirmer and Evans, 1990).
2.2.1.1 Validation of modelling by homology
The programs of Bowie et al. (1991) were used to check that the RMPFK N- and C-
terminal halves were likely to adopt the fold of the bacterial PFKs. ENVIRONMENT
calculated environments for residues of the E.coli PFK crystal structure bound to
products using the secondary structure assignment produced by DSSP (Kabsch and
Sander, 1988). PROFILESEARCH then scanned the supplied sequence database, to
which PFK sequences had been added, for sequences likely to adopt the E.coli PFK
fold. A gap opening penalty of 5 and a gap extension penalty of 0.35 were used.
2.2.1.2 Alignment
A published alignment (Lee etal., 1987) was used as a basis for the manual model
alignments. An alignment produced using CLUSTAL differed in positioning of some
insertions and deletions. The bacterial crystal structure was used to guide the choice.
The alternative which placed the insertion or deletion on the protein surface between
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secondary structure elements was chosen. This has been shown to improve the quality
of alignments when tested on homologous proteins the structures for which are known
(Barton and Sternberg, 1987). Alignments can also be improved by avoiding
disruption of the protein core (Kanaoka et al., 1989). In this case the hydrophobic core
was found to coincide with secondary structure elements and so provided no extra
information. The alignments used for manual modelling are shown in Figs 2.6 and
2.7.
The INSIGHT model alignments were produced using commands in the
HOMOLOGY module. A structural comparison of tht B .stearothermophilus and
E.coli PFK structures produced an alignment containing eight structurally conserved
regions (SCRs). The N- and C- terminal halves of the rabbit muscle enzyme were then
aligned using a standard algorithm, but including SCR information. The RM N-
terminal alignment used is shown in Fig 2.6. The automatic alignment produced for the
RM C-terminal half was extremely poor. The alignment from the manual model was
therefore used modified slightly to take into account SCR information. This is shown
in Fig 2.7.
2.2.1.3 Backbone
Given the close similarity of the B.stearothermophilus and E.coli PFK structures, the
choice of backbone to use for modelling was arbitrary. The B.stearothermophilus
structure was used.
The option to use an average structure over SCR regions for the INSIGHT model was
unavailable so the B.stearothermophilus structure was again arbitrarily chosen.
2.2.1.4 Side Chains
For the manual models, the starting B.stearothermophilus side chains were mutated to
the RM side chains using SYBYL. They were then adjusted manually according to the
rules of Summers and Karplus (1989) using the homologous conformations in both
B.stearothermophilus and E.coli structures. Where no guidance could be obtained
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from these structures, the most common side chain conformation for the relevant
secondary structure (Sutcliffe, 1987b) was generated. A SYBYL macro written for this
purpose is listed in Appendix 1. Further manual adjustments were made to alleviate
any clashes with main chain atoms or previously-positioned side chains.
The side chain conformations of the INSIGHT models were generated completely
automatically. They were transferred from the B.stearothermophilus structure when
identical. Where a mutation was to be made the program transfers as many dihedral
angles as are available and produces an extended conformation for the remainder. No
account was taken of the side chain conformations of homologous residues in the
E.coli structure.
2.2.1.5 Loops
Insertions and deletions in the manual models were generated by two different
methods - a database loop search algorithm and random generation. The basic loop
search algorithm of SYBYL was greatly extended using three macro programs. These
aimed to reproduce as far as possible the approach of Summers and Karplus (1990) and
are listed in Appendix 2.
The first stage of this method involves a standard loop search using SYBYL. Both N-
and C-terminal anchors are three residues in length and only the Ca atoms are used in
the search. The loops showing the best fit to the anchors were then considered in three
further tests (Summers and Karplus, 1990). The first of these tests whether the loop
can be deformed, under constrained energy minimisation, to closely fit the anchors.
Loops passing this test were then subject to two further tests. After further energy
minimisation in the field of the protein the energy per residue of the loop and the energy
consequence of loop insertion were measured. Loops passing these tests were
inspected visually to check for favourable disposition of side chains in relation to
solvent. If no suitable candidates were found for a given anchor pair then the anchors
were iteratively shifted and the procedure repeated (Summers and Karplus, 1990).
If this loop search method failed then a random generation method was employed.
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The S YBYL TWEAK command was used to generate a large number of loops with
randomly chosen <j) and y angles which fitted anchors on either side of the
insertion/deletion site. Loops with main chain torsion angles mostly in favourable areas
of the Ramachandran plot were considered. In cases where the loop contained one or
more Pro residues then favoured Pro torsion angles were required giving greater
selectivity. When a particular type of turn was strongly predicted (Wilmot and
Thornton, 1988) then loops containing corresponding torsion angles were favoured.
For the INSIGHT models, all insertions and deletions were modelled using randomly
generated loops. Loops closely fitting the anchors were judged visually for solvent
exposure of side chains.
2.2.1.6 Energy minimisation of models
Each of the four models was subjected to 200 rounds of energy minimisation in
vacuo using XPLOR. A simulated annealing procedure was then carried out consisting
of lps of molecular dynamics simulation at 600K followed by cooling to 300K over
0.6ps. A further 200 rounds of energy minimisation was then applied to each.
2.2.1.7 Modelling dimers
The RM PFK dimers were constructed by fitting models for the N- and C-terminal
halves over the monomers of the tetrameric bacterial enzyme. Atoms used in this fit
were the Ca atoms of residues defined as active site or allosteric site in the bacterial
enzyme crystal structure (Shirakihara and Evans, 1988) and the Ca atoms of
homologous residues in RM N- and C-terminal halves. No attempt was made to model
the interfaces in detail since the uncertainty in relative positioning was so great. For the
same reason a model of the RM PFK tetramer was not produced.
2.2.1.8 Modelling the T-state C' site with citrate bound.
This model was constructed by mutating side chains of the C site into the
corresponding RMPFK residues (Shirakihara and Evans, 1988). The rules for side
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chain conformations were as above. Low energy conformations for citrate were
investigated using SYBYL's SEARCH command with electrostatics included using
charges assigned by the method of Gasteiger and Marsali (1980). Among the 12
lowest energy conformations there were two groups of three, the members of each
differing only in rotation of the hydroxyl group. Visual inspection showed that these
two groups had carboxylates in similar positions. One of these conformations was
used for subsequent docking. The citrate was initially positioned in the model so two
of its carboxylates were in favourable GRID carboxylate energy contours of about -5
kcal/mol. The GRID program (Goodford, 1985; Boobbyer etal., 1989) was used
extensively for ligand modelling (Chapter 3) and will be discussed there. The DOCK
command of SYBYL was then used (again with Gasteiger and Marsali charges) to
search for lower energy positions. This command provides a continual approximation
of the docking energy which was minimised by manual rotation and translation of the
citrate. This involved movement of the citrate further into the pocket towards Arg21
and enabled relief of a bad contact between one carboxylate and Arg25. The structure
was then energy minimised using SYBYL's ANNEAL command centred on citrate and
with 'Hot' and 'Interesting' radii of 4 and 6A respectively. Inspection of the minimised
structure showed that relocation of Argl54 would place it favourably close to the citrate
carboxylates. After this adjustment the structure was again energy minimised during
which Argl54 and the citrate moved closer together. The final result showed Argl54
salt bridged to the citrate.
2.2.2 Testing
2.2.2.1 PROCHECK
The PROCHECK program was run on each of the four models and for comparison
on the B.stearothermophilus PFK structure upon which the models were built. The
resolution parameter required by the program was set to 2.4A as the resolution to which
the B.stearothermophilus PFK structure was determined.
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2.2.2.2 PROFILE
The PROFILE program was run on each of the four models. The models were
present in the context of the other RMPFK halves which they contact in the RMPFK
dimer model. This was shown to improve their scores compared to the isolated model
presumably by taking into account burial of hydrophobic residues at the interfaces
between RMPFK halves. PROFILE requires a secondary structure definition which
was generated for each model using DSSP.
2.2.2.3 Others
The RMPFK dimer model was checked visually for consistency with biochemical data
from chemical modification with iodoacetate (Latshaw et al. 1987), pyridoxal
phosphate (Kemp et al., 1987) and p»-fluorosulphonylbenzoyl-5 '-adenosine (Weng et
al., 1980) and proteolysis by V8 protease (Valaitis et al., 1987).
2.3 Results and Discussion
2.3.1 Construction of the models
The 3D profile programs of Bowie et al. (1991) showed that the N- and C-terminal
halfs of RMPFK are very likely to adopt the fold of the bacterial PFKs. The output of
the PROFILESEARCH program is shown in Fig 2.8. A line has been added between
those sequences very likely to adopt the fold (those with a Zscore over 8 according to
the authors) and those unlikely to adopt the fold. The bacterial enzymes score very
highly as expected, but in addition, both halfs of RMPFK score over 8, the N-terminal
half 18 and the C-terminal half 8.5. These results justify the use of the bacterial PFK
fold for modelling of RMPFK by homology. The sequences of the known
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Fig2.8 Result of PROFILESEARCH using E.coli PFK
Name ZScore Score Length Documentation ..
X0005 + 62.50 134.85 320. ESCHERICHIA COLI PFK
X0004 + 52.56 115.33 319. B.STEAROTHERMOPHILUS PFK
X0006 + 18.17 48.49 403. RABBIT MUSCLE PFK N-TERMINAL HALF
X0002 + 10.19 32.88 615. PPi-DEPENDENT PFK FROM POTATO TUBER - ISOZYME A
X0003 + 10.04 32.51 512. PPi-DEPENDENT PFK FROM POTATO TUBER - ISOZYME B
X0007 + 8.57 29.34 377. RABBIT MUSCLE PFK C-TERMINAL HALF
A02506 + 3.17 16.45 153. Sperm Whale myoglobin
C8HUB + 3.04 18.60 1565. Complement component C8 beta chain precursor - Hina
MYWHC + 2.64 15.52 153. Jfyoglobin - California gray whale
MYWHL + 2.25 14.83 153. Myoglobin - Killer whale
HUMMHSP7 0F_1 + 2.21 11.12 65. MHC heat shock protein HSP70-2 (AA at 1) 0/0
JWEBT + 2.19 15.46 190. DNA-invertase - Salmonella sp.
FEAH + 1.90 12.36 96. Ferredoxin - Aphanothece sacrum
GNNYH2 + 1.90 16.31 1895. Genome polyprotein - Rhinovirus 2
ODUTMB + 1.87 16.25 804. Cytochrome-c oxidase (EC 1.9.3.1) polypeptide I — T
HUMFIXH 1 + 1.85 12.54 102. Hemophilic factor IX, exon 8 (AA at 1) /ncmgen—'"F9"
HUMFMSB 1 + 1.81 9.73 52. Fms protein, exon 2 (AA 277 at 58) 0/0
KIHUG + 1.78 15.97 417. Phosphoglycerate kinase (EC 2.7.2.3) - Hunan and ho
Myoglobin - BovineMYBO + 1.72 13.91 153.
MYHH + 1.63 13.75 153. Myoglobin - Western European hedgehog
MNIV2 + 1.49 12.66 121. Nonstructural protein NS2 - Influenza A virus (stra
WJFFBX + 1.46 10.65 74. Ultrabithorax homeotic protein - Fruit fly (fragmen
SYECVT + 1.46 15.42 696. Valine—tRNA ligase (EC 6.1.1.9) - Escherichia coli
DROEGFRD 1 + 1.44 15.40 1071. Pre-epidermal growth factor receptor, exon 3 {AA at
B26147 + 1.39 14.49 232. Egg-laying hormone-2 precursor — Little sea hare (f
TARHBG 1 + 1.36 13.17 148. Gamma-globin, exon 1 gamma-globin, exon 2 gamma-glo
FENM2M + 1.36 11.62 98. Ferredoxin II - Nostoc muscorum
HAMQR + 1.35 12.99 141. Hemoglobin alpha chain - Rhesus macaque and Japanes
X0001 + 1.33 15.05 403. PPi-DEPENDENT PFK FROM PROPRIONIBACTERIUM
HUMBHRPA 1 + 1.32 9.07 51. Basic histidine-rich protein precursor /nomgen—"HRG
HJECD2 + 1.31 15.13 788. Helicase II (EC 3.6.1.-) - Escherichia coli
A26147 + 1.30 14.54 263. Egg-laying hormone-1 precursor - Little sea hare
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pyrophosphate-dependent PFKs from potato tuber and Propionibacterium
freudenreichii were also included. There has been debate over whether these enzymes
are evolutionarily related to the ATP-dependent PFKs. The results in Fig 2.8 strongly
suggest that the potato enzymes share the same fold as the ATP-dependent PFKs and
are therefore likely the result of divergent evolution. The Propionibacterium enzyme,
in contrast, scores very poorly suggesting that it has a different fold and is not
evolutionarily related.
Few problems were encountered in applying the side chain subsitution rules of
Summers etal. (1987) during construction of the manual models. Small manual
alterations were sufficient to avoid clashes in the cores of the models. Figure 2.9
shows the backbones of the manual models with the B .stearothermophilus PFK
structure on which they were based. The loops are labelled, with numbering as in
Table 2.1, and coloured red (modelled) and magenta (unmodelled). N- and C-termini
are also labelled and are coloured blue.
Application of the database loop search algorithm was more problematic in some cases
than in others. Table 2.1 shows the modelled and unmodelled insertions. The length
values are positive for insertions and negative for deletions. The source of the fragment
used is shown as the Brookhaven code in brackets. The number of iterations of the
search algorithm required before a loop was selected varied from 3 to 11, with a mean
around 5. Loops that passed the tests describe in Methods were assessed visually for
general packing, exposure of charged side chains and burial of hydrophobic side
chains. In the case of C-terminal half insertion 3 there was a special requirement that
the salt bridge to the 6-phosphate of bound sugar bisphosphate be preserved. This is
provided by Argl62 in the bacterial enzyme. A successful loop search provided a
subtilisin segment that placed RMC Argl62 in a suitable position to form the salt
bridge. This insertion is shown in Fig 2.10. The failure of the loop search algorithm
to provide suitable candidates for the seven-residue insertions was expected since these
are at the upper length limit of the method's capabilities. Modelling of the 15- and 23-
residue insertions was not attempted. The algorithm's failure with the four-residue
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Table 2.1: Modelling of insertions and deletions
Manual Model :N-terminal half
No. Residue preceding Length Modelled?
1 Gly61 2 yes
2 Trp132 23 no
3 Glu232 3 yes
4 Gly265 7 no
5 Asp330 3 yes
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Fig 2.9 Main chain atoms of E.coli PFK crystal structure,
Fig 2.10 Manual C-terminal half model - insertion 3
INSIGHT C-terminal model - insertion 2Fig 2.11
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insertion of the C-terminal half was unexpected. INSIGHT provided a randomly
generated loop candidate for this position in the INSIGHT model, but this performed
poorly in tests (see below). Insertion 3 of N-terminal half was also not satisfactorily
modelled by the loop search algorithm. This contains the sequence PPDDN.
Application of the B turn analysis of Wilmot and Thornton (1988) suggested that a type
I turn was likely here, more probably at the sequence PPDD. The conformations
adopted by prolines and their effect on preceding residues (MacArthur and Thornton,
1991) provided backbone torsion angle constraints which were applied to a set of 100
randomly generated loops from SYBYL's TWEAK command. Candidates with
approximately correct backbone torsion angles were assessed visually as above and the
best candidate chosen.
Randomly generated loops for the INSIGHT models were again chosen for good
packing and solvent exposure. In addition a high percentage of residues with
favourable backbone torsion angles was looked for. This method was able to produce
models for seven-residue insertions. That in the C-terminal half appears well modelled
(see Fig 2.11), burying both Phe96 and Tyr99 and exposing Glu97 to solvent.
2.3.2 Testing
The models were checked for stereochemistry and good solvent exposure using
PROCHECK and PROFILE respectively. They were then checked for consistency
with biochemical knowledge of the enzyme, both of its ligands and of its susceptibility
to chemical modification and proteolysis.
2.3.2.1 PROCHECK
The PROCHECK program was used to compare main chain and side chain parameters
of the models with those expected for good protein structures.
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Overall quality
The Ramachandran plots for the manual and INSIGHT models of the RMPFK N- and
C-terminal halfs are shown in Figs 2.12 - 2.15. For comparison Fig 2.16 shows the
Ramachandran plot for the B.stearothermophilus X-ray crystal structure on which the
models were based. For consistency the crystal structure was subject to the same
energy minimisation and molecular dynamics regime as the models.
On the Ramachandran plots the regions are defined by the analysis of Morris et al.
(1992). The darkest regions correspond to core alpha, beta and left-handed alpha
regions. These are labelled A, B and L. Lighter regions labelled a, b, 1 and p
correspond to allowed alpha, beta, left-handed alpha and epsilon. Lighter still are the
generously allowed alpha, beta, left-handed alpha and epsilon (~a, ~b, ~1, ~p). The
lightest coloured regions are disallowed. The percentage of residues in the core regions
was found to be a good indicator of stereochemical quality with good models at
resolution <2.0A, R factor <20% expected to have at least 90% of residues here.
Table 2.2 summarises the distribution of residues in the models and crystal structure
between these regions. This shows that the manual models, by this criterion, are of
better stereochemical quality than those generated by INSIGHT. The manual models
are comparable to the crystal structure after the molecular dynamics procedure.
Other main chain parameters are summarised by PROFILE in terms of number of
band widths from the mean expected for a particular resolution of structure. Where the
particular value is within one band width of the mean a structure is rated as Better or
Worse. Outside one band width the ratings BETTER or WORSE are given.
Table 2.3 shows these results for the model structures and the crystal structure. The
parameters for bad contacts, zeta angles and H-bond energies are good for all models.
The ratings for % residues in core regions confirm the superiority of the manual models
over the INSIGHT models in this respect. The omega angles parameter is poor for all
models and also, unexpectedly for the crystal structure after minimisation and molecular
dynamics. When PROCHECK was run on the original crystal structure, a rating for

































Table 2.2 Percentage distribution of residues in models
Manual Manual Insight Insight Crystal
Model N Model C Model N Model C
'Residues in
■most favoured 81.9 82.9 67.4 69.8 81.1
regions (A,B,L)
Residues in
allowed 14.6 12.6 23.6 24.8 16.7
■egions (a,b,l,p)
Residues in
generously allowed 1.4 3.7 6.2 2.7 1.1
egions (~a,~b,~l,~p)
Residues in
disallowed regions 2.1 0.7 2.9 2.7 1.1
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Table 2.3 Main chain parameters for model and crystal
structures.
Manual Manual Insight Insight Crystal











Better Better Better Better Better
leta angle
^t.dev.
Better Better Better Better Better
H-bond energy
it.dev.
Better BETTER BETTER Better Better
"able 2.4 Side chain parameters for model and crystal
structures.
Manual Manual Insight Insight Crystal
Model N Model C Model N ModeIC
hi-1 gauche
linus st. dev.
Better Better Better Better BETTER
hi-1 trans
. dev.
Better Better Better Better BETTER
—hi-1 gauche
—us st. dev.
Better BETTER BETTER BETTER Better
—hi-1 pooled
. dev.
Better Better Better Better BETTER
ii-2 trans
dev.
BETTER Better Better Better Better
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minimisation and dynamics could be a consequence of the force field used by XPLOR.
If this is the case then the poor omega ratings given to the model do not necessarily
reflect any intrinsic problems. Although XPLOR worsens the omega angle rating, the
deviations produced are small and do not invalidate the results produced by XPLOR.
A similar rating scheme is given by PROCHECK to various side chain parameters.
The results obtained for the model and crystal structure are shown in Table 2.4. These
values are in the ranges expected for good protein structures and show no overall
difference between the models produced manually and those produced by INSIGHT.
Of all these indicators the most useful are <]>,y distribution, distribution and H-bond
energies. In summary all models showed good values for the latter two with better
performance by the manual models in the <|),\|/ distribution test.
Detailed Examination
The detailed output of PROCHECK was used to conduct a residue-by-residue check
on the models to look for especially poor regions. In particular it was of interest to see
if they contained, or were adjacent to, unmodelled insertions or deletions or modelled
insertions and deletions, perhaps of poor quality. Situation at intra- or intermolecular
interfaces could be another explanation for stereochemically poor regions since the
influence of adjacent subunit halfs was not considered in detail during the modelling
process. The distribution of stereochemically poor residues is summarised in Table
2.5.
Ten non-glycine residues of the manual model of RMPFK N-terminal half fall within
the generously allowed or disallowed regions of the Ramachandran plot and are labelled
in Fig 2.12. D330, T331, A333 and C334 are near the modelled three residue insertion
at D330. C233 and D237 are near the modelled three residue insertion at E232. W132
is near to the unmodelled 23 residue insertion. M75 is at the interface with the C-
terminal half of this subunit in the modelled RMPFK dimer. There are no obvious
explanations for D91 and T359.
The manual model of RMPFK C-terminal half contains 12 residues in the generously
allowed or disallowed areas (Fig 2.13). C174 and Y232 are near the unmodelled four
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manual N 7 1
manual C 5 1
■NSIGHT N 11 5









residue insertion at Lys227. F193 and E194 are by the modelled three residue insertion
at E194. D250 is by the modelled one residue insertion at Lysl61. T216 is at the
interface with the N-terminal half of the same subunit in the RMPFK dimer model.
There are no obvious explanations for 178, S79, CI 16, K218, K246 and R313.
The INSIGHT model of RMPFK N-terminal half contains 25 poorly placed residues
(Fig 2.14). F128 is by the unmodelled 25 residue insertion at G97 while A26 and 1274
are near the modelled insertion at E264. H242, C244, R245 and R246 are all near the
modelled insertion at D241 while V358 is near the modelled deletion at K356. W132
and D134 are near the unmodelled N-terminal portion while A361 is near the
unmodelled connecting peptide. V73, M76 and L338 are at the interface with the C-
terminal half of the same monomer whereas L79 and L338 contact the other monomer
in the RMPFK dimer model. The remaining W70, V83, R88, A142, D173, H211,
D226, E326 and D330 have no obvious explanation.
There are 13 residues in poor <j>,\j/ positions in the INSIGHT model of RMPFK C-
terminal half (Fig 2.15). S79 is near the modelled deletion at A80 while CI 16 is by the
unmodelled insertion at K289. F96 and E97 are part of the modelled insertion at G95
while C228 and N229 are part of the modelled insertion at K227. R17 and R313 are at
the interface with the N-terminal half of the same subunit in the RMPFK dimer model
leaving D35, W56, D235, F236 and 1248 with no obvious explanation.
Overall 21 out of 60 poorly placed residues are near modelled insertions or deletions.
This casts doubt on the accuracy of these loops, in keeping with the general finding that
loops are modelled less accurately in homology-based models than structurally-
conserved regions. Specifically, doubt is cast on the accuracy of loops 3 and 5 in the
manual N-half model and on loops 4 and 6 in the manual C-half model. Loops 2, 3
and 5 of INSIGHT N-half model all contain or are near poorly placed residues. These
too are therefore suspect as are loops 1, 2 and 5 of the INSIGHT C-half model. The
INSIGHT N-half model contains much the largest number of poorly placed residues
for which there is no obvious explanation, an indication of overall poorer quality. The
PROCHECK results suggest that database loop search and random generation methods
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are similarly successful. Three of the five loops from database searches contain or are
near residues with poor main chain stereochemistry. With randomly generated loops
the figure is six suspect out of nine. The one example where a deletion was modelled
simply by excision and end-joining, deletion 4 of the INSIGHT N-terminal model, is
near stereochemically poor residues and is therefore suspect.
2.3.2.2 PROFILE
PROFILE was run on all the model halfs and the B.stearothermophiliis structure in the
context of dimer models or tetrameric structure respectively.
Overall Scores
The total scores are given in Table 2.6. The predicted scores are derived from the
linear relationship seen between protein length and profile score observed for proteins
of the Brookhaven Protein Databank (Liithy et al., 1992). The relationship is not
quantitated by the authors but can be estimated from their data as
PROFILE Score = 0.422 x protein length + 0.556
The crystal structure scores higher than predicted for its length suggesting, like the
PROCHECK results, that it is a very good structure. The manual model for the N-
terminal half of RMPFK comes impressively close to a typical score for a protein this
size. The N-terminal INSIGHT model in contrast gives a poor overall score suggesting
major errors in this model. Conversely, the INSIGHT model of the C-terminal half,
which is slightly shorter, comes closer to its expected score than the manual model.
Detailed Analysis
The profiles of the models and crystal structure generated with a window length of 21
are shown in Figs 2.17-2.19. The residue id does not necessarily correspond exactly
with the numbering of the models due to the incompleteness of the models. The
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Table 2.6 Total Profile scores for RMPFK half models and
crystal structures
Structure Score Length Predicted score
fB.stearothermophilus 155 320 136
crystal structure
Manual model of 122 329 138
vj-terminal half
Manual model of 106 318 135
^-terminal half
■NSIGHT model of 85 320 136
J-terminal half
■NSIGHT model of 111 309 131
>terminal half
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different models of the N- and C-terminal portions do not correspond exactly in residue
ids due to differences in alignment. Regions scoring an average of less than 0.2 are
rare in good protein sructures. Such regions in the models were analysed to try to find
reasons for their probable poor structure.
The manual model of the N-terminal half contains only three such regions, two of
which are very small - E96-R98 and D241-L243. These seem to arise from partial
burial of an Arg and an Asp respectively. There is a dip in the crystal profile to 0.25 at
the corresponding position to the first of these suggesting a probable source of the low
score of the model here. Neither of these regions is close to an insertion or deletion,
modelled or unmodelled, or to an interface. The third low scoring region extends from
P332 to D363. This includes part of the modelled insertion at D330. There is very
little similarity to the bacterial enzymes from R345 onwards. This is the C-terminal
portion which precedes the connecting peptide which is not present in the bacterial
enzymes. The profile suggests that this part of the chain adopts a different
conformation in the RM enzyme and is therefore modelled incorrectly using the
bacterial structure.
There are four regions scoring below 0.2 in the manual C-half model. S66-A80
includes the modelled deletion at L70. The rest of this region shows little similarity to
bacterial enzymes suggesting that the alignment may be incorrect or that this region
adopts a very different structure in the RM enzyme. There is a similar situation with
F193-Q211. This contains a three residue modelled insertion in a region of low
similarity to the bacterial sequences. The third poor region, V222-K246 contains an
unmodelled insertion again in a region of little similarity. The final poor region is
Q318-P335. There are two possible reasons for its poor score. First the large
unmodelled insertion at E290 is adjacent. Secondly this region again shows little
similarity to the bacterial enzymes and precedes the unmodelled C-terminal tail.
The first of five poor regions in the INSIGHT N-terminal model is very large,
covering E67-G97 and after a large unmodelled insertion T127-E131. The explanation
for this lies almost certainly in the alignment produced by INSIGHT. The program
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produced an alignment in this region that differed from the manual model alignment,
failing, for example to align the sequence IGGDGS with the identical sequence in the
bacterial enzymes. The second poor region I145-A147 is also by this large unmodelled
insertion. The third region includes the modelled insertion at D241 in a region of weak
similarity and is also adjacent to the probable position of the unmodelled C-terminal tail.
The fourth region, G271-R285, starts after the modelled insertion at E264 and
continues into a region of low similarity. The final region extends from V335 to the
end of the model at D363. As stated above sequence similarity is very poor here so that
the alignment, which differs from the manual one, may well be incorrect.
The first poor region of the INSIGHT C-terminal half model is R68-A80. This is by
the modelled deletion at A80 and once again shows little sequence similarity. PI 96-
L221 includes a modelled insertion at A204 in a region of little sequence similarity.
R224-K246 includes the modelled insertion at K227 in a weakly similar region. The
score dips below 0.2 finally at F302 and remains there until the final modelled residue
Q324. This region of poor homology precedes the unmodelled C-terminal tail.
The most obvious conclusion from this analysis is that low scoring regions are nearly
always found in stretches of chain showing weak similarity with the bacterial enzymes
used to generate the alignments and build the models. Most probably the alignments
used are incorrect or the RM enzyme shows a very different conformation in these
regions. If this were true then attempts to model insertions or deletions in these regions
would be doomed to failure. The loops indicated as having possible poor
stereochemistry by PROCHECK were compared with loops in low-scoring PROFILE
regions and a remarkable correlation found. Of the eleven loops containing or near
stereochemically poor residues, nine are in the above low scoring regions of low
sequence similarity. Of the seven loops built into high scoring, highly similar regions,
only two were indicated as stereochemically doubtful by PROCHECK. Of the better
loops, those generated by database loop search and random generation are equally
represented suggesting, within this small sample size, that both methods can be used
successfully.
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2.3.2.3 Chemical Modification and Proteolysis
Evidence for assignment of classes of effectors (sugar bisphosphates and AMP/ADP
activating, ATP and citrate inhibiting) to putative effector sites C, A', B' and C' has
been obtained by chemical modification and proteolysis.
Sheep heart PFK has been reacted with the affinity labelling adenosine analog
/?-fluorosulphonylbenzoyl-5'-adenosine. This modification occurred at a site specific
for allosteric activators ADP, AMP and cAMP (Mansour etal., 1978) and was shown
to be due to modification at Lys680 (Weng et al., 1980). Another Lys nearby was
shown to be highly reactive to pyridoxal phosphate suggesting solvent exposure and
proximity to multiple positively-charged residues, as would be expected of a
phosphocompound binding site (Kemp et al., 1987). Both of the models of RMPFK
place both these lysines (numbers 275 and 279 in my RMC numbering) at the C site,
consistent with the identification of this site with AMP/ADP activation by Poorman et
al. (1984).
Citrate has been shown to protect Lys529 against otherwise rapid modification by
pyridoxal phosphate (Kemp et al., 1987). This residue is at the C' site in both manual
and INSIGHT RMPFK models contradicting the suggestion of Poorman et al. (1984)
that this site is the ATP inhibitory site.
Exposure of RMPFK to V8 protease results in the appearance of a form lacking 17 C-
terminal residues which shows reduced inhibition by ATP and citrate (Valaitis et al.,
1987). Equilibrium binding studies showed lower affinity of the proteolysed form for
both. Attention was focussed on ATP however since the synergism of ATP and citrate
binding suggests that lower citrate binding was only a consequence of lower binding of
ATP which was also present. Removal of the C-terminal seven or eight residues by
trypsin did not affect ATP binding (Gottschalk et al., 1983) highlighting the importance
of the sequence His-Ala-His-Leu-Glu-His-Ile-Ser-Arg. The histidines had already
been implicated in ATP binding in diethylpyrocarbonate modification studies of sheep
heart PFK (Setlow and Mansour, 1970). These residues are in the C-terminal tail
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which is not present in the bacterial enzyme and is therefore not built in the models.
The INSIGHT model stops well short of this sequence. The manual model stops 19
residues short but the previous region shows only low homology with the bacterial
enzyme and the model in this region is of doubtful quality (see above). The end of the
manual model is certainly close enough to the C' site for the His residues to be
contributing to ATP binding there. However the uncertainties are too large for this to
be considered strong evidence for identification of the C' site with ATP inhibition.
Several predictions about the environments of methionines and cysteines in RMPFK
have been made from consideration of their rates of reaction with iodoacetate (Latshaw
etal., 1987).
Cys88 reacted most rapidly suggesting a relationship with a neighbouring nucleophile
that lowers its pKa. In the manual model there is a good candidate in Asp91 whose
side chain is within H-bonding distance to the thiol. In the INSIGHT model Asp91 is
not adjacent and there is no likely nucleophile, indeed the closest residue is Arg95.
Cysteines 169 and 232 were found to have high reactivity which was lowered in the
presence of F6P. Cysl69 is close to modelled substrate FBP in both models - 12A
measured from S to P^. Cys 232 is further away (21-22A) consistent with the smaller
effect on activity seen on modification compared with Cys 169.
Unusually, two methionines in the N-terminal half were also highly reactive to
iodoacetate suggesting location in highly positively-charged regions of the enzyme.
Both models show concentrations of basic residues around these methionines. The
distances are shown in Table 2.7 measured S-C(;(Arg), S-N^(Lys) and S-C8(Asp).
There is particular uncertainty over distances to residues in the C-terminal half of the
model since the relative orientation of N- and C-terminal halfs is not accurately known.
Due to differences in alignment Met 74 is in different positions in the two models of the
N-terminal half. In the INSIGHT model Met74 is buried which is inconsistent with its
high reactivity to iodoacetate.
Modification of Met 74 was found to have no effect on ATP inhibition. This is despite
the fact that the manual model and the model of Poorman et al. (1984) both place Met74
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Table 2.7 Distances of Met74 and Met174 from charged
residues
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at the C' site which Poorman et al. allocate to ATP inhibition. However the manual
model does not rule out this assignment since the side chain is solvent exposed and
therefore presumably quite mobile. Certainly the manual model does not suggest that
the Met side chain would contact a putative bound ATP.
2.3.2.4 Phosphorylation
Two serines were identified as phosphorylation sites when RMPFK was incubated
with protein kinase A in the presence of calmodulin or troponin C (Zhao et al., 1991).
These were Ser774 near the C-terminus and Ser376 in the connecting peptide. Since
neither of these regions were present in the RMPFK models suitable exposure of these
residues cannot be used as a criterion by which to judge the models.
2.3.2.5 Binding Sites
The putative binding sites of the models were then examined in more detail to see if
they were consistent with binding any of the known RMPFK ligands. In particular
consistency with the hypotheses of Poorman et al. (see Introduction - Section 2.1.4 )
was tested. Only the manual model of the N-terminal half was studied since the
INSIGHT model is clearly of poor quality (see above). Both models of the C-terminal
half were studied.
The A site
The alternate subunit of bacterial PFK contributes two arginines to the phosphate-6
binding part of this site. These two, Arg 163 and Arg252 in both alignments, are
modelled much better in the manual rather than the INSIGHT model of the C-terminal
half. In the manual model Arg 163 is next to the modelled insertion 3 which comprises
Arg 162 (see Fig 2.7). It is Arg 162 in this model which salt bridges phosphate-6 rather
than Arg 163, while Arg252 too is in good position to bind phosphate-6. In the
INSIGHT model, by contrast, Arg 163 can salt bridge phosphate-6 but Arg252 is too
far away. In addition, the modelled insertion 3, comprising Glyl59, places Thrl60 by
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phosphate-6. Clearly, the manual model is superior to the INSIGHT model in this
region.
The A' site
Inspection of the model of the N-terminal half is fully consistent with the idea that
this site is the sugar bisphosphate activation site. The catalytic Asp 127 of the bacterial
enzyme which is responsible for repulsion of the product F16BP is replaced by a Ser.
The two arginines contributed by the N-terminal half are modelled well in the manual
model and no modelled or unmodelled insertions are near this site.
The B site
The manual model of the N-terminal region which wholly contains this site is very
similar to the B site of the bacterial enzyme, as would be expected from the high degree
of sequence similarity here. No modelled or unmodelled insertions or deletions are
near here. Thus, this site is the ATP substrate binding site.
The B' site
This site is wholly contained within the C-terminal half. In both manual and
INSIGHT models the alignment places a seven residue insertion after Gly95. This is
modelled by random loop generation in the INSIGHT model but is unmodelled in the
manual model. The loop in the INSIGHT model completely blocks the entrance to the
pocket ruling out binding of ligand. Figure 2.20 shows the ADP-bound B site of
E.coli PFK. The blocking loop at the B' site in the INSIGHT model of RMPFK C-
terminal half is shown in red with the dots indicating the van der Waal's radii of the
ADP atoms. There is some doubt in the alignment so that the insertion could be
positioned up to four residues later. However the models show that an insertion of this
size anywhere in this region would have to be accommodated in the pocket thus ruling
out ligand binding here.
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Fig 2.20 An insertion (red) blocks the RMPFK B' site
Fig 2.21 Citrate bound to a T-state RMPFK C' site model
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The C site
The residues defining this site in the bacterial enzyme are well conserved in the rabbit
enzyme and the models are fully consistent with ADP and AMP binding here. There
remains doubt however about the possible role of the connecting peptide which cannot
be modelled. In the E.coli enzyme the C-terminal residue Tyr319 contributes to this site
and it is possible that residues of the connecting peptide are close to this site in
RMPFK.
The C' site
Again the residues comprising this site are similar to those of the C site of the
bacterial enzyme. As discussed above (section 2.3.2.3) there is biochemical evidence
linking both ATP inhibition and citrate inhibition to this site.
The gamma phospho group of ATP putatively bound here is positioned where
residues of the unmodelled C-terminal extension may well lie. This is consistent with
evidence linking histidines of the C-terminal extension to ATP inhibition (Valaitis et al.,
1987).
The alternative idea, that the PEP inhibition site of bacterial PFK, has become the
citrate inhibition site of RMPFK (which also binds PEP, though with lower affinity -
Colombo et al., 1975), seems to be less favoured despite the evidence of chemical
modification work (Kemp et al., 1987). This possibility was investigated by
construction of a model of the C' site using the structure of T-state, phosphoglycollate
bound B.stearothermophilus PFK as a basis (see Section 2.2.1.8). Figure 2.21 shows
citrate positioned in this model with H-bonds appearing as dashed lines. This appears
to be a favourable conformation with all three citrate carboxylates salt bridged to at least
one basic residue and the citrate hydroxyl H-bonded to Lys214. The model shows the
lysine implicated in citrate binding by chemical modification studies, Lys 529, salt
bridged to the citrate. A large uncertainty in this model is the position of Trp70 which
was mutated from the B.stearothermophilus Val54. As shown, it is unfavourably near
to one of the citrate carboxylates. Alternative positions could allow Arg25 to adopt a
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conformation in which it salt bridges additional carboxylates.
2.4 Conclusions
The RMPFK models built by homology well illustrate the strengths and weaknesses,
both of the general approach, and of the manual and automatic methods.
There are good reasons to think that the overall quality of the manual models is good.
Their overall profile scores, particularly the N-terminal model, approach closely the
mean scores for proteins of their size in the protain database and are certainly within the
spread of values seen for crystallographically-determined structures. Both models
exceed 80% of residues on core regions of the Ramachandran plot (Table 2.2) which is
similar to the crystal structure subject to the molecular dynamics regime. For good
structures determined to 2.0A 90% of residues would be expected to be in these regions
so that this performance for models built on a 2.4A resolution structure is creditable. In
addition, all but one of the diagnostic main chain and side chain parameters of
PROCHECK indicate the models to be better than is averagely found for crystal
structures. The sole exception is omega angle standard deviation which poor results
appear to be a consequence of molecular mechanics using XPLOR's force field.
The INSIGHT models seem less good. The PROFILE score of the C-terminal model
is good but that of the N-terminal model is poor. Both models perform more poorly in
putting only 65-70% of their residues in core regions of the Ramachandran plot, but
again all other PROCHECK parameters are better than average. One factor contributing
to the poor Ramachandran plots could be the reliance on random generation for loop
modelling in contrast to the emphasis on database loop searches in the manual models.
The (j> and vy backbone torsion angles generated by the random generation algorithm are
not biased towards those typically seen in proteins whereas by using a segment from
another protein reasonable protein torsion angles are likely to be obtained. However,
with at most 10% of total residues of INSIGHT models modelled by random loop
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generation, this is unlikely to be the whole explanation. It is likely that the lack of
supervision during side chain substitution of the INSIGHT models lead to some
serious clashes with main chain being present in the original model. During
minimisation and dynamics these would have caused distortion of the main chain.
Where the manual and INSIGHT models differ, the manual models are more consistent
with the biochemical evidence.
The decision to produce the INSIGHT models as automatically as possible was made
in order to make the comparison between this very rapid procedure (1-2 days) and the
manual approach which took weeks. A large factor in the relative slowness of the
manual modelling was the complicated loop modelling procedure which aimed to
improve on the results obtainable from standard database loop modelling protocols.
This more involved approach typically took days for each insertion. For the INSIGHT
models, production of ten randomly generated loops typically required less than one
hour and a reasonable loop was usually present in the group. Considering the disparity
in time requirement, the superiority of the sophisticated loop search over random
generation seems quite small although the number of loops modelled is too small to
draw firm conclusions. Of the three loops modelled in regions of good homology by
each method, none modelled by loop search was inaccurate as judged by PROCHECK
whereas one of the randomly generated loops contained poorly positioned residues.
The large misalignment present in the automatic INSIGHT structure alignment is
certainly the reason for many of the poor performance indicators of the INSIGHT N-
half model. The alignment produced for the C-half was so poor as to make its use
futile and a slightly modified manual alignment was substituted. The difference in
quality of the two INSIGHT models emphasises the importance of good alignment.
Overall, comparison of the manual and INSIGHT methods suggests that a middle way
might be the best future approach. Alignment is probably best handled manually unless
a large number of homologous structures are available. Mutation of side chains can be
left to the computer, although a check for bad contacts, and their rational removal seems
to be valuable. Random generation seems to model loops well given its modest time
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demands although lack of bias towards typical torsion angles is a weakness. The
convoluted loop search algorithm used in the manual models seems not to be worth the
extra time outlay. A recent review of secondary structure prediction, subtitled 'Man
versus machine', similarly concluded that both manual and automatic methods have
their advantages and to combine both seems the best policy (Benner and Gerloff,
1993).
The models shed some light on the possible binding sites of the extra RMPFK
effectors, but are frustratingly incomplete in some of the most interesting regions.
There seems to be no doubt about the assignment of sites A and B to substrate F6P and
ATP, nor of sites A' and C' to sugar bisphosphate and adenine nucleotide activating
sites. Site B' seems to be blocked by an insertion in the mouth of the pocket. That
leaves ATP and citrate inhibitory sites to be accounted for by site C' and/or novel sites.
Biochemical evidence comes down equally on the sides of ATP or citrate binding to site
C'. Given the uncertainty at the C' site due to the probable proximity of the
unmodelled C-terminal extension binding of ATP seems possible. The C' site model
derived from the T-state bacterial PFK, on the other hand, suggests that binding of
citrate here is a possibility. The possibility that inhibitory ATP and citrate share a
binding site seems to be ruled out by equilibrium binding measurements (Colombo et
al., 1975). ATP is required before significant citrate binding is observed but in the
presence of ATP up to lmol citrate/mol protomer can be bound. The ATP seems to be
binding to the ATP inhibitory site rather than to the ATP substrate site since ITP cannot
substitute. The two possibilities are therefore that site C (ADP activating; PEP
inhibiting) has become site C' (ATP inhibiting) or site C' (citrate inhibiting). The
former possibility would require the incorrect modelling of Lys529 despite its being in a
region of relatively good homology. The latter possibility would imply the separate
evolution of another nucleotide binding site which may be unlikely. At present,






Rational drug design is the holy grail of medicinal chemistry. Despite recent
advances, traditional random sceening of compounds remains slow and expensive.
Advocates have long held that rational drug design holds the key to more efficient drug
discovery. Past scepticism has been justified to some extent in view of the relatively
small number of rationally-designed drugs which have passed clinical trials to reach
prescription. However, the methodological groundwork has now been laid and an
acceleration in success rate may now be expected as computers become powerful and
cheap enough to run computationally-intensive programs. The potential benefits, both
humanitarian, and, for drug companies financial, are enormous.
It is much easier to design a ligand than a drug. Essential properties of a drug include
selectivity, chemical stability, ease of synthesis and ready formulation. The
pharmacokinetic profile is also important. It may be desirable that the drug is persistent
or, conversely, that it is rapidly broken down or excreted to avoid toxic side-effects. It
is because of these potential problems that the rational ligand designer should aim to
produce many and varied ideas.
The methods available for rational i.e. knowledge-based, ligand design depend very
sensitively on the amount and quality of the knowledge accumulated. Rational design
can be attempted at levels ranging from an identified substrate to protein-ligand complex
X-ray crystal structures. However, the more knowledge is available, the more
sophisticated are the available approaches and the greater the chance of success. For a
review of available methods see Martin (1991).
Of the many approaches developed most are divisible into two stages. In the first,
potential ligand interaction sites are identified for the target region, usually the catalytic
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site of an enzyme or the agonist binding site of a receptor. These can be located directly
from knowledge of protein structure or inferred from information relating to known
ligands. In the second stage known ligands are modified to occupy more interaction
sites or new ligands sought to occupy several interaction sites.
Many of the most successful examples of ligand design employ an iterative scheme
(Appelt etal., 1991). Ligands designed as above are tested in vivo and in vitro and the
most interesting studied crystallographically in complex with the target. The
information so gained is then used to guide further design work aimed at improving
affinity.
I shall first discuss methods of analysing the system of interest to obtain information
useful to the drug design process. Then I shall discuss the exploitation of this
knowledge in attempting to discover new lead compounds.
3.1.1 Finding potential ligand interaction sites
3.1.1.1 From protein structure
GRID - the program
The program GRID (Goodford, 1985; Boobbyer etal., 1989) computes an energy of
interaction at points on a three-dimensional grid between a probe and a target. The
probe consists of a single atom e.g. carbonyl oxygen atom - 0(=C), a small group of
atoms e.g. protonated amino group +NH3 or a small molecule e.g. water. Most multi-
atom probes are represented as 'extended' atoms. By replacing several atoms with a
single 'extended' atom approximating their properties computing demands are much
reduced. The target represents the portion of the macromolecule of interest.
The original formulation of the energy function was
E = Ey + Ed + Ehb
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where Ey is the Lennard-Jones potential, Eej is the electrostatic potential and E^ the
hydrogen-bond term. For the Lennard-Jones interaction a standard (12,6) potential
was used. The electrostatic potential calculation took into account the different
dielectric behaviour of the protein interior and solvent compartments. An empirical
modification to the standard formula for electrostatic interaction was made using the
number of protein atoms within a 4A radius of the probe. The original hydrogen-bond
function has been replaced by a much more sophisticated one (Boobbyer et al., 1989).
This considers
Ehb = Er x Et x Ep
where Ej., Et and Ep are factors depending respectively on the distance apart of the
atoms, the angle made by the H-bond at the target and the angle made by the H-bond at
the probe. The angular functions vary for the different atom types. Other important
advances were the consideration of possible H-bond partner rotation and the
assessment of both possible His tautomers during calculations, with adjustment to the
electrostatic term depending on likely tautomeric form. The energy calculated for the
grid positions is easily converted into contour maps to be displayed using standard
molecular modelling software. A range of different probe-target interaction energy
levels can be shown simultaneously as contours of different colours. As figures later in
this chapter show, the contours often reveal specific regions of particularly favourable
interaction.
The most significant limitation of GRID is its inability to account for changes in both
target and ligand that may occur on binding. Protein conformational changes on ligand
binding are quite common e.g. the change in hexokinase structure on substrate binding.
Changes in electronic distribution of ligands on binding are also possible.
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GRID testing
Both papers describing the program contain examples of GRID use. For example
GRID accurately located water molecules in the crystal structure of phospholipase A2
(Goodford, 1985). In a protein of pharmacological interest - cytochrome P450-CAM,
GRID was able to locate the observed binding position of the hydrophobic substrate
within a -2.0 kcal mol" * methyl group probe contour. The single H-bond between
camphor and the enzyme was also clearly located.
The program has since been widely used. For example GRID was used to suggest
potential glucose analogs that may inhibit glycogen phosphorylase as a treatment for
diabetes (Martin et al., 1991). In this case GRID predictions were not confirmed by
kinetic and crystallographic experiments due to unexpected changes in protein
conformation on binding. GRID has also been used to locate likely positions for
substrates on an unligated phospholipase C crystal structure (Byberg et al., 1992).
From these a probable mechanism was deduced which can now be tested.
Most excitingly, GRID has recently been instrumental in progress towards influenza
sialidase inhibitors (von Itzstein et al., 1993). GRID contours suggested that
replacement of a hydroxyl group of a known inhibitor by an amino group would
improve binding affinity. Indeed, testing showed improved inhibition both of sialidase
in vitro and virus replication in vivo. In addition the new compounds showed
improved specificity for the influenza enzyme over mammalian ones.
Multiple Copy Simultaneous Search
A more recent appoach to finding favourable binding sites for molecular fragments is
the multiple copy simultaneous search method (Miranker and Karplus, 1991).
Several thousand copies of the fragment are randomly placed in the region of interest
and then energy minimised simultaneously. During minimisation the protein is fixed
and interactions between fragments are ignored. Clusters of fragments in similar
positions are identified, less favoured clusters discarded and representative examples of
the remaining clusters studied by molecular graphics.
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Despite the efficiency of simultaneous multiple minimisation this approach is more
computer-intensive than GRID. However there are significant potential advantages to
this method. First, larger fragments are used such as dimethyl ether and acetonitrile.
Secondly the method should be readily extended to take account of protein flexibility.
This would be by allowing the protein to move during the multiple minimisation
although at the cost of increasing computational demands.
Rule-based methods
Many analyses of H-bond geometry in molecules of crystallographic small molecule
databases have been published. Several groups have used this work to identify
possible interaction sites.
The program HSITE (Danzinger and Dean 1989a) infers potential ligand H-bond sites
from consideration of potential H-bond partners on a protein. Allowance is made for
rotation of groups on the protein so that each potential H-bond partner of the protein
produces a locus of potential interaction points.
The program LUDI (Bohm, 1992a,b) takes no account of rotation of potential H-bond
partners. However this program also locates potential hydrophobic contacts,
distinguishing between aliphatic and aromatic contacts.
3.1.1.2 From Ligand Structure
One of the earliest developments in the rational drug design field was Quantitative
Structure Activity Relationships (QSAR) (Fujita, 1990). In QSAR the measured
potencies of a range of ligands are correlated with the values of physical properties such
as pKa, size and hydrophobicity. QSAR properties can be calculated for different
positions of the analogs enabling ligand features to be ranked by importance, hence
guiding further design. Where the 3D structure of the receptor has been determined,
good agreement has been found with the important binding features of the ligands
determined by QSAR.
QSAR methods may be extended to three dimensions (Loew and Burt, 1990). Here
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the first step is the superposition of molecules to maximise similarity. Ideally the
bioactive conformations are experimentally determined, for example by nuclear
magnetic resonance spectroscopy. Reasonably low energy conformations can be
generated by programs such as CONCORD (Rusinko et al., 1988) although ligands
may not always bind in such conformations. Where a molecule has relatively few
rotatable bonds then a systematic search for the lowest energy conformation may be
carried out. Once the 3D structures have been obtained, from whatever method, the
molecules are superimposed. Steric, electrostatic and H-bonding interaction energies
are calculated for the overlaid molecules at a range of grid points round the molecules.
The energies then replace pKa, hydrophobicity etc. in the QSAR positional analysis.
Contour plots may be generated indicating the contributions of different parts of the
molecule to binding affinity. These are equivalent to, and can be used in the same way
as, ligand binding sites inferred from protein structure by methods described above.
Programs are becoming available for the automatic deduction of structure-activity
relationships from experimental data (e.g. Catalyst from BioCAD Corp., 1390
Shorebird Way, Mountain View CA 994043). Such programs can also search 2D and
3D databases for novel molecules that share features with the known active
compounds.
3.1.2 Fitting ligands to potential ligand interaction sites
3.1.2.1 Modification of existing ligands
This approach is particularly applicable to systems where a receptor-ligand complex
structure is available. Modifications are made to the ligand to occupy favourable
interaction sites.
Recent work on purine nucleoside phosphorylase (Montgomery et al., 1993) and
thymidylate synthase (Appelt etal., 1991; Varney etal., 1992) has illustrated the power
of an iterative approach. From an original receptor-ligand complex structure rational
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modifications are proposed and analysed. Promising compounds are then synthesised
and tested with the most interesting co-crystallised with receptor. The new complex
structure is then used to suggest further ideas, and so on. In the best case only three
iterations were required for the transformation of |lM-range inhibitors into nM-range
inhibitors.
Selective inhibition of a trypanosomal GAPDH has recently been demonstrated using
a rationally-modified ligand analog. An added hydrophobic substituent occupied a
hydrophobic pocket present in the trypanosomal enzyme but not in the human enzyme
(Verlinde et al., 1993).
Another important type of ligand modification is well illustrated by the recent
structure-based design of a cyclosporin A analog (Alberg and Schreiber, 1993). By
introducing rings, well away from the binding part of the molecule they were able to
alter the conformational properties of the molecule, as shown by n.m.r. spectrosopy.
They were thus able to ascribe the threefold greater binding affinity of the analog to
more favourable entropic properties. This illustrates the importance of entropy in drug
design. Unfortunately, entropy is still hard to take account of computationally. This is
because entropy relates to degrees of freedom in a system. Assessment of degrees of
freedom would require study of large numbers of conformations which would be a
highly computationally intensive process.
3.1.2.2 Discovery of novel ligands
One of the results of random screening for inhibitors has been the discovery of
inhibitors bearing no chemical resemblance to previous ligands. This has demonstrated
the feasibility of rationally designing new classes of inhibitors. Such classes may have
important benefits such as ease of synthesis, desirable pharmacokinetics, potential for
development etc.
Previous dependence on human ingenuity and skill in suggesting potential new
inhibitors is now being gradually superseded by computer database searches.
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Novel ligands by manual modelling
Ground-breaking work was carried out on haemoglobin. In 1976, the 2,3-
diphosphoglycerate binding site was targeted (Beddell et al., 1976). Dibenzyl-4-4'-
dialdehyde modelled into the site showed good steric fit, with the aldehyde groups in
good positions to form Schiff's bases with Lys residues. More hydrophilic compounds
were also tested, both for increased solubility and for potential salt bridges for higher
affinity. Right-shifting of the C>2 association curves was seen for all the compounds
with potency in the order predicted from modelling.
Further work on haemoglobin illustrated the potential of sites not exploited by nature
for rational drug design. A series of aldehydes designed to occupy the alpha-chain
terminal amino region were tested (Beddell etal., 1984). These showed both left-
shifting of the (^-association curves and anti-sickling action in sickle cells.
Manual fitting of compounds into pockets has not yet been totally superseded. In
recent work on thymidylate synthase, two series of leads were developed from
manually positioned ring systems (Appelt et al., 1991). Initial positioning and
modification made extensive use of the GRID program.
Novel ligands by database searches
Fitting ligands to proteins
Several programs have been developed to scan databases of small molecules to search
for good fits into a user-defined site. The most successful has been DOCK. Even in
its original simple formulation judging fit solely on steric grounds, this was able to
locate a sub-millimolar inhibitor of HIV protease from the Cambridge Structural
Database of small molecules (DesJarlais et al., 1990). The program has recently been
refined to rank molecules by energy of interaction and found several sub-millimolar
inhibitors of thymidylate synthase. This work used a larger database of 3D chemical
structures, originating not from crystallography, but from programs generating 3D
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structures from 2D formulae. The current position with DOCK has been reviewed
recently (Kuntz, 1992). Refinements being contemplated include searching ligand
conformational space, correction for desolvation on binding and consideration of the
subtle differences between closely-related enzymes.
A more recent preogram CLIX (Lawrence and Davis, 1992) obtains initial fits of
molecules from a database on steric grounds while ensuring at least three highly
favourable contacts. It then ranks them by binding energy. This it approximates as the
sum of the energies obtained from precalculated GRID maps for several probes together
comprising the molecule. The program performed well in test cases but has not yet
been applied to new problems.
Sudarsanam etal. (1992) have had success with a much simpler approach. They
approximate the shape of each molecule in a database to an ellipsoid and compare the
dimensions of each to the ellipsoid obtained from a cast of the binding pocket. This
rapid, purely steric approach was able to reproduce some of the results of DOCK and to
discover sub-micromolar inhibitors of cysteine proteases.
Other programs dock small fragments from a database and then try to link them
together to form a viable inhibitor. The advantages of this fragment-based approach
have been pointed out in a series of papers by Chau and Dean (1992a,b,c). In
particular, the use of fragments from known structures automatically removes the
potential problems with impossible or unstable atomic arrangements that an automatic
structure generator might otherwise encounter. Also important is the greater
predictability of atomic properties found for a particular atom type in a certain atomic
arrangement compared to the same atom type in its full range of possible atomic
arrangements. The authors first generated a database of the most commonly occurring
molecular fragments (Chau and Dean, 1992a) then determined values and transferability
for their bond lengths (Chau and Dean, 1992b) and atomic residual charges (Chau and
Dean, 1992c).
LUDI (Bohm, 1992a) begins by locating potential sites for H-bonds to, and
hydrophobic contacts with, a user-defined site. Fragments, typically of 5-20 atoms,
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excluding hydrogens, are then fitted to these potential interaction sites. They are scored
according to goodness of fit to these sites, contact with protein and size. Further
searches are then made for fragments that can be linked to the first and that have
additional favourable interactions with the protein. The program has been refined by
modification of the interaction site location method and inclusion of a facility to add
fragments to known inhibitors (Bohm, 1992b). Suggested improvements to known
inhibitors were found to be favourable experimentally where data were available.
GroupBuild (Rotstein and Murcko, 1993a) works similarly. An initial fragment is
fitted to seed atoms defined by the user, guided for example by GRID. Further
fragments are 'grown' from available hydrogens of the first fragment. These are
scored by energy using a precalculated potentials grid with correction for changes in
solvent-accessible surface areas. GroupBuild was able to reproduce key features of
known inhibitors.
Fitting ligands to other ligands
Searching databases for molecules similar to known ligands can involve either 2D or
3D search methods. The former use only measures of atomic connectivity whereas the
latter consider the 3D arrangement of atoms and groups. Interest in 3D similarity
searches for ligands has been stimulated by the availability of large databases of 3D
molecule structures. These are derived from 2D databases using sophisticated molecular
mechanics programs such as CONCORD (Rusinko et al., 1988). A comparison of
four different 3D similarity search methods and a 2D similarity search has been made
(Pepperrell and Willett, 1991). Narrowly the best of the 3D similarity search methods
was Atom Mapping. For two molecules A and B, this involves individually locating
the atoms in B most like those in A. The overall similarity between A and B is then the
sum of the individual atomic similarities. Interestingly, the method was not superior to
the 2D similarity search al thought the output was different. Subsequent attempts to
combine the 2D and 3D methods failed to produce a better result than either method
individually. Attempts have been made to take account of the flexibility of molecules in
the search database (Clark et al., 1992; Clark et al., 1993). This work has shown that
the simplest index of flexibility, the number of rotatable bonds in a structure, produces
the same ranking of molecules as more complex indices. Ranking of molecules in a
database, so that the least flexible are considered first, has been shown to significantly
speed up the search process (Clark et al., 1993).
2D similarity searches can be carried out using various topological indices as search
criteria (Rouvray, 1993). The usual approach is to calculate several or many indices for
each molecule. Each molecule is then 'plotted' as a point in multidimensional space,
with each axis representing an index, and its similarity to the reference molecule
calculated as a distance by Pythagorus' theorem. Typical indices are derived from
atomic connectivity, with or without consideration of atomic types, or molecular
fragments present in each molecule. Topological similarity searching has recently
found reverse transcriptase inhibitors (Romero etal., 1991) which have been developed
into clinical candidates (Romero et al., 1993).
The most common type of 3D ligand search used to date firstly involves identification
of a pharmacophore. A pharmacophore is identified from a superposition of known
ligands. It consists of a series of features common to potent ligands (and therefore
assumed to be important for binding) such as acidic groups or aromatic systems. The
geometric arrangement of these features is defined in terms of distances and angles. In
a series of papers the efficiency of a two-pass search technique for scanning molecular
databases has been demonstrated (Jakes and Willett, 1986; Jakes etal., 1987; Clark et
al., 1991). In a rapid first pass most molecules are discarded on the basis simply of
intramolecular distances. A second pass then considers geometric arrangement.
3D similarity searching has recently been used successfully in combination with the
DOCK program mentioned above for the design of thymidylate synthase inhibitors
(Stoichet et al., 1993). DOCK produced a lead compound with a binding constant of
900|lM. Similarity searches produced other compounds which were scored by docking
and the highest-ranking tested. This scheme ultimately produced a compound of
binding constant 3pM.
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Novel ligands by computer generation
Computer generation of putative inhibitors has at least two important advantages over
the database search approach. The first of these is the ability to cover a wider range of
possible structures, novel molecule types as well as those previously studied.
Secondly, there is the potential to produce molecules of superior complementarity to
those present in databases.
In a series of papers (Danzinger and Dean, 1989a; Danzinger and Dean, 1989b; Lewis
and Dean, 1989a; Lewis and Dean, 1989b) Dean and colleagues have investigated
automated site-directed drug design. The first step is the location of potential H-bond
partners. Planar, polycyclic molecular skeletons are then fitted to the protein to
optimise the fit of skeleton vertices to site points. After pruning of the skeleton to
remove parts that sterically clash with the protein, the skeleton can be converted into
putative ligands, taking into account chemical considerations. Using observed
interaction sites in dihydrofolate reductase (DHFR) and trypsin this approach was able
to produce molecular templates strongly resembling known inhibitors.
This approach has recently been combined with the program DOCK (Lewis et al.,
1992). Compounds found by DOCK that are suitably relatively positioned are
combined to produce molecular skeletons. These require no pruning since the DOCK
compounds were selected for steric fit.
Another program, LEGEND, by Nishibata and Itai (1993), builds ligands by adding
atoms one at a time. The initial starting structure can be part of a known inhibitor or a
computer-generated fragment designed to interact with a functionally important region
of the target molecule. During molecule generation, required numbers of rings and H-
bonding atoms can be specified. Only carbon atoms are added, but these are changed
to heteroatoms if the electrostatic potential shows this to be favourable. Selection from
among the generated molecules is by energetic assessment, both inter- and intra-
molecularly. The program proved capable of generating the skeletons of known
inhibitors of DHFR and provided many other suggestions, although these have yet to
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be synthesised and tested.
Very similar to LEGEND is Genstar (Rotstein and Murcko, 1993b). However,
Genstar considers intermolecular interactions during molecule generation and allows a
realistic range of bond angles and lengths. Once again the program could produce
molecules similar to known inhibitors when provided with the protein structure.
An alternative automatic design approach is the construction of a putative ligand from
small fragments. The GROW program (Moon and Howe, 1991) automatically
produces ideas for peptide and peptide-like ligands by iteratively adding residues from a
library of conformations to an initial seed. The seed position is user-controlled so that
any of the previously mentioned methods for identification of potential ligand binding
sites can be used. The addition of library residues is guided by an energetic assessment
which includes steric and electrostatic interaction with the receptor, internal strain
energy of the putative ligand and consideration of solvent effects. GROW was able to
reproduce crystallographically-determined conformations of known peptide-like
inhibitors. More impressively, using a renin structural model built by homology, the
program found a novel heptapeptide that proved to inhibit with Kj=30|lM.
3.2 Methods
3.2.1 General Molecular Modelling
For general purposes such as molecule building, movement and display the program
SYBYL was used (SYBYL 5.5 Manual). Energy minimisation may be carried out
using the manufacturer's own force field (Clark etal., 1989). This was used for some
small jobs for convenience but all major molecular mechanics was done with the
program XPLOR (Briinger, 1990). Like most programs, SYBYL was run on an
Evans and Sutherland ESV 20 graphics workstation.
The program INSIGHT was also available (INSIGHT II User Guide) with a similar
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range of functions to SYBYL. This was used occasionally for manipulation of LUDI
results. INSIGHT (including LUDI) ran on a Silicon Graphics Indigo workstation.
3.2.2 GRID
The GRID programs were kindly supplied by Dr. Peter Goodford (Molecular Design
Ltd., Oxford). They were run, unless otherwise indicated, with default parameters and
with appropriate probes chosen by menu. The crystal structure of E.coli PFK bound to
ADP and FBP (Shirakihara and Evans, 1988) was used as the target. Of the slightly
different 'open' and 'closed' conformations seen in this structure, the 'open' one was
arbitrarily chosen. GRID was run in a box with coordinates xmjn = 0, xmax =16;
ymin = Ymax = zmin = zmax = ® (coordinates in A). This box generously
enclosed the FBP binding site. The GSYB program was used to convert the GRID
output into contours that could be displayed using SYBYL. Three or four contour
levels were generally displayed covering energies of interaction in the range minimum
to around half-minimum.
3.2.3 LUDI
The program LUDI was available in the Ligand_Design module of the INSIGHT
program. It was run with default parameters except for the Max RMS value. This
defines how well the geometry of a particular fragment must fit that of the protein in
order to be considered. Experiment showed that with the default value of 0.3A very
few fits were produced. Previous work had also suggested that 0.3A might be
unnecessarily prohibitive (Verlinde et al., 1993). For this reason a value of 0.5A was
used.
The whole of the active site of the product-bound E.coli PFK crystal structure
(Shirakihara and Evans, 1988), both ADP and FBP sites, was used as receptor for
attempted fragment fitting. This was accomplished using three runs; one for a sphere
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radius 8A around Asp 127 Cy, one for a sphere 10A around 04 of ADP and the third
for a sphere 7A around lie 130 C5. Two further runs, intended to focus on regions of
potential difference between E.coli and RM PFKs were carried out with a Max RMS
value of 0.4A. These were spheres of 10A around His223 Ne2 and 9A around Arg305
CC.
In the second stage of searching for new fragments to link to original finds, spheres of
8A centred on the original find and a Max RMS value of 0.3A were used.
3.2.4 2D similarity searches
The 2D similarity search of the Cambridge Crystallographic Database (Allen et al.,
1979) was carried out using the resident Quest88 software on a Vax computer running
VMS.
The 2D similarity search for naphtho compounds used a proprietory algorithm based
on the distribution of significant chemical groupings (P.Taylor, personal
communication). The database used was the Fine Chemical Directory of about 50,000
compounds.
3.2.5 Molecular mechanics with XPLOR
XPLOR was used for both energy minimisation and molecular dynamics simulations
of PFK bound to putative inhibitors. The starting protein structure was again the
'open' conformation of the active site seen in the product-bound E.coli PFK crystal
structure (Shirakihara and Evans, 1988). The following standard procedure was used.
In the large majority of cases water was included in the system. The coordinates of
water were generated using SYBYL's SOLVENT command and default parameters. A
subset of these water molecules, around 200-250 in an approximately spherical region
around the putative inhibitor, was extracted using SYBYL. For both energy
minimisation and molecular dynamics simulation, three zones were defined. These
97
were a zone completely free to move, a zone fixed and an intermediate 'buffer zone' in
which the atoms are tied by harmonic constraints to their starting coordinates. The free
zone included the putative inhibitor, ADP, Mg~+ and all water molecules. Also
included were residues defined as contacting FBP and ADP in the complex crystal
structure (Shirakihara and Evans, 1988). These were Gil, Y41, R72, F73, R77,
D103, G104, S107, G108, T125, D127, D129, M169, G170, R171, E222, H249,
R252. Excluded, due to limitations in the molecular modelling software, were the
residues that contribute to the P6 binding site from the alternate subunit - R162 and
R243. The P6 atom of FBP modelled analogs was fixed in an admittedly crude attempt
to compensate for their exclusion. The buffer zone comprised residues S9, G10, D12,
G40, L42, Y45, A71, P74, E75, F76, D78, R82, G102, Y106, A109, Rill, G124,
1126, N128, 1130, T136, V168, Y172, T221, H223, G248,1250, Q251 and G253.
Charges for protein and water and ADP were as defined in standard XPLOR
parameter files. Charges for FBP analogs and LUDI compounds were calculated using
the SYBYL command QCPE MOPAC with default parameters. This provides an
interface to the MOPAC program which performs a molecular orbital calculation on a
given molecule, one of the results of which is a charge assignment for the atoms. This
method was shown in tests to produce very similar charges, for example for amino
acids, to those present in XPLOR's supplied parameter files. Charges for united atoms
were obtained by adding the charges of contributing atoms; a CH2 united atom charge
from the carbon and two hydrogens, for example. The only other modification made to
defined charges was averaging of chemically equivalent groups such as carboxylate
oxygens. The MOPAC command sometimes produced different charges for these,
presumably because of the conformation-dependent component in its calculation.
Energy minimisation consisted of 200 rounds of Powell-method conjugate gradient
minimisation. Before molecular dynamics simulation the atoms were given Maxwellian
velocities corresponding to a temperature of 600K. One picosecond simulation at 600K
(1000 femtosecond time steps) was then carried out. Finally, 0.6 ps simulation was
carried out during which the temperature was decreased in 25K steps from 600K to
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300K. A further round of energy minimisation as above was then carried out.
3.3 Results and Discussion
3.3.1 Small phosphocompounds
A two-dimensional database search was carried out of the Cambridge Crystallographic
Database containing approximately 90,000 compounds. The search template used is
shown in Fig 3.1. This was designed to produce compounds with tetrahedral sulphur
or phosphorus moieties which could bind into the 6-phosphate binding pocket of
E.coli PFK. The results can be summarised as follows.
Many nucleotides were suggested, but their effects on PFKs are well known.
Pyridoxal compounds were also present in the output. Several naturally-occurring
small phospho-compounds were suggested - the phosphates of choline, ethanolamine,
serine, glycerol and glycerate. The sulphates of choline and ethanolamine were also
present. Other suggestions were propargyl phosphate and the 1,2-
bismethylsulphonates of ethane, propane and butane. Some of these suggestions are
shown in Fig 3.1.
The compounds were then modelled into the FBP-bound E.coli PFK crystal structure
so as to place the tetrahedral sulphur or phosphorus part of the molecule in the position
occupied by the 6-phosphate of FBP. At this stage it was apparent that the
bismethylsulphonates were not interesting since there was not room at the 6-phosphate
site for the methoxy group. Modelling of propargyl phosphate, the pyridoxal
compounds and phosphoglycerate all produced serious steric clashes with the protein
which ruled out these compounds as potential inhibitors.
Modelling of phosphoethanolamine (PE) produced a more interesting result. Placing
the phosphate in the 6-phosphate binding pocket put the protonated amino group in
good position to salt bridge Glu222. Modelling of phospho-D-serine (PDS) from this
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PE conformation placed the carboxylate, favourably, pointing out into solution. The
carboxylate of modelled phospho-L-serine (PLS), however, clashed with the protein.
Phosphocholine (PC) was also modelled similarly but resulted in unfavourable
positioning of the -NMe3+ group against Glu222. At this stage PE and PDS looked
promising and the modelled conformations were subjected to a standard energy
minimisation/molecular dynamics simulation in the presence of about 300 water
molecules around the small phosphocompound. After this procedure, the salt bridges
between phospho group and 6-phosphate binding pocket, and amino group and Glu222
were strengthened. In addition, movement of the phosphocompound and Metl69
towards each other produced more favourable hydrophobic contacts. The resultant
conformation of PDS is shown in Fig 3.2.
Since these small phosphocompounds bear some resemblance to PEP and
phosphoglycollate, known allosteric inhibitors, the attempt was also made to model
them into the effector site. The phosphoglycollate-bound, T-state
B.stearothermophilus PFK crystal structure was used (coordinates kindly supplied by
Dr Phil Evans, Cambridge). The phosphate and adjacent carbon of PE were overlaid
on the respective atoms of phosphoglycollate. Substituting PE for phosphoglycollate
involves putting CP^NE^"1" in place of COO". In the crystal structure the phosphate of
phosphoglycollate is completely buried and the pocket wraps around the
phosphoglycollate with the carboxylate group at the surface 'stapling the two rims of
the cleft together' (Schirmer and Evans, 1990). It was therefore not surprising to find
that PE, which is larger than phosphoglycollate, could not be positioned without
avoiding serious steric clashes with the protein. In addition the carboxylate of
phosphoglycollate is near to several basic residues which are thus unfavourably close to
the NHg"*" of modelled PE. PC and the phosphoserines are larger than PE and
therefore cause even greater steric clashes.
The effector site pocket can expand to accommodate the much larger ADP (Schirmer
and Evans, 1990). Hence, binding of small phosphocompounds to another, more
open, conformation of the pocket cannot be ruled out. Modelling of such a putative
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Fig 3.2 PDS after molecular mechanics
Fig 3.3 Format of FBP analogs
102
conformation would involve too many uncertainties to be justified.
Thus, the modelling studies suggested that small phosphocompounds, PDS and PE in
particular, might bind to PFK. It was decided to test PC and PLS as well. Differences
in the behaviour of these four compounds could then be explained using their different
structural features.
3.3.2 Bisphosphate compounds
3.3.2.1 Design of fructose- 1,6-bisphosphate analogs
Several classes of FBP analogs were modelled. Many were of the formula shown in
Fig 3.3 with the PI region of the molecule modified at bridging atom X and/or at atom
Y The rationale behind modification here was twofold. First, substitution of oxygens
at X and Y would prevent the hydrolysis off of the 'P6' moiety by the 'backward'
reaction of PFK. This is clearly essential for any useful inhibitor. Secondly,
modifications here would reduce the negative charge on this portion of the molecule
from the -2 carried by FBP. This would be predicted to improve binding affinity since
PI in the crystal structure is very close to, and indeed may H-bond the catalytic Asp 127
and residue Asp 129 (via a water molecule). This charge repulsion is probably
responsible for the expulsion of product FBP during 'forward' enzyme action so that
its reduction would be favourable.
An alternative way to reduce charge here is the substitution of pentavalent phosphorus
by hexavalent sulphur. Even with X and Y both remaining oxygens making a sulphate,
this gives a charge of -1 compared to the -2 of FBP.
Several attenuated FBP derivatives were also modelled where there was no tetrahedral
group attached to CI. These more resemble F6P than FBP. F6P is known to bind
with around three orders of magnitude greater affinity.
Also considered were some simple modifications of ring substituents. These alone
would not produce non-hydrolysable compounds but could be easily combined with
other modifications.
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GRID was used in two ways during the design process. In the first the program was
used to suggest starting conformations for the molecular mechanics procedure. For
example, the Y=Me modification was studied. There are three oxygen atoms of the 1-
phosphate group which are chemically equivalent, but differently positioned in the
crystal structure. 'Mutating' these to methyl groups would give three distinct possible
starting conformations for this analog. GRID enabled a rational choice to be made
between these possibilities. A methyl probe was used with GRID and produced a
'tube' of favourable contour to which one of the three oxygens was much closer than
the others. That oxygen was therefore the obvious choice for conversion to Me before
molecular mechanics. The other way in which GRID was used was to suggest entirely
new possibilities. For example, contours produced with a protonated primary amino
group probe revealed several highly advantageous positions near active site acidic
residues (Fig 3.4). Amino groups placed in these energy minima could be linked to the
tetrahedral centre by carbon chains. In Fig 3.4 the contours coloured green, yellow,
orange and red indicate, respectively, probe-target interaction energies of -9, -12, -15
and -18 kcal mol"*. The colour scheme for different elements that is used here is
standard throughout this thesis. White atoms represent carbon and red, blue, cyan,
orange and yellow are used for oxygen, nitrogen, hydrogen, phosphorus and sulphur
respectively.
Proper assessment of the results of molecular mechanics on putative inhibitors
required that the intrinsic variability of the procedure be ascertained. The molecular
dynamics procedure has a large random element so that somewhat different results
would be expected from the same starting position after different runs. This was
indeed seen on comparision of three applications of the procedure to the hydrated
crystal structure. Particular variability was noted in the positions of active site arginine
residues 72 and 171, and to a lesser extent 252. This is consistent with their disorder
in determined crystal structures. Also seen was a significant variability in the position
of His249. A large movement of FBP out of the pocket is seen; the PI atom moves
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Fig 3.4 GRID NH^"1" contours at the FBP binding site (see text)
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2.7, 3.1 and 3.5A in the three simulations. In all three cases Metl69 moves to maintain
contact with the FBP as it is pushed out of the pocket and water partially fills the gap
left behind.
The observation of such variability in the protein after runs from identical starting
situations means that differences observed in these regions for runs with analogs are
not necessarily analog-specific.
It was originally envisaged that the compounds would be ranked by energy
measurement. However, the energy measured was sensitively dependent on the
number of water molecules included in the calculation. Arbitrary choices of included
water molecules - 50, 100 etc., lead to different rankings of compounds, diminishing
confidence in this method of assessment. The measurements would in any case have
been of limited utility since they include no entropic component, a factor which would
be expected to vary quite widely among the variously sized molecules studied.
Any reliable method of assessment of compounds should suggest that F6P binds
significantly more tightly than FBP as seen from fluorescence measurement (see Fig.
4.6). The potential objection to this argument is that studies were carried out on a PFK
structure bound to FBP and therefore possibly specifically conformationally changed
by its binding. However, this appears invalid in view of the fact that the various PFK
structures determined appear to vary surprisingly little in the region of the active site
(Schirmer and Evans, 1990). Another method of ranking the molecules, by then-
buried surface area, was unable to predict F6P binding favoured over FBP.
Ultimately then, only fairly qualitative methods were available to judge the likely
binding affinity of compounds. Clearly, H-bonds and salt bridges would contribute to
improve binding affinity. An obvious difference between the molecular mechanics
results for weak binding FBP and tight binding F6P was the complementarity of
enzyme and compound. Thus, a marked movement out of the pocket, presumably
driven by PI - Aspl27 repulsion, was seen for FBP, resulting in the buried face of
FBP pulling away from the enzyme. This also resulted in the loss of the strong H-
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bond to Glu222. In contrast, F6P remains in good contact with the enzyme, its 1-
hydroxyl H-bonding Aspl27. Movement out of the pocket was hence used as an,
admittedly crude, indication of poor binding affinity.
Experiment confirmed that reducing the charge on the PI region, by bonding the
phosphorus to carbon atoms rather than oxygen atoms, seems to produce tighter
binding analogs. The modelled derivative in which X=CH2, and an overall charge here
therefore of -1, moves less far out of the pocket than FBP itself. After molecular
mechanics the phosphorus atoms of duplicate runs were 2.0 and 1.9A from the position
of PI in the crystal structure. This compares with 2.1-3.5k for FBP itself. In addition
this derivative retains the H-bonds observed in the crystal structure. The derivative in
which X is deleted and P directly bonded to CI (called here the null derivative) also has
a charge of -1 on the PI region. However, the loss of one bond places the PI portion
rather closer to Asp 127. This is probably the reason for the greater movement out of
the pocket seen with this compound. Final P atom positions in two null derivative
structures are 2.7 and 2.1A from the PI position in the crystal. In addition, H-bonds
present in the crystal between ligand and protein are broken with for this derivative.
The charge on the PI region is zero for a third studied derivative in which X is again
absent and Y=CH3. This moves very little during the molecular mechanics procedure,
if anything deeper into the pocket, and retains H-bonds. Thus the prediction would be
that X=CH2 and X=-, Y=CH3 more so, would bind with higher affinity than FBP.
Several sulphur derivatives were modelled. Some of the more interesting were null
derivatives in which X is absent. The sulphonate with Y=0" moved very little during
the molecular mechanics and retained the H-bonds found in the crystal. A sulphonyl
fluoride derivative X=-, Y=F was modelled to see if suitable nucleophiles were near the
sulphur in the final structure. Sulphonyl fluorides are a well known class of
irreversible enzyme inhibitors. However, no suitable nucleophiles were seen and the
molecule moved quite far out of the pocket so that the F finally H-bonded Argl71. One
of the most interesting compounds of all was the sulphonamide X=-, Y=NH2 which
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has a charge of zero in this region. Not only does this compound retain the H-bonds of
the crystal structure and pack very well against the enzyme, but the new amide group
forms H-bonds with Aspl27 (Fig 3.5). In Fig 3.5, as elsewhere in this thesis, inferred
H-bonds, as defined by SYBYL, are shown as yellow dotted lines. Another
sulphonamide - X=0, Y=NH2, was less interesting; it retained the original H-bonds
but with the new amide group forming no new ones.
Amongst the group of compounds suggested by GRID maps was X=0, Y=CH20H.
Two different favourable positions were obtainable for the hydroxyl group given the
crystal position of the PI moiety. In both cases molecular mechanics produced good
final structures which retained the H-bonds found in the crystal structure. In one case
the new hydroxyl was H-bonded to Thrl25 and Aspl27, in the other to Gly 11
backbone alone. Several compounds were modelled as a result of the observation of
highly favourable GRID contours for an NH34" probe (Fig 3.4). The compound
X=CH2, Y=CH2CH2NH3+ produced a structure in which the new amino group salt
bridges both Asp 127 and Asp 129 and H-bonds Thrl25. This is achieved without
breaking the H-bonds present in the crystal structure and with the new phosphorus only
1.4A away from the PI crystal position. On the debit side is the addition of two
rotatable bonds whose freezing out of rotation on binding would be unfavourable
entropically. The shorter compound X=CH2, Y^C^NH^4" also looked interesting,
again retaining the crystal's H-bonds and with the new amino group salt bridging
Aspl27 and H-bonding Thrl25. Of the attenuated compounds lacking a tetrahedral
centre attached to CI, only the molecule with a chain CH2NH34" looked very
interesting. This becomes buried deeper into the pocket during the molecular
mechanics procedure enabling the placement of the amino group between Asp 127 and
Glu222.
Possible favourable modification of FBP ring substituents focussed on the
replacement of either C3 or C4 hydroxyl with a primary amino group (NH34"). GRID
contours suggested that either substitution would be favourable but favoured C3,
whereas there appeared to be more space for the new NH34" at the C4 position.
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Modelling and molecular mechanics of the C3-substituted analog produced a highly
attractive structure with the amino group salt bridging both Asp 127 and Glu222 (Fig
3.6). Displacement of the PI group was comparable to FBP itself at 2.6A.
Substitution at C4 yielded a structure in which the new amino group salt bridged only
Glu222 but this appeared to be sufficient constraint to reduce PI movement to 1.6A. In
both cases substitution of OH with CH2NH34" produced poorer structures. Thus OH
to NH3+ substitutions at C3 and C4 of the fructose ring of FBP both appear very
favourable, particularly since they could be combined with favourable PI
modifications.
3.3.2.2 Modelling of available bisphosphates
Two epoxy derivatives of FBP, a and [3 anomers were available (kind donations of Pr.
Jacque Perie, Toulouse). Their structures are shown in Fig 3.7. In addition to having
an epoxide group in place of C3 and C4 hydroxyls, these derivatives were methylated
at the C6 hydroxyl in order to preserve anomericity. Epoxy compounds are of interest
as potential irreversible enzyme inhibitors since they can react with nucleophilic groups
on the enzyme such as aspartates and glutamates. A recent example is the covalent
modification at a glutamate and consequent inhibition of carboxypeptidase A by a
designed substrate analog (Kim and Kim, 1991; Yun et al., 1992).
In the FBP-bound PFK complex crystal structure the FBP is bound as the p anomer.
The p epoxy derivative was modelled from the crystal structure of FBP and energy-
minimised to correct the geometry of the new epoxide group. The FIT command of
SYBYL, using both phosphates and ring atoms, was then used to optimally overlay the
P epoxy derivative onto the FBP crystal position. In this position neither of the
potential nucleophiles for reaction with the epoxide group, the side chains of Asp 127
and Glu222, were well placed. They were both too far away and in poor geometric
relation to the epoxide group.
The a epoxy derivative was modelled by alteration of the p structure. This produced a
relatively symmetric structure so both PI and P6 of the derivative were tested in the P6
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Fig 3.6 The C3 -> NH3+ derivative salt bridges both Asp 127 and
Glu222 after molecular mechanics regime.
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Fig 3.7 Available bisphosphate compounds
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binding pocket. With the derivative P6 placed in this pocket bond rotations were made
to place the ring as close as possible to the FBP crystal structure. However the
resultant structure was poor with PI clashing with Metl69. Placing of PI in the P6
binding pocket produced a more promising result. Bond rotation was able to overlay
four out of five ring atoms onto crystal positions, thus placing the hydrophobic epoxy
group favourably close to Metl69. In this position the derivative P6 could be rotated to
only 1.5A away from the crystal PI position. The methoxy group clashes with Argl71
but this residue, along with other active site arginines is known to be flexible from its
disorder in crystal structures and from molecular dynamics simulations. However, in
this conformation too, neither Asp 127 or Glu222 possesses the correct geometry and
the required proximity to the epoxide group for reaction to be likely. In addition, in
neither this position or in the fitted p analog conformation is there a suitable proton
donor for the nascent -O" that would be generated during reaction.
Thus the modelling studies were pessimistic about possible covalent reaction of either
epoxy compound.
Also available was the phosphorylated furan molecule 'Compound 233' shown in Fig
3.7 (another kind gift of Pr. Perie). This was modelled from scratch using the
SKETCH command of SYBYL. The furan ring has a very different shape to the ribose
ring, being planar with coplanar bonds to the phosphate-bonded carbons. Nonetheless,
with one phosphate placed in the 6-phosphate binding pocket, bond rotation enabled the
other to be placed close to the position occupied by the 1-phosphate of FBP in the
crystal structure. However, the planar furan ring fits very much more poorly than the
puckered ribose ring. This and the loss of several H-bonds due to the absence of




The LUDI runs typically produced several hundred fitted fragments, so that analysis
of each was not feasible. The main selection criterion used was LUDI score. LUDI
produces a score for each fragment fitted, including components relating to goodness of
fit, number of hydrogen bonds and size of fragment. The cut off value was set at 400
or 450 and only those fragments scoring better than this further considered. All of
these were inspected visually. This enabled more to be discarded since some fragments
contained unprotonated amines which were sometimes unrealistically shown H-bonded
to arginines, for example. Another selection criterion was used later after experiment
showed little inhibition by tested compounds. Since the size component in the LUDI
score is relatively weak the larger fitted fragments (those having more than 24 non-
hydrogen atoms) were separately extracted and examined. This produced a few new
ideas. Those fragments approximating whole molecules were then checked for
commercial availability.
3.3.3.2 Further modelling
For most of the interesting fitted fragments, further LUDI runs were carried out to
look for new fragments that might be linked to the original in order to produce a larger,
tighter binding inhibitor. LUDI has options to search for new fragments that can link to
the original at either one or two atoms. Both searches were carried out for each
fragment. The resulting large amount of data will not be discussed in detail,
particularly since experimental testing failed to produce evidence of inhibition by any
LUDI compounds. Instead some representative examples will be discussed to illustrate
the strengths and limitations of this approach, which will undoubtedly be important in
future drug design efforts.
It was immediately obvious that linking new fragments would be of more use in some
cases than others. The original fragments differed widely in the number of potential
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sites for new linkages. Fig 3.8 shows the high scoring fragments from the major
LUDI run of the FBP binding site. Sites to which LUDI found extra fragments could
be linked are shown as starred atoms (one atom linked to new fragments) and bold
bonds (two atoms linked). The number of new fitted fragments suggested varied
widely for these fragments; from zero to 41.
Fig 3.9 illustrates the variety of suggestions for new linked fragments produced for
just one original fit. The original fitted fragment, 4-nitrodiphenylamine (A 18 in LUDI's
nomenclature), is shown in Fig 3.9a H-bonding both Glyll and Asp 129 and with
hydrophobic contacts to Tyrl72. As elsewhere in this thesis, dots are plotted at the van
der Waal's radii of the atoms. The dots are used to give some indication of molecular
volume. In Figs 3.9b-e the new linked fragment is shown according to atom type and
the original A18 fit shown in green. Amongst the suggestions for new fragments
doubly linked to the original are those shown in Figs 3.9b and 3.9c. In Fig 3.9b LUDI
has suggested adding a phenylene group, making the phenyl group of A18 into a
naphthyl group, producing further hydrophobic contacts with Tyrl72. In Fig 3.9c an
ethylene group has been added to A18 bridging the two rings. This produces no
further ligand-enzyme contacts but is a favourable modification since it prevents
rotation of the bonds between the two aromatic groups. This removes the unfavourable
entropic effect of 'freezing out' their rotation on binding that would otherwise occur.
Figs 3.9d and 3.9e illustrate two typical new fragments linked singly to A18. In Fig
3.9d an oxocyclohexyl group has been added, producing further hydrophobic contacts
with Tyrl72 and a new H-bond with Arg 305. Fig 3.9e illustrates the small addition of
a hydroxymethyl group which produces two new H-bonds, with Aspl29 and Thrl25.
In a few cases more detailed modelling was carried out. An illustrative example is the
compound phenylene-1,4-diacetate (BA4), whose original fit appeared to visual
examination to be sub-optimal, which was analysed as follows.
Charges were calculated and the improper torsion angle definitions required to
maintain ring planarity defined by analogy with tyrosine. A selection of calculated
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Fig 3.8 Linkage potential of fitted fragments
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Fig 3.9a Original LUDI A18 fit showing contacts with enzyme
Fig 3.9b Added ring Fig3.9c Intramolecular addition
r / *
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Fig 3.9d Another added ring Fig3.9e Added hydroxymethyl
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water molecules within 10A of BA4 yielded 288 molecules. The energy minimisation
and molecular dynamics protocol described in the Methods was then carried out.
Residues of the protein within 5A of BA4 were mobile during this procedure with a
'buffer zone' defined as residues within 8A of BA4. The result is shown in Fig 3.10.
H-bonds are indicated and the dots indicate the atomic radii of BA4 and of GlylO and
Arg72 with which BA4 forms hydrophobic contacts. This final conformation is the
product of large movements of both BA4 and protein. The atoms of BA4 have moved
2-3A. The largest protein change is the swing of Tyr41 towards the hydrophobic BA4.
The hydroxyl oxygen of Tyr41 moved more than 5A and a new H-bond with Glyl04
backbone oxygen was formed. This conformation looks much more favourable than
that found by LUDI, particularly in respect of H-bonds. The BA4 carboxylate salt-
bridging Arg72 in the LUDI conformation now additionally salt-bridges Argl71. The
other has moved so that two H-bonds, to Phe93 and GlylO backbone NH groups, are
present compared to one in the LUDI structure. The improvement in conformation seen
after the molecular mechanics procedure illustrates the value of visual examination of
potential ligand structures. As elsewhere in this thesis, is is apparent that there remains
an important role for the human operator; a combination of computer and human seems
to produce the best results.
3.3.3.3 Potential species selectivity
With its approach of linking new, sometimes large, fragments to an original fitted
fragment, LUDI was considering regions of the protein quite distant from the catalytic
site. A check was therefore made to see if any of the E.coli PFK residues contacted by
fragments were different in RMPFK. Radical differences could form the basis of
binding specificity between the two enzymes and hence possible species selectivity.
Of the residues in the vicinity of the FBP binding site the most interesting were E.coli
PFK His223 which is replaced by Gly at the RMPFK active site and Arg305 which is
Asp in RMPFK. Lysl31 in E.coli PFK is replaced by Cys in RMPFK. Also different,
but less so, were Tyrl72 (His in RMPFK) and lie 130 (Phe in RMPFK).
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A scan of previous search results showed that fragments contacting His223 fell into
two categories. The first was fragments of a guanidino type shown H-bonding
His223. Binding of this is made unlikely by charge considerations and is an indication
of one LUDI limitation: its ignoring of charge. The second class showed only
hydrophobic contacts to His223 whereas exploitation of the His residue's H-bonding
potential would appear to be a better route to enzyme inhibition specificity. A
search was therefore carried out in the region around His223. Among the most
promising fits was 1,2 benzene dimethanol (HI7 in LUDI's nomenclature). This
fragment can be fitted to H-bond Glu222 and Argl71 as well as His223, and also to
form hydrophobic contacts to His223. Further runs were carried out to find fragments
that could be advantageously linked. Amongst the candidates were a tetrahydrofuranyl
group that H-bonded Argl71 as well as providing two further hydrophobic contacts to
Tyrl72, and a hydroxyethyl group that H-bonded His249. The original H17 fit and the
linked tetrahydrofuranyl group are shown in Fig 3.11. Interestingly, a P6 site filling
motif - an ethanoylamino group H-bonding His249 and Arg252, that had been
previously seen, reappeared. Other extra fragments were found that further contacted
His223.
A de novo search around Arg305 produced several ideas, the most interesting of
which was isatin (AM7 in LUDI's nomenclature). Both carbonyl groups are H-bonded
to Arg305 while the NH can H-bond Asp 103. In addition this fragment seems close
enough to the ATP site to hinder binding. A particularly favourable extra fragment to
link to this was a 8-valerolactam ring which produced two extra H-bonds.
A search in the vicinity of lie 130 suggested that a 2,5-diaminopyrimidine (DAP)
moiety could be a favourable component of a viable inhibitor . This overall positively-
charged fragment can be placed within H-bonding distance of three aspartates - residues
103, 127 and 129. Interestingly, extra fragments can be linked to this base to H-bond
Arg305. Simultaneous extra fragments can H-bond Glyl 1 backbone. Figure 3.12
shows the fitted DAP fragment with a linked N-methyl-2-pyrrolidinone fragment H-
bonding Arg305.
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Fig 3.11 Original LUDI H17 fit and linked fragment
120
3.3.4 Naphtho compounds
3.3.4.1 2D similarity search
The compound naphthoquinone-4-sulphonic acid (NQS) (see Fig 3.14) was tested
experimentally (Chapter 4) as a result of a resemblance to a LUDI find pointed out by
Pr. Perie. The compound proved interesting and was therefore used as input for a 2D
similarity search. A representative selection of the results is shown in Fig 3.13 and
their names in Table 3.1. The two significant limitations on the number of compounds
that could be tested were commercial availability and the likely insolubility of many of
the suggestions. Those selected for further testing are shown in Fig 3.14 and will be
referred to as HNNS, AHNS and ANQ. ANQ was not suggested by the similarity
search, probably because of non-inclusion in the database, but was commercially
available. One of these, AHNS, was found to be unstable with solutions discolouring
over days even in the dark at 4°C. No further testing of this compound was carried
out. The three remaining compounds were of such variety as to enable the testing for
importance of features of the NQS molecule. Thus, ANQ has the quinone grouping of
NQS but not the sulphonic acid group. Similarly, HNNS retains the sulphonic acid
group of NQS but is not a quinone.
3.3.4.2 Molecular modelling
After the naphtho compounds were found to affect PFK, the attempt was made to find
potential binding sites for them on the PFK structure. Attention was focussed on the
F6P binding site by the cooperative character of some of the effects (see Fig 4.26).
Also borne in mind was the apparent order of potency ANQ > NQS > HNNS (Fig
4.26).
Several GRID maps were used in the search for potential binding sites. The common
factor between the naphtho compound is the large hydrophobic naphthalene carbon
skeleton. The GRID program was run on a region encompassing the F6P binding site
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Fig 3.13 Some 3D similarity search results
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Table 3.1 Some 3D similarity search results
Number Name of compound
in Fig 3.13
1 4-fluorosuiphonyl-1-hydroxy-2-naphthoic acid








with an aromatic CH probe. Contouring at -4.5, -4, -3.5, -3, -2.5 kcal/mol produces a
large relatively favourable region due to a hydrophobic protein patch near Met69 and
He 126. The naphthalene skeleton can be fitted into this region so that most of its
carbon atoms are within the favourable contours (Fig 3.15).
The two carbonyl oxygens of NQS were considered next. GRID output for a
carbonyl oxygen probe was contoured at -4.5, -4, -3.5 and -3 kcal/mol. With only a
small movement of the naphthalene skeleton both NQS oxygen atoms could be placed
in favourable contours. The deeper of these contours is due to the nearness of the
He 126 backbone NH to which a carbonyl oxygen could hydrogen bond. In this
position the sulphonic acid group of NQS overlaps the end of the Argl71 side chain.
The several Arg side chains at the active site are known to be very flexible, both from
molecular dynamics simulations and from their disorder in crystal structures. An
alteration in Argl71 side chain position would enable a salt bridge to be formed with
the NQS sulphonic acid group and so this model seemed to suggest a plausible NQS
binding mode. However, this conformation is not consistent with the observed order
of potency ANQ > NQS since the sulphonic acid of NQS would be favoured over the
amino group of ANQ in the position near Argl71.
An alternative conformation was obtained by rotating the naphthalene skeleton 180°
around its long axis. In this position, only one of the carbonyl oxygens of NQS can be
placed in the favourable contours while retaining most of the carbon in the CH
contours. The other is very close to Argl71, but this is very flexible.
The new positions of NQS sulphonic acid and ANQ amino groups were compared
with GRID maps of sulphur double-bonded oxygen (contoured at -5.5, -5, -4.5, -4, -
3.5 kcal/mol) and a :NH2 group (contoured at -12, -10.5, -9, -7.5 kcal/mol).
Interestingly, patches defined by -9 kcal/mol :NH2 and -5 kcal/mol 0= contours were
found to coincide between Glyl 1 and Ilel26. By a small movement of ANQ, a
compromise position partially satisfying 0(=C), :NH2 and CH contours was found.
For this conformation, only minor clashes could be seen between the ANQ surface and
a solvent-accessible surface calculated for the protein in the vicinity. This conformation
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Fig 3.15 Naphthalene skeleton fitted to GRID aryl CH contours
enables the H-bonding of both carbonyl oxygens to the protein at Thrl25 and Argl71
(Fig 3.16). This conformation was also consistent with the order ANQ > NQS since,
while there was room for the larger SO3" group, none of the three oxygens was even in
the -3.5 kcal/mol contours.
The consistency of this position with the order NQS > HNNS was considered next.
The two carbonyl oxygens were replaced with hydroxyl and nitroso groups. The
GRID hydroxyl contours (at -8, -7, -6 and -5 kcal/mol) encompassed the HNNS OH in
the -5 kcal/mol region. The GRID program does not have a nitroso oxygen (0=N)
probe and so both 0=C and 0=S were used. However, no amount of rotation of the
nitroso group could place the oxygen in favourable contours for either of these, despite
lack of steric problems.
Thus a plausible binding position for the naphtho compounds at the F6P binding site
has been found. Semi-quantitative considerations can reasonably explain the potency
order ANQ > NQS > HNNS.
Interestingly, the sulphonylfluoride compound (molecule 1 in Fig 3.13) when placed
in this conformation has its sulphur atom only 3.2A from the side chain oxygen of
Thrl25. The hydroxyl group of this molecule is also favourably placed to H-bond to
Argl71. This suggests at least the possibility that this molecule might covalently react
with PFK. Reaction at the F6P binding site would of course permanently destroy
activity.
3.4 Conclusions
A variety of methods have been applied to the same problem - the design of potential
inhibitors of E.coli and RM PFKs. The variety of established methods, many
unavailable to test here, is a reflection of the intense effort focussed on the field of
rational drug design. The different methods produced results of varying quality (see
Chapter 4). The relationship between results and method employed will be discussed
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in Chapter 5.
Both database searches carried out were relatively rapid, each taking under an hour.
The main limitation with each was the size of the database used. This was about
50,000 for the Fine Chemical Directory and about 90,000 (with many duplications) for
the Cambridge Crystallographic Database (CCD). The CCD search looked for
molecules having a relatively small motif that might fit into the P6 pocket. This, and
the size of the database, made it unlikely that high affinity compounds would be found
by this method. Nonetheless phosphoethanolamine and phospho-D-serine particularly
were worthy of further investigation. The Fine Chemical Directory search produced
many ideas. Here the most significant limitations were commercial availability and, to a
lesser extent, water solubility. Unfortunately, one of the remaining three compounds
appeared to degrade in solution with time. However, the other two were significantly
and usefully different to the search molecule. After the observation of activity for these
compounds GRID was used to attempt to locate a likely binding site. A plausible site
was found which was consistent with characteristics of their activity.
Three donated bisphosphates were modelled. These were designed as potential
aldolase inhibitors rather than with PFK in mind. They more resemble FBP, which
binds PFKs with low affinity, than substrate F6P. Given this, and the fact that their
differences to FBP seemed unfavourable in terms of PFK binding, the likelihoods of
their binding with high affinity seemed small.
The designed FBP analogs are a different matter. The fact that they share a large
fraction of molecular structure with known PFK ligands suggests that they are highly
likely to bind to the enzyme. The fact that generally only small changes were made to
the known crystal FBP complex structure also has an important consequence for the
validity of the modelling studies. This, and the fact that the modifications that were
made were positioned in the light of GRID results, suggests that, after even the
relatively short 1.6ps molecular dynamics simulation, an approximation to the global
minimum should have been reached. The results themselves were generally in good
agreement with GRID results. Thus ligand substituents were found in favourable
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GRID contours. Significant exceptions were found in sterically tight positions so that
the position adopted by the amino group of in these places did not coincide
perfecdy with NH34" contours. However these results overall generally further
emphasise the high quality of GRID results. The validity of the notion of reducing the
charge on the 'PI' part of the analogs in order to reduce repulsion from Asp 127 was
amply supported by the results with uncharged analogs particularly favoured. The
results also suggest that substitution of ring hydroxyls with primary amino groups
would produce tighter binding. Incidentally, this is precisely the change made by von
Itzstein et al. (1993) in their fruitful work on influenza sialidase inhibitors. The great
limitation of these FBP analogs has been their entailing specialised synthesis. Indeed,
unfortunately, none of these compounds has been made and so suggestions of their
usefulness remain essentially speculative. This was also the slowest design method
used; the molecular mechanics procedure alone took several hours for each modelled
compound. A particularly good candidate for any later synthetic work would be the
sulphonyl chloride (X=-, Y=C1). This would be readily transformed into a variety of
potentially interesting compounds including the sulphonic acid and the sulphonamide.
The LUDI method of drug design had intermediate time requirements; each run
typically took under an hour. One apparent disadvantage was the program's ignoring of
charge on fragments and protein. This led to its suggesting unrealistic H-bonds
between groups almost certain to be similarly charged. Systematic user oversight was
therefore essential. This method produced the widest variety of ideas, but with the
significant limitation that most of the fragments in the database were quite small (fewer
than 20 atoms). This is a reflection of the LUDI approach of linking several fragments
to make an inhibitor. The small size, however, does impose a limit on the tightness of
binding that may be expected, so that fragment testing for inhibition would be expected
to have only limited success. This is important since it hinders the sequential approach
of finding one fragment with significant affinity and then building further on that. If
fragment combinations must be tested experimentally as a first step then the approach
also has chemical synthesis as a limiting factor. An important strength of LUDI over
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the substrate analog approach is evident when considering possible enzyme selectivity.
Significant amino acid differences between E.coli and RM PFKs are only found at a
distance from the FBP binding site. They are too far away for FBP modifications such
as those described in Section 3.3.2.1 to contact. In contrast LUDI suggests fragments
to bind to these different amino acids with other linked fragments able to overlap






4.1.1 How to study ligand interaction
The most fundamental property of a ligand-receptor system is its binding affinity.
Once this has been determined then further studies can be carried out to locate the site of
any binding and detailed changes in receptor behaviour arising from it.
Detection of ligand binding usually demands a detectable change in one or more
properties of the receptor on binding. From the broad repertoire of detection methods it
is likely that only a subset will be appropriate for a particular receptor-ligand system.
For example, binding may cause no change in the receptor property or the ligand under
investigation may interfere with the method of observation.
Spectroscopic methods are often convenient ways to assess ligand binding. For
example, fluorescence and CD spectra are often sensitive to ligand binding. These
methods depend on suitably positioned aromatic residues (usually Trp) or prosthetic
groups. Nuclear magnetic resonance gives much more detailed information but
requires sophisticated instrumentation. All spectroscopic measurements are susceptible
to interference by ligand absorption. This may impose an upper limit on the
concentration of ligand tested. This can be particularly undesirable during early stages
of ligand screening when trying to detect relatively weak binding.
It is usually possible to perturb the quaternary structure (dissociation of subunits) or
tertiary and secondary structure (denaturation) using heat or chemicals such as urea or
GdnHCl. Ligand interaction often stablises the receptor against such insults thus
providing an indirect method to detect binding. The association state of the receptor can
be determined by, for example, gel filtration or intra-molecular cross-linking followed
by quantitation on SDS-PAGE gels. Receptor denaturation is monitored by loss of
activity or changes in fluorescence or optical activity. Protection against chemical
modification or proteolysis may also be conferred by ligands and is another way to
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assess their binding.
The most direct method of measuring ligand interaction is equilibrium dialysis. This
will detect binding which produces no change in receptor properties, but is limited by
its requirement for radioactive ligand. Radioactive ligands are more expensive and/or
more difficult to prepare than non-radioactive ligands. In addition the method is only
applicable to tight binding since the free ligand concentration must be changed by the
protein.
4.1.2 Detection methods applied to E.coli PFK
4.1.2.1 Kinetics
Enzyme assays for PFK reaction in both directions have been standardised. F16BP
synthesis is assayed by conversion to glyceraldehyde-3-phosphate by aldolase and
triose phosphate isomerase. This is converted to glycerol-3-phosphate by glycerol-3-
phosphate dehydrogenase with the concomitant oxidation of NADH monitored at 340
nm. Creatine kinase and creatine phosphate are included to convert the ADP produced
back to ATP (Kotlarz and Buc, 1982). In the reverse direction F6P is acted upon by
phosphoglucose isomerase and glucose-6-phosphate dehydrogenase. The latter step is
coupled to reduction of NADP+ to NADPH again monitored at 340 nm. Glycerol and
glycerol kinase are included to regenerate ADP from ATP (Hellinga and Evans, 1987).
4.1.2.2 Fluorescence
The E.coli PFK tetramer contains one Trp residue (Trp 311) per subunit. These
tryptophans are situated at the subunit interface within each dimer of the dimer-of-
dimers structure (see Section 1.3.1.1). They can be selectively excited by radiation at
295 nm and have a fluorescence emission peak around 337 nm. The magnitude of the
fluorescence is sensitive to the binding of ligands to both catalytic and regulatory sites
(Berger and Evans, 1991; Deville-Bonne and Garel, 1992). The fluorescence
behaviour of E.coli PFK provides much information about the nature of its allosteric
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behaviour and has already been discussed in Section 1.3.1.2.
4.1.2.3 Protection against denaturation
The dissociation and denaturation of E.coli PFK have been studied in some detail.
Agents able to induce these processes are urea (Le Bras et al., 1989; Teschner et al.,
1990a), GdnHCl (Teschner and Garel, 1989), thiocyanate (Deville-Bonne etal., 1989),
high hydrostatic pressure (Deville-Bonne and Else, 1991) and heat (Teschner et al.,
1990b). Dissocation and denaturation can then be observed in several ways.
In the absence of ligands the pathway followed by E.coli PFK on exposure to
denaturant is
N <=> 2 D <=> 4 M <=> 4 U
where N represents the native tetramer and D, M and U the dimeric, monomelic and
unfolded species. As previously stated, the tetramer crystal structure shows two kinds
of inter-dimer interfaces. The smaller one of around 1200 A2 contains the active site
(the A interface) and the larger one of 1800 A2 the regulatory site. With increasing
concentrations of denaturant, the A interface dissociates first with simultaneous loss of
enzyme activity (Le Bras et al., 1989; Deville-Bonne et al., 1989). The R interface
contains the Trp residues so that its later dissociation can be monitored by a large
change in fluorescence as the Trp becomes solvent-exposed. At still higher denaturant
concentrations the enzyme unfolds. This secondary structure loss can be monitored
using ellipticity at 222 nm.
F6P strongly protects the tetramer against dissociation into dimers (Deville-Bonne et
al., 1989; Teschner et al., 1990a; Deville-Bonne and Else, 1991). This is consistent
with its situation in the crystal structures between subunits. In the presence of
saturating F6P the A interface becomes at least as stable as the R interface. No dimers
can then be detected during the denaturation with the enzyme displaying all-or-nothing
dissociation.
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The regulatory sites of the dimeric species can still bind PEP but have lost their ability,
seen in the tetrameric species, to bind GDP. PEP, but not GDP, is seen to stabilise the
dimeric form against further dissociation (Deville-Bonne et al., 1989).
ATP is seen to cause little or no protection against denaturation (Deville-Bonne and
Else, 1989; Le Bras etal., 1989). This is presumably because ATP binds to residues
within a single subunit, rather than binding between two subunits as F6P does (see
Section 1.3.1.1)
4.1.2.4 Other methods
The regulatory ligands of E.coli PFK, GDP and PEP, have been found to protect the
enzyme against subtilisin proteolysis whereas F6P gave little protection (Le Bras and
Garel, 1982). The proteolysed form showed no regulation by GDP or PEP. In the
light of the crystal structures these results are readily explained. The C-terminal residue
contributes to the regulatory site so that its loss abolishes regulation. Similarly, ligand
binding to the native enzyme stabilises the C-terminal tail reducing its susceptibility to
proteolysis.
Recently, important information has been obtained using equilibrium dialysis with
radioactive substrates (Deville-Bonne and Garel, 1992). Surprisingly, only binding of
two F6P molecules per tetramer could be detected whereas the expected four ATP
binding per tetramer was seen. The source of this 'half-of-sites' reactivity is unknown
but may be related to visible signs of asymmetry in the dimer-of-dimers crystal
structure. For example, in the PFK.ADP.FBP ternary complex two of the active sites
are in an 'open' conformation and two in a different 'closed' conformation.
4.1.3 Detection Methods applied to Rabbit Muscle PFK
RMPFK seems to yield much less information to standard ligand binding studies.
Using tryptophan fluorescence (excitation at 294nm and emission at 335nm) two
nucleotide binding sites were identified, one associated with an increase in fluorescence
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and the other a decrease (Pettigrew and Frieden, 1979). By the responses of different
nucleotides the former was identified with the active site and the latter with the
inhibitory site. F6P had only a very small effect on fluorescence.
Fluorescence also showed that the environments of tryptophan residues altered on
formation of RMPFK tetramer (Cai et al., 1990). CD was also used in this study and
showed no significant changes during formation of RMPFK tetramer. CD also showed
that no large changes in secondary or tertiary structure were produced on binding of
ligands to RMPFK.
The binding of ATP to RMPFK and its dependence on concentration of inhibitors
citrate, PEP and phosphoglycerate has been investigated by equilibrium dialysis
(Colombo etal., 1975).
These results, taken together, suggest that only equilibrium dialysis, which requires
radioactive ligands, or kinetic studies are useful for studying ligand interaction with
RMPFK. RMPFK activity can be monitored using the same coupled enzyme systems
as for E.coli PFK (see Section 4.1.2.1).
4.2 Materials and Methods
4.2.1 Materials
4.2.1.1 Enzymes
The coupling enzymes aldolase, triose phosphate isomerase, glyceraldehyde-3-
phosphate dehydrogenase, phosphoglucose isomerase, glucose-6-phosphate
dehydrogenase and glycerol kinase were all from Sigma Chemical Co. (Poole U.K.).
Rabbit Muscle phosphofructokinase was also from Sigma as an ammonium sulphate
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suspension. Creatine kinase was from Boehringer Mannheim (Lewes, U.K.).
4.2.1.2 Chemicals
Tryptone and yeast extract were from Oxoid Ltd. (Haverhill, U.K.) or Difco Labs.
(East Molesly, U.K.). Agar was from Oxoid.
Sodium chloride, calcium chloride, potassium chloride, urea, EDTA and Tris were
all from Sigma as were ampicillin, IPTG, Meldola blue and MTT. F6P, FBP, NADH
and NAD+were also from Sigma. GdnHCl was Sigma Grade 1. Phospho-D-serine,
Phospho-L-serine, phosphoethanolamine, phosphocholine and phosphocreatine were
also from Sigma. Also from Sigma were the proteolysis inhibitors 1,10-
phenanthroline, dichloroisocoumarin and E64.
Glycerol and phosphoric acid were from Aldrich Chemical Co. (Poole, U.K.) as
were the LUDI compounds shown in Table 4.4.
Sodium hydroxide and sodium azide were from BDH (Poole, U.K.)
4.2.1.3 Bacteria and Plasmids
The E.coli PFK expression plasmid pHLl (Lau et al., 1987) was the kind gift of Dr.
P.R. Evans (University of Cambridge) as was the plasmid carrying the K213A mutant
sequence. Dr Evans also generously supplied a culture of the E.coli PFK strain
DF1020 which lacks a genomic copy of the E.coli PFK gene. This was used for
preparation of mutant PFK.
4.2.1.4 Hardware
Spectrophotometry was carried out on a Unicam 8700 Series UV/Visible
spectrophotometer. Fluorescence measurements were made on a Perkin-Elmer LS-3B
fluorescence spectometer. A Beckman J2-21 centrifuge with JA20 rotor was used for
cell harvesting and during generation of competent cells. Ultracentrifugation was using
a Beckman TL100 machine with TL100.3 rotor. A Pharmacia FLPC system was used




Competent cells were prepared by the method of Cohen etal. (1977). 0.5 ml of an
overnight culture of E.coli was innoculated into 50 ml of 2xTY medium (16 g 1"^
tryptone, 10 g 1~ ^ yeast extract and 5 g 1" ^ NaCl) and grown until the OD600 was in the
range 0.3-0.5. The cells were recovered by centrifugation in a JA20 rotor at 5000
r.p.m. for 15 mins at 4°C. The pellet was resupended in 10 ml of ice-cold 0.1M CaCl2
and stored on ice for 30 mins. The cells were recovered as before by centrifugation.
For transformation, three 200 pi aliquots were taken into microfuge tubes. 2 pi of
pHLl miniprep were added to tube 1. For a DNA control, 1 pi of a 10 ng pl~l
preparation of pUC18 was added to tube 2. Nothing was added to tube 3 which served
as a blank control. The bacteria were then subjected to a heat shock of 42°C for 90
seconds before chilling on ice for 2 minutes. After the addition of 200 pi 2xTY
medium, the bacteria were allowed to recover for 30 minutes at 37°C. 200 pi from
each tube was then transferred to a 1.5% agar plate made from lxTY and including 100
pg ml"! ampicillin. After overnight incubation at 37°C, colonies were seen on plates 1
and 2. A stock preparation of TGI transformed with pHLl was made by transferring a
single colony, by toothpick, to 10 ml of 2xTY containing 100 pg ml"^ ampicillin. This
was grown overnight in an orbital shaker at 37°C before storage at -20°C as a 15%
glycerol solution.
4.2.2.2 Preparation of E.coli PFK
100 pi of the TGl/pHLl glycerol stock was innoculated into 10 ml of 2xTY
containing 100 pg ml"^ ampicillin and grown overnight at 37°C with shaking. Three
250 ml flasks each containing 150 ml 2xTY with 100 pg ml"^ ampicillin and IPTG at
70 pg ml'l were prepared and 1.5 ml of the overnight culture innoculated into each.
The cells were grown for about 24 hours at 37°C with shaking and harvested by
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centrifugation at 3000 r.p.m. in a JA20 rotor at 4°C for 20 minutes.
The cells were resuspended in 10 ml of low-salt buffer (LSB) comprising 50mM Tris
buffer pH 7.9, ImM EDTA and lOmM DTT. Protease inhibitors were then added to
the following concentrations - 100 jiM dichloroisocoumarin, 100 (iM 1,10-
phenanthroline and 20 qM E64. The cells were then sonicated on ice for three 30
second bursts with two minutes between each burst. The resultant solution was spun
for 20 minutes at 100,000 r.p.m. and 4°C in an ultracentrifuge. The supernatant was
applied to a 2 ml Cibacron blue 3GA column previously equilibrated with LSB. After
washes with 2 ml LSB and 6 ml LSB + 1.5M NaCl, PFK was eluted with 9 ml of LSB
+ 2mM ATP and lOmM MgC^. The column was cleaned with 6 ml of 8M urea +
0.5M NaOH and stored in LSB + 0.02% sodium azide.
Fractions containing PFK were purified further by gel filtration using a Superose
S200 column. The buffer used was 50mM Tris, 4mM EDTA, 2mM DTT at pH 7.9.
PFK eluted in a peak at 10 ml and was stored at 4°C.
4.2.2.3 Enzyme Assays
'Forward. Assay'
The assay contained lOmM MgC^, lOmM NHqCl, 40mM KC1 and lOmM creatine
phosphate in 33mM Tris acetate buffer at pH 8. Around 0.4 qg NADH from a solution
made fresh each day was present in each assay. Coupling enzymes were present in the
following amounts 0.6 U aldolase, 3 U glycerol-3-phosphate dehydrogenase, 26 U
triose phosphate isomerase, 4 U creatine kinase. ATP and F6P were added from stock
solutions of lOOmM and 20mM respectively. The total assay volume was 1 ml.
Reaction was started by addition of PFK and the reaction rate measured as the rate of
decrease of A34Q in a spectrophotometer connected to a 25°C circulating water bath.
When acidic or basic compounds were being tested, the buffer concentration was
increased to around 260mM Tris.
Because of the limited quantities of epoxy compounds available, F6P response
curves were determined for single reactions. The concentration of F6P in the cuvette
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was sequentially increased by addition of small aliquots from a 20mM solution. After
each addition the reaction rate was allowed to stabilise for two minutes before rate
measurement over the next minute. Calculations showed that at the reaction rates
produced, levels of reactants were not significantly depleted during the course of the
experiment.
'Backward Assay'
lOmM MgC^, lOmM NH4CI, 40mM KC1 and around 0.5 pM NADP+ were
present in the 30mM Tris acetate buffer which also contained 10% glycerol. The buffer
concentration was again increased when assaying acidic or basic potential inhibitors.
Coupling enzymes were present in the following amounts 2 U phosphoglucose
isomerase, 0.5 U glucose-6-phosphate dehydrogenase, 0.4 U glycerokinase. ADP and
F16BP were added from stock solutions of 50mM and lOOmM respectively. The total
assay volume was 1 ml. The reaction was started by the addition of PFK and measured
as the rate of increase of A34Q at 25 °C.
Some of the compounds to be tested absorbed strongly at 340 nm severely limiting the
concentration that could be tested. In these cases a modified assay was used. A dye
mix was prepared from 250 pi of a frozen stock solution of 1 mg ml"^ Meldola Blue
and 6 mg MTT made up to 1 ml with water. 50 pi of this mix was included in each
assay enabling the rate to be monitored at 540 nm.
Rabbit Muscle phosphofructokinase
Before enzyme assay, RMPFK was dialysed overnight against one litre of 33mM Tris
acetate buffer pF18 with ImM EDTA and ImM DTT. Particulate matter was removed
by filtration through a 0.2pm filter. The preparation was found to be unstable and so
was used within the next day. Assay conditions were exactly as for E.coli PFK.
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4.2.2.4 Fluorescence
Intrinsic E.coli PFK fluorescence was measured as the emission at 337 nm on
excitation at 295 nm. PFK was present at around 30 pig per experiment, in the region
in which PFK fluorescence depends linearly on concentration (Berger and Evans,
1991). The buffer used was 33mM Tris acetate pH8 or 495 mM Tris acetate pH8 for
acidic and basic compounds. Aliquots of concentrated test compounds were added and
the change in fluorescence recorded at 25°C. Correction was made for changes in
volume. When ADP fluorescence response was determined lOmM MgCl2 and lOmM
KC1 were included.
4.2.2.5 Protein Assay
This was by a modification of the method of Bradford (1976). Dye reagent was
prepared by dissolving 20mg Coomassie Blue G-250 in 20ml 85% phosphoric acid and
10 ml 95% ethanol then adding 160 ml water and 10ml 1M NaOH. Protein samples of
up to 10 |il and up to 2(ig were mixed in cuvettes with 1ml of the reagent. After 5
minutes incubation, A590 was measured and the protein concentration determined by
comparison with a standard curve constructed using bovine serum albumin.
4.2.2.6 Denaturation by GdnHCl
Duplicate incubations were set up over a range of GdnHCl concentrations. Each
Eppendorf tube contained 4 jag PFK in a volume of around 10 |al plus 20 |ll of 495mM
tris acetate buffer pH 8. The volume was made up to 100 |ll with 8M GdnHCl and
water to give the desired concentration. For binding testing some of the water was
substituted with a solution of the compound to give concentrations that were saturating
for known ligands or as high as possible for putative ligands. The tubes were then
incubated at room temperature, originally overnight and later for 4 hours. ImM DTT
was included in the later assays. The residual activity was measured using the forward
assay or, in the case of F16BP protection assays, the backward assay.
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4.2.2.7 Thermal Denaturation
Thermal denaturation of E.coli PFK was carried out in the absence or the presence of
various concentrations of ligand simultaneously using the cell transport facility of the
spectrophotometers. Within each set of experiments the amount of PFK was identical
at 20-30 (ig. The volume of PFK solution was made up to 1 ml with 33mM Tris
acetate buffer pH 8 and/or ligand solution in quartz cuvettes. The cuvettes were then
transferred to a spectrophotometer prewarmed by circulating water to 60°C. In later
experiments ligand solution was prewarmed to 60°C before addition of PFK.
The absorbance at 280 nm was monitored and for each incubation a maximum rate of
change estimated from the trace. In some cases maximum change seen was
informative. Both quantities were expressed as a % of the control containing no ligand.
4.2.2.8 Analytical Gel Filtration
The association state of E.coli PFK was monitored by FPLC. A Superose 12 column
was used and a 50mM Tris buffer pH 7.9 containing ImM EDTA and 2mM DTT and
various concentrations of PDS used throughout. Detection was at 280nm. Peaks
corresponding to PFK tetramer and monomer were seen at elution volumes of 9.8ml
and 14.8ml respectively.
4.2.2.9 Curve Fitting
Fluorescence and kinetic data were fitted to either the hyperbolic (Michaelis-Menten)
equation, which for fluorescence is
F=FmaxS/(S+Ks)
or the sigmoidal (Hill) equation
F=FmaxS"/(S" + S0.5n).
Here, F is the observed fluorescence change at concentration S of ligand. The
calculated parameters are Fmax, the fluorescence change at saturating ligand, Ks, the
ligand's dissociation constant, Sq 5, the concentration of ligand required for half-
maximal fluorescence change and n, the Hill coefficient (sometimes called npj). The
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program Fig.P for Windows Version 1.1 (Fig.P Software Corporation, Durham, North
Carolina) was used. This calculates a standard error (S.E.) for each parameter. Values
are cited as mean ± S.E.
4.3 Results and Discussion
4.3.1 Developments of enzyme assay
4.3.1.1 Effect of solvents on assay
Many of the potential ligands to be tested were found to be poorly soluble in water.
The effect of more hydrophobic solvents on the enzyme assays was then determined to
see if the compounds could be added to the assay from stock solutions in these
solvents.
Figure 4.1 shows the effects of ethanol, methanol, DMF and DMSO on measured
E.coli PFK rate in the standard 'forward' assay. Methanol and ethanol show similar
behaviour with an immediate decline in rate observed at 5% solvent and further
decreases to less than 20% original rate at 20% solvent. In contrast, the less
hydrophobic solvents DMF and DMSO appear not to affect rate at 5% solvent, but
produce a decline thereafter.
Figure 4.2 shows the results of a similar experiment using RMPFK. Again, ethanol
even at 5% decreases the observed rate, and at 20% solvent stops the reaction entirely.
However, as with E.coli PFK it seems that 5% DMSO can be present without affecting
the observed rate.
In the light of these results, water-insoluble compounds were made up as DMSO
solutions and added to the assay at up to 5% DMSO.
4.3.1.2 Monitoring at 540nm with dyes
The effect of addition of 65gl of 3.9mM NADH on the spectrum of a solution of
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0.00025% Meldola Blue, 0.03% MTT in 33mM Tris acetate buffer pH8 is shown in
Fig 4.3. Large increases in absorbance in the region 460nm to 600nm can be seen. The
effect of addition of aliquots of the same NADH solution to another dye solution are
shown in Fig 4.4. Almost linear changes in absorbance at 540nm and 570nm can be
seen as the amount of NADH added increases. The tailing off of absorbance change is
only significant after the addition of amounts of NADH in excess of the total NAD+
present in the standard 'backward' assay.
The rate of change of A540 with respect to enzyme concentration was then determined
in a standard 'backward' assay mix containing the dyes. Fig 4.5 shows the linear
dependence seen with rate measured between 2 and 4 mins after addition of enzyme.
Further experiments showed that DMSO had no effect on the electron transfer from
NADH to Meldola Blue and MTT and that these dyes did not affect the rates of PFK or
the coupling enzymes of the 'backward' assay.
Taken together these results suggested that the Meldola Blue/MTT system could




The intrinsic fluorescence of E.coli PFK due to Trp311 is responsive to a variety of
natural ligands. Typical traces for F6P, F16BP and ADP are shown in Fig 4.6 with
parameters from curve fitting summarised in Table 4.1. Both F6P and F16BP show
similar sigmoidicity and maximum fluorescence quench. ADP in contrast gives a
purely hyperbolic fluorescence response.
The sigmoid fluorescence response to F6P differs from previous work (Deville-Bonne
and Garel, 1992; Berger and Evans, 1991) which found a hyperbolic response. The
fluorescence behaviour of PFK does seem to be very sensitive to conditions. For
example, Deville-Bonne and Garel report a maximum fluorescence quench of 20% by
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Figure 4.3 Effect of NADH on spectrum of dve solution
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F6P whereas Berger and Evans find a 35% quench. However, the finding of a
sigmoid fluorescence response in this work could also imply the presence of ATP in the
enzyme preparation. This would be surprising after a gel filtration purification step, but
the possibility should be borne in mind. Other values in Table 4.1 are in line with
previous findings.
4.3.2.2 Thermal denaturation
F6P was found to be able to slow the increase in A2$q produced by heating PFK at
60°C. Fig 4.7 shows the change in A2gg wi4i time for PFK solutions in the presence
of various concentrations of F6P. Fig 4.8 shows how the maximum rate of change of
A28O *s affected by concentration of F6P. The sigmoid curve fit shown has parameters
max inhibition = 103±3%, Sq 5=180±9p.M, nj^=1.9±0.2. Table 4.2 compares
parameters for F6P derived from kinetics (Berger and Evans, 1991; no confidence
limits given), fluorescence and thermal denaturation studies. The Sq 5 value from
thermal denaturation is much higher than the constants from other studies. This
suggests that the PFK species whose binding to F6P slows A2gQ increase may not be
the native form, but possibly some intermediate along the denaturation pathway. The
fact that sigmoidicity is still observed strongly suggests that this form is still tetrameric
and therefore not too dissimilar to the native form. The difference between the npj
value of 4.0 from steady state kinetics and the value of 1.8 for binding alone probably
indicates a catalytic as well as a binding component to measured kinetic cooperativity
(Berger and Evans, 1991).
ADP and ATP were found to have little effect on PFK denaturation. PEP was mildly
destabilising, capable of doubling the rate of change of A2gQ at around 2mM.
4.3.2.3 GdnHCl Denaturation
Both 2mM F6P and 40mM F16BP were able to stabilise E.coli PFK against GdnHCl
denaturation (Fig 4.9). In the absence of ligand, 50% denaturation of PFK occurs at
about 0.4M GdnHCl. F6P is capable of shifting this to 1.7M GdnHCl whereas
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Figure 4.7 Effect of F6P on thermal denaturation of
E.coli PFK
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F16BP shifts the midpoint to about 0.9M GdnHCl. 2mM ATP had no effect on the
denaturation (Fig 4.10) and lOmM PEP was found to be destabilising.
RMPFK was found to be very susceptible to GdnHCl. After three hours incubation
in the presence of GdnHCl, negligible activity remained even at concentrations as low
as 0.16M. In the presence of 2mM F6P a very sharp transition is seen at 0.5-0.6M




The effect of the small phosphocompounds on PFK enzyme activity proved
impossible to determine since they all inhibited at least one coupling enzyme of both
'forward' and 'backward' PFK assays. Both metabolism of added F16BP to glycerol-
3-phosphate in the 'forward' assay and metabolism of F6P to 6-phosphogluconic acid
in the 'backward' assay were significantly affected by the presence of phosphocholine
(PC), phosphoethanolamine (PE), phospho-L-serine (PLS) or phospho-D-serine
(PDS).
4.3.3.2 Fluorescence
The effects of PLS and PDS on E.coli PFK fluorescence are shown in Fig 4.12 and
those of PC and PE in Fig 4.13. These represent typical results from several
experiments.
PC produces a maximal fluorescence quench of 9+1% with an approximately
hyperbolically-shaped curve. PE gives only a 2±0% fluorescence quench. The two
isomers of phosphoserine give indistinguishable fluorescence responses. In both cases
the slope of the quench vs. concentration curve increases up to about 23mM
phosphoserine before reaching a plateau at about 70% fluorescence quench.
The mutant E.coli PFK K213A was also studied in order to try to determine the
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Fig 4.11 GdnHCI denaturation of RMPFK
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binding site for the small phosphocompounds. This mutant possesses a defective
effector site which binds effectors less tightly than the wild-type enzyme. Since the
small phosphocompounds under study bore some resemblance to known effectors such
as PEP and phosphoglycollate, the effector site was one candidate for the binding site
of the phosphoserines and/or PC. The preparation was shown to be the required
mutant from its much reduced sensitivity to PEP inhibition compared to the wild-type
enzyme. The mutant was also found to show a fluorescence increase in the presence of
ADP in contrast to the quench seen for the wild-type PFK. Fig 4.14 shows the
fluorescence response of the mutant to the phosphoserines and Fig 4.15 its response to
PC and PE. The only change in fluorescence behaviour seen is a raised PC Ks value
for the mutant. This is 3±lmM for the wild type enzyme but is increased to 10±2mM
for K213A. This suggests that PC may produce its effect on fluorescence by binding
to the effector site. Also suggestive is the 9% fluorescence quench seen for saturating
PC, matching the 8-10% quench seen for saturating PEP (Deville-Bonne and Garel,
1992) which is known to bind to the effector site. PE and the phosphoserines affect the
fluorescence of K213A similarly to the wild-type enzyme suggesting that they do not
exert their fluorescence effects by binding to the effector site.
The size of the fluorescence quench produced by the phosphoserines was much larger
than that seen for any of the natural ligands. A 70% quench implies a very large change
in the environment of the fluorophores, in this cases Trp311. When E.coli PFK is
dissociated into monomers by 3M urea a fluorescence change of similar magnitude
(75%) is observed (Le Bras etal., 1989). This suggested that the phosphoserines were
causing a change in the association state of the enzyme.
The observation that saturating F6P shifts the fluorescence quench curve to the right
(Fig 4.16) was consistent with this idea since F6P is known to protect E.coli PFK
against dissociation and denaturation by a variety of agents.
4.3.3.3 Analytical gel filtration
The dependence of E.coli PFK association state on PDS concentration was determined
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4.14 Phosphoserines and K213A fluorescence
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by analytical gel filtration. The height of the PFK tetramer peak was seen to decrease
as the concentration of PDS increased (Fig 4.17). The height of the monomer peak
could not be accurately monitored since it was superimposed on another large,
unidentified peak.
The negative correlation between fluorescence quench and tetramer peak height
confirms that the phosphoserines do indeed effect dissociation of E.coli PFK.
4.3.3.4 Thermal denaturation
All of the small phosphocompounds affected the thermal denaturation of E.coli PFK.
Both the effect on rate of increase in A2gQ and the maximum change in A2gQ were
affected. Fig 4.18a shows the effects on rate and Fig 4.18b those on maximum
change, both relative to controls containing no small phosphocompound.
For rate first, different effects are again seen for the three compounds. Phosphoserine
shows a biphasic effect on the rate of increase of A2gg- There is a rapid increase to
around 15 times control rate at around 8-12mM PS followed by a decline so that at
40mM PS no increase in A2gq is observed. Again the effects of PDS and PLS are
indistinguishable. The effect of PC is much more modest; a doubling of control rate
followed by a slow decline to around 80% control rate at 40mM PC. PE increases the
rate of change of A2gQ by up to 12-fold at 20mM followed by a tailing off. Fitting of a
saturation curve to the PE data gives a maximum acceleration of rate of 13-fold with
half maximal effect seen at lOmM on a slightly sigmoid curve (nH=1.7±0.4).
Effects on the maximum change in A2gQ seen are more similar between the
compounds (Fig 4.18b). With increasing concentration, both phosphoserines and PE
are seen to double the maximum change in A2gg- With the phosphoserines the
maximum occurs at around 2mM and is followed by a sharp decline. The PE
maximum is between 10 and 15mM and tails off only slowly.
Observation at 280nm means that these results are not easy to explain in detail.
Several overlapping processes, each affecting A2gQ, are probably occurring
simultaneously. However, the initial increase in A2gQ seems likely to result from
159
8 Phosphocompounds and thermal denaturation
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exposure of aromatic residues to solvent as the tetramer dissociates and denatures. The
sharp concentration dependence of the effects of PDS is therefore consistent with the
data in sections above: denaturation of monomers will occur more rapidly than
denaturation of tetramers. The absence of an A2gQ change in the presence of high
concentrations of phosphoserine may indicate an acceleration of transformation of
denatured PFK to later low-absorbance species such as large aggregates. Almost as
large an acceleration of rate is caused by high concentrations of PE suggesting again
destabilisation of the enzyme. This could be a result of binding to either the same site
as phosphoserine or a different one. PE differs only from phosphoserine in the
absence of one carboxylate. If PE bound to the same site then the absence of a large PE
fluorescence effect would mean that that carboxylate was essential for the PDS
dissociation effect. The ability of intermediate concentrations of PE and phosphoserine
to double the maximum change in A2gQ is most readily explained as being simply a
consequence of the accelerated denaturation. Accelerated denaturation followed by
relatively slow conversion to low-absorbance species would lead to an accumulation of
high-absorbance denatured protein.
4.3.3.5 GdnHCl denaturation
The effects of the small phosphocompounds on the GdnHCl denaturation of PFK
after four hours incubation are shown in Fig 4.19. lOmM PDS destabilises PFK to
denaturation so that 0.2M GdnHCl causes 50% loss of activity compared to the
experiment with no phosphocompound. PC also seems to cause a small destabilisation
whereas PE has no effect.
4.3.4 Bisphosphates
4.3.4.1 Enzyme assay
Compound 233 at concentrations of up to lOmM had no effect on the rate of PFK.
The effects of 5mM epoxy compounds on the response of PFK to F6P concentration
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were determined (Fig 4.20). Both a- and p-epoxy compounds are competitive
inhibitors with respect to F6P. Sigmoidal curve fitting gives a Sq 5 value for F6P in
the absence of inhibitor of 46O±10|iM. In the presence of 5mM a- and p-epoxy
compounds the apparent Sq 5 values were 650±10(iM and 610±10|iM respectively.
Assuming pure competitive inhibition this implies Kj values of 13.7mM and 17.7mM
for the a- and P-epoxy compounds respectively.
No evidence of covalent attachment of either epoxy derivative to the enzyme was seen.
When reaction was allowed to continue for one hour an absolutely constant reaction rate
was seen. A decline in rate would be expected if covalent bonding was occurring.
4.3.4.2 Fluorescence
Compound 233 did not quench PFK fluorescence. Little change was seen up to
25mM concentration. A change would be expected if compound 233 bound in the
same way as F16BP so the absence of effect suggests that compound 233 does not
bind to E.coli PFK.
Both epoxy compounds quench PFK fluorescence. Fig 4.21 compares their
fluorescence responses with those produced by F16BP. The parameters derived from
these curves by sigmoidal curve fitting are shown in Table 4.3. They show that the
epoxy compounds bind more weakly than F16BP itself. The a-epoxy compound is the
more tightly binding of the two, in agreement with its greater inhibitory effects (see
above). The three compounds bind with a similar degree of sigmoidicity. The greater
Fmax values for the epoxy compounds were unexpected. This suggests that the
presence of the epoxide group, in either a or (3 conformation, effects an additional
conformational change altering the environment of Trp311.
4.3.4.3 GdnHCl denaturation
Compound 233 at a concentration of lOmM had, if anything, a slightly destabilising
effect on E.coli PFK incubated with GdnHCl (Fig 4.22). Insufficient quantities of the
epoxy compounds were available for testing by this method.
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The LUDI compounds will be referred to by abbreviated names, mostly
corresponding to LUDI's own nomenclature. The abbreviations and the full compound
names are shown in Table 4.4.
4.3.5.1 Enzyme assay
A variety of compounds suggested as possible PFK ligands by the LUDI program
were tested in PFK assays for inhibition. In many cases the maximum concentration
that could be tested was limited by absorption of the LUDI compound at the wavelength
being used to monitor reaction. In cases where the compound was dissolved in
DMSO, the effect of DMSO alone on PFK activity (Fig 4.1) limited the concentration
that could be tested. A reproducible inhibition of greater than 10% was seen for none
of these compounds with either E.coli or RM PFK. Table 4.5 summarises some data
relating to inhibition testing and includes the maximum concentration tested for each of
the compounds.
4.3.5.2 GdnHCl denaturation
Concentrations in the range l-5mM of AQDS, AM7, DAS, AF5, GUI, CDO, BA4
and DAP were tested to see if they could stabilise E.coli PFK against GdnHCl
denaturation. In all cases presence of the compound either had no effect on or
destabilised the enzyme. This is despite the fact that several of these were dissolved in
DMSO which alone was shown to stabilise the enzyme (Fig 4.23).
In the presence of 0.16M GdnHCl RMPFK shows negligible activity after three hours
incubation. The following compounds at 2mM were tested to see if they could maintain
significant RMPFK activity under these conditions PAA,GU1, CDA, AQDS, GBA,
A66, BA6, BA4, DAS, AF5, BA2, A18, DAP. None of these proved capable of
protecting RMPFK against denaturation.
165































A63 no poorly no 0.1
A66 no poorly no 0.5
BA4 no yes no 0.3
AF5 no yes yes 1
GU1 yes no 3
PAA yes no 3
DAP yes yes 5
BA2 no no
Y41 no no
BA6 no yes no 5
CDA yes no 6
DAS yes yes 2.5
AM7 inhibits a coupling enzyme
AQDS inhibits a coupling enzyme
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4.3.5.3 Thermal denaturation
The following concentrations of LUDI compounds were tested for their effect on the
thermal denaturation of E.coli PFK 5mM BA4, 0.5mM GBA, 0.2mM CDA, ImM
BA6, 0.3mM A18, ImM BA2, 0.25mM A66, O.lmM CDO, 0.2mM AQDS. In many
of these cases, an upper limit on the concentration of compound to test was imposed by
the absorbance of the compound at 280nm. None of these compounds affected the
thermal denaturation. However, an effect was seen with A66. This compound reduces
the maximum change in A2gQ produced in a concentration-dependent fashion (Fig
4.24) implying an effect on one of the reactions of PFK thermal denaturation.
4.3.6 Naphtho compounds
4.3.6.1 Enzyme assay
Testing of the naphtho compounds was hampered by two factors. First, testing of
ANQ proved to be impossible since the compound absorbed strongly, not only at
340nm, the wavelength used in the standard assay, but also at 540nm where the
modified assay operates. HNNS and NQS did not absorb so strongly at 540nm but
were found to inhibit the coupling enzymes of the modified 'forward' assay. 4mM
HNNS was found to inhibit the metabolism of added F16BP by about 70% and 4mM
NQS by about 85%. It does seem likely that HNNS at least inhibits PFK - 4mM
HNNS in the PFK assay gave an apparent inhibition of 95%. However, the multiple
effects prevent accurate measurement of PFK inhibition.
4.3.6.2 GdnHCl denaturation
All three naphtho compounds were found to destabilise E.coli PFK towards GdnHCl
denaturation at a concentation of 2mM (Fig 4.25).
4.3.6.3 Thermal denaturation
These studies provided clear evidence of binding of the naphtho compounds to E.coli
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Fig 4.24 Effect of A66 on PFK denaturation
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PFK. The effect of compound concentration on the rate of increase of A2gQ is shown
in Fig 4.26. Inhibition in a concentration-dependent manner is seen for all three
compounds. Only the NQS data, however, are of sufficiently high quality for reliable
curve fitting. Fitting of a sigmoid curve yielded the parameters:- Max inhibition
101±5%, Sq 5=43±4p.M, nj_j=1.9±0.2. Inspection of the other traces suggests that
ANQ is more potent than NQS with half inhibition seen at around 15|xM. Conversely,
HNNS is less potent with half inhibition around 75jlM. In both these cases some
sigmoidicity is suggested.
The clear sigmoidal character of the NQS results is particularly interesting since two
inferences can be made from it. First, the F6P/F16BP binding site is the only one on
E.coli PFK capable of cooperative ligand binding. NQS, and almost certainly HNNS
and ANQ too, therefore seem to bind to this site. Secondly, cooperativity would only
be seen for oligomeric forms of PFK. Hence the naphtho compounds seem to exert
their effect on PFK denaturation by binding to an oligomeric species. This does not
necessarily mean that they exert their effect by the binding to the native state of the
enzyme; they could be binding to an oligomeric intermediate of the denaturation
pathway. There seems to be a precedent for this in the protective effect of F6P (see
section 4.3.2.2). There a similar degree of sigmoidicity was observed but the Sq 5
value did not match any of those determined by other techniques for the native state.
4.3.6.4 Fluorescence
The effects of naphtho compounds on PFK fluorescence were determined. Since
these compounds absorb significantly at the wavelengths used for excitation and
detection, a correction was made using the compound N-acetyltryptophanamide (NAT).
Fluorescence reponses to naphthocompounds of PFK and NAT were determined and
the 'true' fluorescence change (that due to change in Trp311 environment) obtained by
subtraction. Fig 4.27 shows the raw data, determined in duplicate, and Fig 4.28 the
'true' fluorescence changes.
Fig 4.28 suggests that NQS, HNNS and ANQ are all capable of binding to PFK and
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thus altering its fluorescence. Curve fitting was not performed since the curves do not
conform to standard binding models; in particular the fluorescence decrease observed
declines at higher concentrations of naphtho compound. The reason for this is not
known but may be a result of deficiencies in the correction method.
These compounds can be modelled into the F6P binding site of E.coli PFK (see
Section 3.3.4.2) yet give maximum changes in fluorescence smaller than that seen for
F6P or F16BP (about 20%). The failure of the naphtho compounds to reach this level
could have the same cause as the decline in fluorescence decrease at higher
concentrations. Alternatively, the naphtho compounds may not have all the structural
necessities for the full fluorescence change.
Table 4.6 presents a summary of the testing of the different classes of compound by
the different methods available. 'Yes' indicates that at least some of the compounds in a
particular class produced changes in PFK behaviour observable by a particular method.
'No' indicates an absence of response. 'N.D.' means that a particular combination of
compound class and analytical technique was not tried.
4.3.7 Combinations of compounds
4.3.7.1 Thermal denaturation
PDS andNQS
Experiments were carried out to see if the protective effect of NQS towards thermal
denaturation of PFK could counteract the destabilising effect of PDS. With 7.5mM
PDS present in all cuvettes except the control, NQS was present at 0, 20, 50, 100 and
200|iM. The curves showing A2gg against time for these last five incubations were
essentially superimposed. They all showed an acceleration of control rate of increase of
A280 °f around 13-fold, in agreement with previous results. Thus NQS cannot protect
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Table 4.6 Summary of liaand testing








N.D. yes yes yes
Bis-
phosphates
yes/no N.D./no N.D. yes/no
LUDI
compounds
no yes yes N.D.
naphtho
compounds
yes yes yes yes
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against the effects of PDS.
PDS and F6P
In the same way the effect of combining PDS and F6P was determined. F6P was
present at 0, 100, 200, 400 and 800pM with 7.5mM PDS. A very different result was
seen (Fig 4.29). When inhibition of rate is plotted against F6P concentration the data
fit well to a sigmoid curve (Fig 4.30). The parameters derived from this fitting - Max
inhibition 101+2%, Sq <;=114±5|lM, npj=2.1±0.2, agree very well with those
obtained for F6P in the absence of PDS (Max inhibition 103±3%, Sq 5=180±9(lM,
njj=1.9±0.2). However there are differences between the traces obtained in the
presence and absence of PDS (compare Fig 4.7 with Fig 4.29). In the presence of
PDS two phases to the traces may be defined. In the first all non-control traces show
an increase in A2gQ of about 0.04. There is no lag before this increase appears so that
here the traces resemble more those found for PDS alone than F6P alone. In the
second phase the rate is F6P-dependent and the traces resemble more those for F6P
alone than PDS alone.
An explanation for these results may lie in the PDS gel filtration results. They suggest
that 7.5mM PDS would effect about 30% dissociation of PFK. The constant change
seen in the first phase of the above results may represent the denaturation of this
fraction of the PFK. The remaining tetrameric fraction would then be protected by the
F6P in the observed concentration-dependent manner. If this is the case then the F6P-
bound portion would have to be insensitive to PDS dissociation. In contrast the results
from combination of NQS and PDS suggest that the NQS bound forms of PFK must
be PDS-sensitive. This is interesting since the lack of extra protection from NQS in the
presence of F6P (data not shown) suggests that NQS and F6P may compete for the
same site.
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Figure 4.29 Effect of F6P on thermal denaturation ot
E.coli PFK in the presence of PDS
Fig 4.30 Effect of F6P+PDS on thermal denaturation




Small phosphocompounds and natural ligands
The fluorescence responses of PFK to F6P and ADP were determined in the presence
of lOmM PE, PC and PDS. The F6P results are shown in Fig 4.31a and the ADP
results in Fig 4.31b. The parameters derived from these data are shown in Tables 4.7a
and 4.7b. Sigmoid curve fitting was applied to the F6P data. Sigmoid curve fitting of
the ADP data gave npj values of 0.8+0.2 so hyperbolic curve fitting was applied.
In general PE and PC seem to have similar effects with PDS somewhat different.
This might be expected from a significant difference in their chemical structures; PDS
has an extra charged, bulky carboxylate group that is absent in PC and PE.
Considering the F6P effects first, it is surprising to note that PC and PDS seem
capable of increasing the maximum fluorescence quench. This is despite the fact that
lOmM PDS itself produces a 5% fluorescence quench and lOmM PC a 7%
fluorescence quench. One possible explanation is that binding of PC and PDS loosens
the structure (in the case of PDS sufficiently to effect dissociation) so that the
conformational changes on binding of F6P produce bigger changes in the environment
of Trp311. Both PC and PDS lower the Hill constant to near one and lower the Sq 5
values for F6P. These results would be explained by conversion of T-state to R-state
PFK which could arise from binding to the effector site. If PC or PDS bound in the
same way as PEP the opposite effect would be expected. For PDS at least modelling
into the T-state structure in place of the PEP analog phosphoglycollate produces serious
steric clashes. The difference in PC fluorescence response between wild-type and
K213A enzymes (Section 4.3.3.2) suggests that PC does bind to the effector site.
However, if PC (or PDS) do bind to the effector site, then they must do so in such a
way as to emulate ADP rather than PEP. It is possible that PDS is binding to more than
one site with an altered fluorescence quench resulting from the K213A mutation
swamped by another larger contribution. In contrast to PC and PDS, PE produces a
lower Sq 5 value for F6P without lowering nj^. This is less easy to explain.
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Table 4.7 Effect of small phosphocompounds on
PFK fluorescence responses
a) F6P fluorescence response
no addition PE PC PDS
^max (0//°) 18±0 19±0 24±1 2810
s0.5/^M 9.6±0.5 4.0±0.0 3.7±0.2 6.510.2
nH 1.8±0.2 2.0±0.0 1.110.2 1.410.1
b) ADP fluorescence response
no addition PE PC PDS
^max (°/o) 16±1 17±0 1610 2711
Ks /jiM 12±2 13±1 811 3112
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PE and PC have little effect on the ADP fluorescence response. The raising of Ks by
lOmM PDS would be most easily explained by competition for the same (effector) site.
However, this is not consistent with the similar PDS fluorescence response of the
K213A mutant unless we again suppose that it binds in a different way to the natural
ligands ADP and PEP. The maximum fluorescence quench produced by ADP is
increased by PDS. Some synergism between PDS and ADP is suggested since after a
7% fluorescence change due to lOmM PDS, ADP can produce a further 27% quench.
ADP alone produces only a 16% fluorescence quench.
NQS and F6P
The F6P fluorescence response of E.coli PFK was determined in the presence of 25,
50, 75 and lOOfiM NQS. Because of the absorbance by NQS at excitation and
emission wavelengths, volume changes were kept very small, less than 3%, during
each experiment. This enabled changes in absorbance due to NQS to be ignored. The
data, means of two determinations, are shown in Fig 4.32 fitted to sigmoid curves.
The percentage quench is related to the fluorescence value after addition of NQS which
caused an initial non-specific fluorescence decrease. The parameters derived from this
curve fitting are shown in Table 4.8.
NQS has a definite effect on the F6P fluorescence reponse, most obviously seen in the
decline in Fmax seen as NQS concentration increases. Also seen is a slight fall in
Sq g although this may be within experimental error. The apparent increase in npj is
not convincing. This parameter is determined less accurately than the other two. In
particular, a real np^ value of 2.3 seems unlikely given that F6P can only bind to two
sites on the tetramer (Deville-Bonne and Garel, 1992).
The thermal denaturation data strongly suggest that F6P and NQS compete for the
same site or overlapping sites. These fluorescence data are not consistent with that
idea. If the two compounds were to compete then an increase in Sq g for F6P would
be expected without a change in Ffj^. In fact, no increase in Sq g is seen and Fmax is
decreased.
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Fig 4.32 Effect of NQS on F6P fluorescence response
[F6P]/pM
Table 4.8 Effect of NQS on F6P fluorescence response
[NQS]/|iM ^maxW S05/J1M nH
0 18.1±0.2 9.610.5 1.810.2
25 15.810.3 14.710.6 1.610.1
50 13.010.7 12.111.4 1.410.2
75 8.110.1 10.310.3 2.010.1
100 6.110.2 9.410.6 2.310.3
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In this scheme E represents the tetrameric enzyme. The stoichiometry of two F6P
molecules per tetramer shown in F6P-bound species is known from equilibrium
dialysis experiments (Deville-Bonne and Garel, 1992). The stoichiometry of the NQS-
bound species is unknown. The important feature of this model is the postulated
E.(F6P)2.(NQS)2 species. This would arise by binding of NQS to the two F6P
binding sites left unoccupied in the F6P-saturated enzyme. The four enzyme species in
the scheme are shown with different fluorescence properties. This is consistent with
fluorescence data in this thesis. F6P alone causes an 18% fluorescence quench (Fig
4.6) and NQS alone a 7% fluorescence quench (Fig4.28). NQS alters the F6P
fluorescence response in a concentration-dependent way (Fig 4.32). The above scheme
is also consistent with thermal denaturation data. NQS in the above scheme is binding
to the F6P binding sites so that the observed sigmoidicity in the protection against
denaturation vs. [NQS] curve could be explained by cooperative NQS binding. All of
the ligand-bound species would have the same thermal stability in the above scheme.
This seems inconsistent with the observation that F6P, but not NQS, can stabilise
E.coli PFK against dissociation by PDS. Therefore it must be argued either that
thermal- and PDS-induced changes proceed by different pathways, or that PDS
binding, to an unknown site, interacts differently with F6P and NQS binding.
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4.4 Conclusions
A variety of classes of compound deriving from a variety of design methods have
been tested for binding and interaction to both E.coli and Rabbit Muscle PFK. The
goal of discovery of new potent PFK inhibitors has not been achieved. This was
probably an unrealistic target given the time and facilities available. However much
information has been accumulated relating to the enzymes and the methods that may be
applicable for the design of inhibitors.
Three main problems were encountered in the testing of LUDI compounds for PFK
inhibition. First, a majority of the LUDI compounds tested absorbed strongly at
340nm, imposing a severe upper limit on the concentration of the compound that could
be tested in the assay. Here the extension of the enzyme assay using MTT and Meldola
Blue dyes to enable rate measurement at 540nm proved to be a useful innovation,
although some compounds absorb at 540nm as well. Another possibility would be the
linking of NADPH oxidation to reduction of O2 to H2O2 via an intermediate electron
carrier. An oxygen electrode could then be used to measure the rate of reaction so that
absorbance by putative inhibitors would not interfere with the assay. Secondly,
coupled enzyme assays are not ideal for inhibition measurement since the effect of
potential inhibitors on the coupling enzymes must be determined. If inhibition of
coupling enzymes is discovered then the assay must be discounted as a reliable
indicator of primary enzyme activity. Direct measurement of the conversion of, for
example, radioactive ATP to ADP may be one solution to the problem. Substrate and
product would be separated by, for example, ion exchange chromatography and their
radioactivity measured by scintillation counter. However, this method would
undoubtedly be very laborious and time-consuming. Another possibility would be the
assay of ATP produced by the 'backwards' reaction, either in denatured reaction mix or
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in some purified form, by a luciferin/luciferase assay. This is more attractive though
initial trials ran into reproducibility problems and were not followed up. The third
major problem encountered during testing was the relative insolubility of some
compounds. The finding that 5% DMSO could safely be included in both E.coli and
Rabbit Muscle PFK assays provided a partial solution to the problem, but solubility
was still occasionally the limiting factor in concentration of compound able to be tested.
The small phosphocompounds suggested by the 2D connectivity search proved
interesting though it should be immediately emphasised that high concentrations were
required for effects: in no way are these drug leads. The case of the small
phosphocompounds was one in which the problems associated with coupled enzyme
assays were apparent. Thus their effect on PFK activity could not be determined. It
seems likely that ambiguities arising from the results of other methods could be
resolved by determination of the effects of the compounds on enzyme rate. The
phosphocompounds affected the E.coli PFK behaviour seen by all the other methods
applied, showing that they bind to the enzyme. To which site(s) they bind seems less
clear.
The ability of both phosphoserines to effect dissociation of PFK, as shown by
fluorescence and analytical gel filtration, was unexpected. The fact that both isomers
were equally effective suggests first that the effect arises not from binding to the F6P
binding site; PDS but not PLS can be satisfactorily modelled here. Secondly, it was
suggestive of some merely physical effect in an analogous way to urea, thiocyanate etc.
However the lack of effect of phosphoserines on control proteins phosphoglucose
isomerase, BSA and lysozyme (data not shown) seems to rule this out. Also the
concentrations required are relatively small. This leaves us with phosphoserines
binding specifically to PFK most likely at or near the subunit interfaces. The effector
site is the most obvious candidate but the identical effects of phosphoserines on the
K213A mutant argue against this. Alternatively it is possible that phosphoserines bind
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to some novel site. Crystallographic or nuclear magnetic resonance spectroscopic study
of PFK in the presence of phosphoserine would distinguish between these possibilities.
PC is not modelled satisfactorily intc the active site and affects the K213A mutant
differendy from the wild type enzyme. The similar maximal fluorescence quenches
seen for PC and PEP further support the idea of PC binding to the effector site.
However, the effect of PC on the F6P fluorescence response means that if this was the
case, then PC would have to bind in such a way as to emulate ADP rather than PEP.
Fluorescence data fail to suggest an obvious binding site for PE.
The destabilising effect of phosphoserine is again evident from the denaturation
studies. The rate of increase of A2gQ during thermal denaturation is increased 15-fold
by lOmM PDS and the midpoint of transition in the GdnHCl studies shifted from
around 0.5M GdnHCl to 0.2M GdnHCl. PE can cause a similar destabilisation of
PFK, assessed by thermal denaturation, but at higher concentration. It is therefore
tempting to conclude that PE and phosphoserine share a destabilising binding site, and
that the presence of the extra carboxylate group on the phosphoserines causes additional
destabilisation sufficient to dissociate the enzyme into monomers.
The ability of phosphoserines to dissociate E.coli PFK may not be of just academic
interest. If nothing else, it illustrates another possible method of action for rationally
designed inhibitors. The vast majority of PFKs known are oligomeric and are inactive
as monomers so that specific dissociative agents could be as effective as specific
catalytic site-directed compounds. In a situation where an enzyme must be oligomeric
for activity, non-conservative mutations at subunit interfaces are unlikely to be tolerated
so that interface residues would diverge more slowly than surface ones during
evolution. This argument is supported by the model of the Rabbit Muscle PFK; no
insertions or deletions, for example, were located at presumed interfaces. If this is the
case then suitable sites for rationally designed dissociative agents probably exist on
RMPFK and other larger PFKs. In addition, RMPFK seems less stable overall than
the E.coli enzyme. The GdnHCl denaturation results (compare Figs 4.9 and 4.11)
illustrate this point. Thus, an E.coli PFK structure in the presence of phosphoserine
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would enable the identification of a site whose homologue in higher PFKs could be a
useful, novel target for rational drug design.
Compound 233 was not expected to bind to PFK. It lacks all three hydroxyl groups
of F16BP, each of which forms H-bonds to the enzyme in the FBP-bound crystal
structure. Modelling compound 233 into the structure in place of FBP puts the
hydrophobic furan ring unfavourably into a largely hydrophilic pocket. Testing
confirmed that the compound does not bind.
Lack of material prevented comprehensive testing of the epoxy derivatives. However,
the fluorescence and enzyme activity studies provide convincing evidence of their
binding to E.coli PFK. The results show that both derivatives bind more weakly than
FBP itself, presumably due to steric hindrance from the epoxy groups. The lack of
covalent modification by either epoxy compound is consistent with the pessimistic
modelling results (see Section 3.3.2.2)
Disappointingly, none of the LUDI compounds showed any evidence of PFK
inhibition or protection against GdnHCl denaturation. In some cases, solubility or
other factors limited the concentration of compound that could be tested. Despite this
most were tested at concentrations of greater than ImM so that even had the compounds
bound only weakly, their effects would have been evident. Many of the compounds
destabilised PFK against GdnHCl implying some sort of interaction. However it
seems likely that this may be non-specific; several of the compounds, for example,
have distinct hydrophobic and hydrophilic regions perhaps conferring detergent-like
properties on them.
A single compound, A66, influenced the denaturation of E.coli PFK. A
concentration-dependent decrease in maximum change was seen. However, the
compound did not affect the rate of increase of A2gQ. Since this is related to the first
step of denaturation i.e. the process involving native tetramer, any ligand interacting
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with native protein would be expected to influence this quantity. For this reason it
seems likely that A66 may be affecting some later step of the denaturation pathway and
is therefore not of interest as an inhibitor.
Since all of the LUDI compounds can be fitted into the PFK structure to form multiple
H-bonds and/or hydrophobic contacts, the failure of any to inhibit is disappointing.
This is particularly so since detailed modelling can produce convincingly
complementary complexes (see Section 3.3.2.2). However, it must be remembered
that the original LUDI concept envisaged fitting of multiple fragments and their linking
together to produce larger viable inhibitors. Some of the compounds tested were quite
small so that exceptional complementarity would have been required for tight binding.
The naphtho compounds certainly bind to E.coli PFK as shown by protection against
thermal denaturation protection and effects on fluorescence. The two techniques show
opposite orders of effectiveness with protection against denaturation in the order ANQ
> NQS > HNNS and Sq 5 values for fluorescence effect in the order HNNS > NQS >
ANQ. However, the fluorescence data are not ideal; the apparent tailing off in
fluorescence quenching at high concentration of compound is more likely to be the
result of somehow deficient data correction than a genuine finding. That said, the
reverse order may be the result of the two methods measuring binding to different
species. Fluorescence quenching results from effects on a native, 'ground-state' form
of the protein whereas the protection against thermal denaturation may arise from
effects on an intermediate of the denaturation pathway. This seems to be the case for
denaturation protection by F6P where the Sq 5 value obtained fails to match values
derived by other techniques relating to native enzyme. In both that case and protection
by naphtho compounds, the clear cooperativity seen means that the form of the enzyme
acted upon is still oligomeric. As stated before, this also identifies naphtho compound
binding with the F6P binding site. A model of the type proposed in Section 4.3.7.2 is
consistent with most of the experimental data. However, ligands tend to stabilise PFK
similarly against dissociation and denaturation by various agents. Therefore the similar
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stabilisation by NQS and F6P to heat, contrasting with their different stabilisation to
PDS, was unexpected and requires explanation.
These data and the apparent evidence of enzyme inhibition, despite measurement
difficulties, raise the question of whether these compounds could form the starting
point for a rational drug design project - are they lead compounds? Of all the data the
most potent effect is half protection from thermal denaturation by ANQ at around
15pM. This compares with typically sub-micromolar values for half inhibition of target
shown by industrial drug leads. However, the naphtho compounds are small compared
to most drug leads and would therefore be expected to have lower affinities. There is
plenty of scope for adding other favourable functionalities, perhaps suggested by
LUDI, to the naphtho compounds to improve affinity. The F6P pocket is quite large
and adjacent to the even larger nucleotide binding site. In favour of these compounds is
their naphthalene carbon skeleton whose chemistry is well known. Addition of other
groups to such skeletons is by standard, relatively straightforward reactions.
Much less effort was expended in testing compounds for possible effects on Rabbit
Muscle PFK. Only two techniques were used - enzyme assay and GdnHCl
denaturation, with neither producing effects for other than natural ligands. The lack of






Accurate modelling of proteins, ligands and protein-ligand complexes is an important
part of the rational drug design process. In many cases, particularly for parasite
enzymes, there is no crystal structure available for the target enzyme. Several factors
may cause this including difficulties in obtaining and purifying material, and the
intrinsic slowness of the X-ray crystallography method for structure determination.
Much more likely to be available is the amino acid sequence of the target enabling, in
favourable cases, a model of the structure to be built by homology to a known 3D
protein structure (see Section 2.1.2). Accurate protein models are essential for protein-
structure based ligand design methods since ligand binding is known to be highly
sensitive to changes in target structure. This is readily explained at an atomic level by
consideration of, for example, the sensitive angular- and distance-dependence of H-
bonds (Fersht, 1985) which frequently contribute to binding affinity. Indeed this
sensitivity to the target structure is the premise on which species-selective drug design
is based.
Accurate modelling of ligands is important for the same reason although database
searches based only on 2D ligand structure can be successful (Pepperrell and Willett,
1991). A major step towards accurate ligand modelling is the development of programs
like CONCORD (Rusinko etal., 1988) which are capable of determination of
reasonably low energy structures for small molecules. However, probably more than
with proteins, ligand flexibility is a complicating factor; ligands do not always bind to
proteins at, or even near, their minimum global energy conformation. Attempts to deal
with ligand flexibility are therefore important (Clark et al., 1993).
Results in this thesis shed some light on the accuracy with which proteins can be
modelled by various methods. Several protein- and ligand-based ligand design
procedures, using different levels of information, can be compared for the quality of
their results. An overall conclusion of the following analysis is that human intelligence
and intuition still have an important part to play alongside brute force computational
techniques. Interestingly, artificial intelligence techniques have recently been applied to
some of the ligand design operations currently carried out by humans (Cohen and
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Shatzmiller, 1993), although this work is at an early stage.
Objective methods have been used to compare models of RMPFK built either mostly
manually or mostly by computer. In general, the much slower manual design produced
the better model although one of the slowest components, the complex loop modelling,
seemed not to be worth the time outlay. Human intervention in the automatic design
procedure would seem likely to improve the rather poor results. Inadequacies of the
computer-only modelling method were particularly obvious at the alignment stage and
during substitution of side chains, when manual relief of steric clashes would seem
advantageous.
A variety of ligand design methods were tried. These do not span the full range of
procedures under investigation since ligand design programs have great commercial
value and are frequently not freely available. Two 2D ligand-based database searches
were carried out. Fitting of molecular fragments to protein with LUDI was tried, but
fitting of whole molecules from databases, as by the program DOCK, was not an
approach that could be tested. Programs for the automatic generation of putative ligand
structures, another important field into which energy is being directed, were also
unavailable. The protein-ligand complex structure-based approach of ligand
modification was, however, attempted.
Both 2D database searches were successful in producing interesting compounds. The
small phosphocompounds tested as a result of the very rapid CCD database search
proved to bind to PFK, though not with high affinity. The discovery that phospho-D-
serine produced dissociation of E.coli PFK was of particular interest. It reveals an
alternative available means of enzyme inhibition to the usual targeting of the active site.
It remains to be seen whether suitable sites for rationally designed dissociative agents
exist on other PFKs. A search of a larger database could be carried out. This would
provide more ideas and/or enable the use of a more specific search structure.
The database search using NQS provided many ideas. Commercial availability limited
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the number of ideas that could be tested to two but both these were active, one more so
than NQS. It is worth remembering that NQS was suggested for testing as a result of
its resemblance, noted by a chemist, to a LUDI compound being tested. This is
evidence, depending on viewpoint, for the importance of either people or serendipity in
the rational ligand design process.
None of the LUDI compounds tested could be shown to bind to the E.coli PFK
'ground state' (A66 probably binds to E.coli PFK at a later stage of the thermal
denaturation pathway). This is at least partly expained by their small size, and maybe,
in some cases, by the limits imposed by compound absorbance or solubility on the
concentration that could be tested. In no cases were compounds derived from linked
fragments (the original design concept) available for testing. Hence no conclusion can
be drawn about the effectiveness of LUDI. What can be said is that the program runs
very rapidly; large runs took less than an hour.
It is difficult to judge the effectiveness of the FBP analog design approach since none
of the suggested compounds was available for testing. It was however noted that the
results of the molecular mechanics procedure agreed with the predictions made by the
GRID program. It can also be said that some of the derivatives modelled looked so
favourable as to be very likely to be good inhibitors. There is circumstantial support
for the quality of molecular modelling from the predictions made about the likely
effectiveness of the available bisphosphates - the epoxides and compound 233. The
generally pessimistic predictions were confirmed by experiment. This ligand design
approach was by far the slowest. This must be taken into account in any future
assessment of the method.
The question of species selectivity has been addressed. In the case of this model
system of E.coli and RM PFKs, significant exploitable differences between the two
were found only quite distant from the substrate binding sites. This meant that only
one of the ligand design methods used, LUDI fragment fitting, was applicable to the
species selectivity problem. This method, however, produced promising results.
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Fragments that were highly complementary to regions differing in the two enzymes
were found. Further fragments could be plausibly linked to these in order to occupy at
least part of the substrate binding sites.
An important question is whether species selectivity between parasite and mammalian
host would be easier or harder to obtain than selectivity between E.coli and RM PFKs.
As noted (Section 1.2.2), parasites possess either an ATP-dependent PFK or a PPj-
dependent PFK. Species-selective drugs against the ATP-dependent enzyme would
probably be harder to obtain than E.coli PFK inhibitors in the model system. Although
no parasite ATP-dependent PFK sequences are known it is highly likely that they will
more closely resemble mammalian PFKs than E.coli PFK does.
The situation with the PPj-dependent parasite PFKs is more promising. The limited
amount of sequence data available so far suggests that they are 40-60% identical to the
bacterial PFKs. This means that a structural model would be easily built by homology
with those enzymes. This would be expected to be of greater overall quality than the
RMPFK structures which were produced here on the basis of 30-40% sequence
identity. The F6P binding site of the PPj-dependent PFK model could be targeted as in
this thesis. Another attractive possibility is to target the PPj binding site. PPj analogs
would be unlikely to harm the host since PPj metabolism is not thought to be significant
in mammals. Also, the PPj binding site is likely to be significantly different to the ATP
binding site of host PFKs. This is advantageous for species selective drug design,
although it should be borne in mind that this fact simultaneously increases the
likelihood of inaccuracies at the PPj binding site in the homology model of the PPj-
dependent parasite PFK. PPj analogs are the focus of current synthetic efforts as
antiviral agents (Kluger and Huang, 1991). This chemical expertise will be useful if
targeting of the PPj binding site proves promising.
In conclusion, the question of species-specific rational drug design has been
addressed using a PFK model system. Protein and ligand modelling studies have
illustrated some of the possibilities and problems involved. It seems likely that studies
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such as these will soon be able to expedite the discovery of effective anti-parasitic
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Appendix 1
A SYBYL macro to automatically set preferred side chain torsion angles. A
sample of the data file pref.data follows the program to illustrate its format.
# A macro to add preferred side-chain angles to a selected range of a.a.s
# Values taken from Sutcliffe et al. Prot.Eng. 1987 1 385-392







%promptif("$1" "int Start" "Residue number of start")
setvar length \
%promptif("$2" "int Length" "Number of residues to set")
uims v off
#
# Open data file
#
setvar f %open(pref.data "r")
#






setvar alphabeta "alpha" "beta"
#
# Enter loop to go through range
#
for res in %range("$start" %math($start + $length -1))
#
# See if closer to alpha or beta
#
setvar atoml %atom_info(%cat(%subst_info(%math($res-1) name) ".C") id)
setvar atom2 %atom_info(%cat(%subst_info($res name) ".N") id)
setvar atom3 %atom_info(%cat(%subst_info($res name) ".Ca") id)
setvar atom4 %atomJnfo(%cat(%subst_info($res name) ".C") id)
setvar atom5 %atom_info(%cat(%subst_info(%math($res +1) name) ".N") id)
measure torsion $atom1 $atom2 $atom3 $atom4 >dummy |




setvar numstart %math(%pos("=" "$report") +2)
setvar numend %math(%pos("Deg" "$report") -2)
setvar PHIres %substr("$report" $numstart %math($numend - $numstart +1))
%close($g)
measure torsion $atom2 $atom3 $atom4 $atom5 >dummy |
setvar g %open(dummy "r")
setvar dummy %read($g)
setvar report %read($g)
setvar numstart %math(%pos("=" "$report") +2)
setvar numend %math(%pos("Deg" "$report") -2)
setvar PSIres %substr("$report" $numstart %math($numend - $numstart +1))
%close($g)
setvar deltaalpha %sqrt(%math(%pow(%math($PHIres - $PHIalpha) 2) + \
%pow(%math($PSIres - $PSIalpha) 2)))
setvar deitabeta %sqrt(%math(%pow(%math($PHIres - $PHIbeta) 2) + \







# What to look for
#
setvar lookfor %cat(%substr(%subst_info(%cat("{" "$res""}") name) 1 3) $ab)
#
# Enter loop to look for it
#
%rewind($f)
while %not(%streql($lookfor %substr(%read($f) 1 4)))
endwhile
#





# Enter loop to alter angles
#
echo "Setting" %subst_info($res name) "to preferred"\
%arg(%pos($ab "ab") $alphabeta) "angles"
for setloop in %range(1 $noang)
















































Three SYBYL macros which, when mn sequentially, emulate the loop search






%promptif("$1" "string" Loop run name" \
"Run name e.g. loopl to find loop1_1 ,loop1_13 etc.")
#
setvar gapstart \
%promptif("$2" "int""" "Gap start" "Residue number of start of gap")
#
setvar gapend \
%promptif("$3" "int" Gap end" "Residue number of end of gap")
#
setvar database \
%promptif("$4" "string" "newloop.mdb" "Database" \
"Name of the database containing the loops and model")
#
setvar model \
%promptif("$5" "string" "model_n_20_3" "Name of model" \
"Name of model protein including region to replace")
#
setvar nanchlength \
%promptif("$6" "int" "3" "N_anchor length" \
"Length of the N-terminal anchor region")
#
setvar canchlength \
%promptif("$7" "int" "3" "C_anchor length" \
"Length of the C-terminal anchor region")
#
setvar loopseq \
%promptif("$8" "string" "val=asp=gly=gly=asp=his" "Loop sequence" \
"Sequence of loop INCLUDING anchors in format XXX=YYY=...")
#
# Open output file
#
setvar f %open(%cat("danloop_" $runname ".out") "w+")
#
data open $database update
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# Exit immediately if no matches
setvar startdb %database(%cat($runname "*"))
setvar noloops %count($startdb)
if %eq(0 $noloops)






# Set minimisation conditions
#
tailor set maximin2 min_energy_change 0 ||
tailor set maximin2 minimization_method bfgs | |
tailor set force_field parameter_set koll_all ||




data get $model ml
default ml
setvar gapminus %subst_info(%math($gapstart -1) name)
setvar gapplus %subst_info(%math($gapend +1) name)
#
# Get the six constraints on minimisation. Use just end-to-end in first
# round BUT all six in second round
#
setvar sourceatom "%cat($gapminus ".C")" "%cat($gapminus ".N")" \
"%cat($gapminus ".CA")" "%cat($gapminus ".CA")" \
"%cat($gapminus ".N")" "%cat($gapplus ".CA")"
setvar destatom "%cat($gapplus ".N")" "%cat($gapplus ".CA")" \
"%cat($gapplus ".CA")" "%cat($gapplus ".C")" \
"%cat($gapminus ".CA")" "%cat($gapplus ".C")"
setvar distances %open("dummydist" "w+")
for finddistance in %range(1 6)
setvar atoml %arg($finddistance $sourceatom)
setvar atom2 %arg($finddistance $destatom)
setvar deltax %math(%atom_info($atom1 x) - %atom_info($atom2 x))
setvar deltay %math(%atomJnfo($atom1 y) - %atom_info($atom2 y))
setvar deltaz %math(%atom_info($atom1 z) - %atom_info($atom2 z))













# Enter outside loop to cycle through all matches to loop run name
#
setvar nopassed 0
for loopcount in %range(1 $noloops)
setvar currloop %arg($loopcount $startdb)
data get $currloop m2
default m2
setvar loopstart %subst_info(%arg(1 %substs(*)) name)
setvar loopend %subst_info(%arg(%count(%substs(*)) %substs(*)) name)
remove atom {sidechain}-*.cb
bio addh * essential_only
#
# Do first minimisation round
#
default m2
define constraint distance %cat($loopstart ".C") %cat($loopend ".N") \
$endtoend 600
tailor set maximin2 maximumjterations 250 ||
tailor set anneal hot 0 int 0 ||
anneal m2 m2(*) continue done interactive
#
# Enter second round of minimisation with extra five constraints to fix
# geometry of ends of loops
#
define constraint distance %cat($loopstart ".N") %cat($loopend ".CA") \
$further1 250
define constraint distance %cat($loopstart ".CA") %cat($loopend ".CA") \
$further2 250
define constraint distance %cat($loopstart ".CA") %cat($loopend ".C") \
$further3 250
define constraint distance %cat($loopstart ".N") %cat($loopstart ".CA") \
$further4 250
define constraint distance %cat($loopend ".CA") %cat($loopend ".C") \
$further5 250
tailor set maximin2 maximumjterations 200 ||
anneal m2 m2(*) continue done interactive
#
# Now do fit and get RMSins
#
fit %cat("m1(" $gapminus ".CA)") %cat($loopstart ".CA") \
%cat("m1(" $gapminus ".C)") %cat($loopstart ".C") \
%cat("m1(" $gapplus ".N)") %cat($loopend ".N") \
%cat("m1(" $gapplus ".CA)") %cat($loopend ".CA") \
| solve exit >dummy
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setvar g %open(dummy "r")





setvar nstart %math(%pos(":" "$int") + 1)
setvar rms %substr("$int" $nstart 9)
#
# Report to output file on rms and add minimised, repositioned loop




%write($f "Loop :" $currloop " passes RMSins test with value" $rms)
setvar suffix"_pass"
setvar nopassed %math($nopassed +1)
else
%write($f"")
%write($f "Loop :" $currloop " fails RMSins test with value" $rms)
setvar suffix Mail"
endif
setvar newname %cat($currloop Mmsins" $suffix)
%write($f "New database entry is :" $newname)
remove atom *.cb
remove atom %cat($loopstart ".H")
remove atom %cat($loopstart ".N")
remove atom %cat($loopstart ".CA")
remove atom %cat($loopend ".O")
remove atom %cat($loopend ".C")
remove atom %cat($loopend ".CA")
modify molecule name m2 $newname
data add m2
#
# Create parameter file for this loop to run danloop2
#




















# A macro to do Emin and Esub tests given output of danloopl
#
setvar parsource \
%promptif("$2" "string" "danloop.pars" "File containing danloopl parameters"
"Filename in format danloop.parsX where X is the loop number")











setvar gapplus %math($gapend +1)
setvar gapminus %math($gapstart -1)
tailor set merge consider_uniq no ||
data open $database update
#
# First get model and remove gap
# first gap subs only
#
data get $model m2
default m2
remove substructure %cat("{" %subst_info($gapstart name)\
%subst_info($gapend name) "}")
modify molecule name m2 tempminus
data add m2 replace
#
# Then - further atoms (see paper)
#
setvar gapminusname %subst_info($gapminus name)
setvar gapplusname %subst_info($gapplus name)
remove atom %cat($gapminusname ".O")
remove atom %cat($gapminusname ".C")
remove atom %cat($gapplusname ".N")
215
modify molecule name m2 tempminusminus





# Set minimisation conditions
#
tailor set maximin2 min_energy_change 0 ||
tailor set maximin2 minim bfgs ||
tailor set force_field parameter_set koll_all ||
tailor set anneal hot 0 int 12 ||
#
# Get loop into m2
#
data get $currloop m2
default m2
setvar loopstart %subst_info(%arg(1 %substs(*)) name)
setvar loopend %substJnfo(%arg(%count(%substs(*)) %substs(*)) name)
setvar Isno %substr($loopstart 4 3)
setvar leno %substr($loopend 4 3)
setvar Isplusno %math($lsno +1)
setvar leminusno %math($leno -1)
setvar Isid %subst_info($loopstart id)
setvar leid %subst_info($loopend id)
setvar Iscid %atom_info(%cat($loopstart ".C") id)
setvar lenid %atom_info(%cat($loopend ".N") id)
#
# Change loop residues to correct sequence - this adds side-chains too
#




# Fix any prolines
#
setvar fixstart %substr("$lsid" 2 4)
setvar fixend %substr("$leid" 2 4)
forfixloop in %range(%math($fixstart +1) %math($fixend -1))
setvar fixname %subst_info(%cat("#" $fixloop) name)
if %pos("PRO" $fixname)




# - for anchors take conformation from intact model got into m3
#
data get $model m3
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for nanchloop in %range(1 $nanchlength)
default m3
setvar copyuse %cat("m3(" %substJnfo(%math($gapminus + $nanchloop) name)
T)
default m2
bio copy $copyuse \
%cat("m2(" %subst_info(%math($lsno + $nanchloop) name)")") \
chi 1 ,chi2,chi3,chi4
endfor
for canchloop in %range(1 $canchlength)
default m3
setvar copyuse %cat("m3(" %subst_info(%math($gapplus - $canchloop) name) ")")
default m2
bio copy $copyuse \




# - for others use prefauto
#
uims v off
prefauto %math($lsno + $nanchlength +1) %math($leminusno - $lsplusno -2)
uims v on
#




for makedummy in %range(1 %math($leno - $lsno +1))
modify substructure name %subst_info(%cat("#" $makedummy) name)
%cat("dummy" \
%math($lsno + $makedummy +99))
endfor
setvar noatoms %mol_info(m3 natoms)
#
# Now merge in model - correct atoms (from tempminusminus) so that we are
# minimising the loop in the field of the molecule
#
data get tempminusminus ml
merge ml (*) m2
default m2
scan %cat("{sidechain}&{" $loopstart$loopend "}")
#
# Save parameters for danloop3
#
%close()
setvar pars %open("temp.pars" "w")
%write($pars $noatoms)
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